Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-16-750066.txt : 20161028 0001193125-16-750066.hdr.sgml : 20161028 20161027201159 ACCESSION NUMBER: 0001193125-16-750066 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161028 DATE AS OF CHANGE: 20161027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RESMED INC CENTRAL INDEX KEY: 0000943819 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980152841 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-15317 FILM NUMBER: 161956732 BUSINESS ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 BUSINESS PHONE: 8587462400 MAIL ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 10-Q 1 d265875d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-15317

ResMed Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

98-0152841

(I.R.S. Employer Identification No.)

9001 Spectrum Center Blvd.

San Diego, CA 92123

United States of America

(Address of principal executive offices)

(858) 836-5000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

At October 20, 2016, there were 140,965,500 shares of Common Stock ($0.004 par value) outstanding. This number excludes 41,086,234 shares held by the registrant as treasury shares.

RESMED INC. AND SUBSIDIARIES

INDEX


Part I	Financial Information	3

Item 1	Financial Statements	3

	Condensed Consolidated Balance Sheets (Unaudited) as of September 30, 2016 and June 30, 2016	3

	Condensed Consolidated Statements of Income (Unaudited) for the Three Months Ended September 30, 2016 and 2015	4

	Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the Three Months Ended September 30, 2016 and 2015	5

	Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended September 30, 2016 and 2015	6

	Notes to the Condensed Consolidated Financial Statements (Unaudited)	7

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3	Quantitative and Qualitative Disclosures About Market Risk	25

Item 4	Controls and Procedures	27

Part II	Other Information	28

Item 1	Legal Proceedings	28

Item 1A	Risk Factors	29

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	29

Item 3	Defaults Upon Senior Securities	29

Item 4	Mine Safety Disclosures	29

Item 5	Other Information	29

Item 6	Exhibits	30

	Signatures	31


PART I – FINANCIAL INFORMATION		Item 1

Item 1. Financial Statements

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(In US$ thousands, except share and per share data)


	September 30, 2016			June 30, 2016
Assets
Current assets:
Cash and cash equivalents	$	781,658		$	731,434
Accounts receivable, net of allowance for doubtful accounts of $11,293 and $12,555 at September 30, 2016 and June 30, 2016, respectively		347,137			382,086
Inventories (note 3)		253,828			224,456
Prepaid expenses and other current assets		92,229			81,743

Total current assets		1,474,852			1,419,719

Non-current assets:
Property, plant and equipment, net (note 4)		390,797			384,276
Goodwill (note 6)		1,062,758			1,059,245
Other intangible assets, net (note 7)		289,673			299,808
Deferred income taxes		62,926			55,496
Other assets		41,258			38,161

Total non-current assets		1,847,412			1,836,986

Total assets	$	3,322,264		$	3,256,705

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	80,489		$	92,571
Accrued expenses		153,969			156,805
Deferred revenue		47,665			50,009
Income taxes payable		38,807			39,166
Short-term debt (note 9)		299,625			299,438

Total current liabilities		620,555			637,989

Non-current liabilities:
Deferred revenue		45,736			40,281
Deferred income taxes		8,920			9,061
Other long-term liabilities		974			1,211
Long-term debt (note 9)		873,511			873,332

Total non-current liabilities		929,141			923,885

Total liabilities		1,549,696			1,561,874

Commitments and contingencies (note 13)
Stockholders’ equity: (note 11)
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued		-			-
Common stock, $0.004 par value, 350,000,000 shares authorized; 181,974,343 issued and 140,888,109 outstanding at September 30, 2016 and 181,747,157 issued and 140,660,923 outstanding at June 30, 2016		564			563
Additional paid-in capital		1,321,522			1,303,238
Retained earnings		2,190,028			2,160,299
Treasury stock, at cost, 41,086,234 shares at September 30, 2016, and June 30, 2016		(1,546,611	)		(1,546,611	)
Accumulated other comprehensive loss		(192,935	)		(222,658	)

Total stockholders’ equity		1,772,568			1,694,831

Total liabilities and stockholders’ equity	$	3,322,264		$	3,256,705

See the accompanying notes to the unaudited condensed consolidated financial statements.


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited)

(In US$ thousands, except per share data)


	Three Months Ended September 30,
	2016			2015
Net revenue	$	465,450		$	411,647
Cost of sales (excluding amortization of acquired intangible assets)		196,266			173,028

Gross profit		269,184			238,619

Operating expenses:
Selling, general and administrative		128,851			111,095
Research and development		34,446			27,192
Amortization of acquired intangible assets		11,741			2,307

Total operating expenses		175,038			140,594

Income from operations		94,146			98,025

Other (loss) income, net:
Interest (expense) income, net		(2,493	)		3,422
Other, net		1,272			(2,003	)

Total other (loss) income, net		(1,221	)		1,419

Income before income taxes		92,925			99,444
Income taxes		16,818			16,527

Net income	$	76,107		$	82,917

Basic earnings per share	$	0.54		$	0.59
Diluted earnings per share (note 2)	$	0.54		$	0.58
Dividend declared per share	$	0.33		$	0.30
Basic shares outstanding (000’s)		140,785			140,309
Diluted shares outstanding (000’s)		142,090			142,280

See the accompanying notes to the unaudited condensed consolidated financial statements.


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income (Unaudited)

(In US$ thousands)


	Three Months Ended September 30,
	2016		2015
Net income	$	76,107	$	82,917
Other comprehensive income (loss):
Foreign currency translation gain (loss) adjustments		29,723		(122,108	)

Comprehensive income (loss)	$	105,830	$	(39,191	)

See the accompanying notes to the unaudited condensed consolidated financial statements.


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

(In US$ thousands)


	Three Months Ended September 30,
	2016			2015
Cash flows from operating activities:
Net income	$	76,107		$	82,917
Depreciation and amortization		27,775			18,403
Stock-based compensation costs		12,049			12,383
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable		36,207			30,498
Inventories		(28,073	)		(17,194	)
Prepaid expenses, net deferred income taxes and other current assets		(19,115	)		(3,526	)
Accounts payable, accrued expenses and other liabilities		(18,707	)		1,127

Net cash provided by operating activities		86,243			124,608

Cash flows from investing activities:
Purchases of property, plant and equipment		(14,560	)		(16,403	)
Patent registration costs		(2,471	)		(2,423	)
Business acquisitions, net of cash acquired		(3,090	)		-
Investments in cost-method investments		(2,758	)		(4,582	)
Proceeds (Payments) on maturity of foreign currency contracts		9,710			(39,341	)

Net cash used in investing activities		(13,169	)		(62,749	)

Cash flows from financing activities:
Proceeds from issuance of common stock, net		6,330			4,352
Purchases of treasury stock		-			(57,857	)
Proceeds from borrowings, net of borrowing costs		25,000			200,000
Repayment of borrowings		(25,000	)		(8	)
Dividend paid		(46,378	)		(42,079	)

Net cash (used in) from financing activities		(40,048	)		104,408

Effect of exchange rate changes on cash		17,198			(61,463	)

Net increase in cash and cash equivalents		50,224			104,804
Cash and cash equivalents at beginning of period		731,434			717,249

Cash and cash equivalents at end of period	$	781,658		$	822,053

Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds	$	28,261		$	18,118
Interest paid	$	6,401		$	1,247

Fair value of assets acquired, excluding cash	$	1,891		$	-
Goodwill on acquisition		457			-
Deferred payments		742			-

Total cash component of purchase price	$	3,090		$	-

See the accompanying notes to the unaudited condensed consolidated financial statements.


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

(1)	Summary of Significant Accounting Policies

Organization and Basis of Presentation

ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, France, Malaysia and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2017.

The condensed consolidated financial statements for the three months ended September 30, 2016 and 2015 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2016.

New Accounting Pronouncements

In May, 2014, the FASB issued Accounting Standards Update (ASU), ASU No. 2014-09, “Revenue from Contracts with Customers”, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the company beginning in the first quarter of fiscal year 2019. Early application is not permitted. We are currently assessing the impact on our financial condition, results of operations and cash flows as a result of the adoption of ASU 2014-09, however, we do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.

In April, 2015, the FASB issued ASU No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable International Financial Reporting Standards (IFRS) by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The new standard was effective for us beginning in the first quarter of fiscal 2017. As a result of the adoption, we reclassified debt issuance costs of $0.6 million and $1.7 million, from other assets to short-term debt and long-term debt, respectively, in our consolidated balance sheet as of June 30, 2016. The adoption of this guidance did not impact our consolidated statements of earnings, comprehensive income, stockholders’ equity, or cash flows.

In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this guidance more closely align the measurement of inventory in GAAP with the measurement of inventory in IFRS. The new standard is effective for us beginning in the first quarter of fiscal 2018. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.

In February 2016, the FASB issued ASU No. 2016-02, “Leases”. Under the new guidance, lessees are required to recognize lease assets and liabilities on the balance sheet for leases classified as operating leases under current GAAP. This ASU is effective for the company beginning July 1, 2019. We are currently evaluating the impact of this standard on our consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting”, which requires companies to recognize additional tax benefits or expenses related to the vesting or settlement of employee share-based awards (the difference between the actual benefit for tax purposes and the tax benefit initially recognized for financial reporting purposes) as income tax benefit or expense in earnings, rather than in additional paid-in capital, in the reporting period in which they occur. This ASU also requires companies to classify cash flows resulting from employee share-based payments, including the additional tax benefits or expenses related to the vesting or settlement of share-based awards, as cash flows from operating activities rather than financing activities. The new standard is effective for annual reporting periods beginning after December 15, 2016, with early adoption permitted. We elected to early adopt this ASU during the fourth quarter of fiscal year 2016 and are therefore required to report the impacts as though the ASU had been adopted on July 1, 2015. Accordingly, we recognized a reduction in income tax expense and an increase in operating cash flows related to the vesting or settlement of employee share-based awards of $2.5 million in each of the three month periods ended September 30, 2016 and September 30, 2015.


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

(2)	Earnings Per Share

Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.

Stock options and restricted stock units of 264,672 and 98,697, for the three months ended September 30, 2016 and 2015, respectively, were not included in the computation of diluted earnings per share as the effect would have been anti-dilutive.

Basic and diluted earnings per share for the three months ended September 30, 2016 and 2015 are calculated as follows (in thousands except per share data):


	Three Months Ended September 30,
	2016		2015
Numerator:
Net Income	$	76,107	$	82,917
Denominator:
Basic weighted-average common shares outstanding		140,785		140,309
Effect of dilutive securities:
Stock options and restricted stock units		1,305		1,971
Diluted weighted average shares		142,090		142,280
Basic earnings per share	$	0.54	$	0.59
Diluted earnings per share	$	0.54	$	0.58

(3)	Inventories

Inventories were comprised of the following at September 30, 2016 and June 30, 2016 (in thousands):


	September 30, 2016		June 30, 2016
Raw materials	$	65,416	$	67,121
Work in progress		4,859		3,939
Finished goods		183,553		153,396
Total inventories	$	253,828	$	224,456

(4)	Property, Plant and Equipment

Property, plant and equipment were comprised of the following as of September 30, 2016 and June 30, 2016 (in thousands):


	September 30, 2016			June 30, 2016
Machinery and equipment	$	197,075		$	197,485
Computer equipment		163,787			154,105
Furniture and fixtures		44,363			40,776
Vehicles		7,477			9,060
Clinical, demonstration and rental equipment		83,152			79,641
Leasehold improvements		34,126			33,795
Land		55,194			54,338
Buildings		233,047			229,502
		818,221			798,702
Accumulated depreciation and amortization		(427,424	)		(414,426	)
Property, plant and equipment, net	$	390,797		$	384,276


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

(5)	Cost-Method Investments

The aggregate carrying amount of our cost-method investments at September 30, 2016 and June 30, 2016, was $36.6 million and $33.8 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets.

We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered. We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values that can be market supported and unobservable inputs including future cash flows. We have determined that the fair value of our cost-method investments exceed their carrying values.

The following table shows a reconciliation of the changes in our cost-method investments during the three months ended September 30, 2016 and 2015 (in thousands):


	Three Months Ended September 30,
	2016		2015
Balance at the beginning of the period	$	33,815	$	25,600
Investments		2,758		4,582
Balance at the end of the period	$	36,573	$	30,182

(6)

Goodwill

Changes in the carrying amount of goodwill for the three months ended September 30, 2016, and 2015 were as follows (in thousands):


	Three Months Ended September 30,
	2016		2015
Balance at the beginning of the period	$	1,059,245	$	264,261
Other adjustments, net		457		-
Foreign currency translation adjustments		3,056		(1,443	)
Balance at the end of the period	$	1,062,758	$	262,818


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

(7)	Other Intangible Assets

Other intangible assets were comprised of the following as of September 30, 2016 and June 30, 2016 (in thousands):


	September 30, 2016			June 30, 2016
Developed/core product technology	$	203,041		$	202,050
Accumulated amortization		(72,493	)		(63,825	)
Developed/core product technology, net		130,548			138,225
Trade names		48,624			47,897
Accumulated amortization		(5,733	)		(3,832	)
Trade names, net		42,891			44,065
Non-compete agreements		3,133			3,089
Accumulated amortization		(2,013	)		(1,899	)
Non compete agreements, net		1,120			1,190
Customer relationships		119,293			118,528
Accumulated amortization		(29,905	)		(26,783	)
Customer relationships, net		89,388			91,745
In-process research and development		4,100			4,100
Accumulated amortization		-			-
In-process research and development, net		4,100			4,100
Patents		78,388			74,034
Accumulated amortization		(56,762	)		(53,551	)
Patents, net		21,626			20,483
Total other intangibles, net	$	289,673		$	299,808

Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, and we amortize them over the estimated useful life of the assets, generally between two and fifteen years. There are no expected residual values related to these intangible assets. In-process research and development is amortized over the estimated useful life of the assets, once the research and development efforts are completed. At least on an annual basis, we evaluate the in-process research and development balances for impairment.

(8)	Product Warranties

Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the three months ended September 30, 2016 and 2015 are as follows (in thousands):


	Three Months Ended September 30,
	2016			2015
Balance at the beginning of the period	$	15,043		$	9,823
Warranty accruals for the period		5,243			1,790
Warranty costs incurred for the period		(2,855	)		(2,039	)
Foreign currency translation adjustments		147			(691	)
Balance at the end of the period	$	17,578		$	8,883


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

(9)

Debt

Debt at September 30, 2016 and June 30, 2016 consisted of the following (in thousands):


	September 30, 2016			June 30, 2016
Short-term debt	$	300,000		$	300,000
Deferred borrowing costs		(375	)		(562	)
Short-term debt, net		299,625			299,438
Long-term debt		875,000			875,000
Deferred borrowing costs		(1,489	)		(1,668	)
Long-term debt, net		873,511			873,332
Total debt	$	1,173,136		$	1,172,770

Credit Facility

On October 31, 2013, we entered into a revolving credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger, providing for a revolving credit facility of $700 million, with an uncommitted option to increase the revolving credit facility by an additional $300 million. On April 4, 2016, in connection with our acquisition of Brightree LLC (“Brightree”), we entered into a first amendment to the revolving credit agreement to increase the size of the revolving credit facility from $700 million to $1 billion, with an uncommitted option to increase the revolving credit facility by an additional $300 million, and to make other modifications to provide for the acquisition of Brightree. The credit facility terminates on October 31, 2018, when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At September 30, 2016, the interest rate that was being charged on the outstanding principal amount was 2.0%. A commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility. The credit facility also includes a $25 million sublimit for letters of credit.

Our obligations under the revolving credit agreement are unsecured but are guaranteed by certain of our direct and indirect U. S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree, Brightree Services LLC, Brightree Home Health & Hospice LLC and Strategic AR LLC, under an unconditional guaranty. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio.

At September 30, 2016, there was $875.0 million outstanding under the revolving credit facility.

Term Loan

On April 4, 2016, in connection with the Brightree acquisition, we also entered into a credit agreement (the “term loan credit agreement”) providing a $300 million senior unsecured one-year term loan credit facility.

Our obligations under the term loan credit agreement are unsecured but are guaranteed by certain of our direct and indirect U.S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree, Brightree Services LLC, Brightree Home Health & Hospice LLC and Strategic AR LLC, under an unconditional guaranty. The term loan credit facility terminates on April 3, 2017, when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the term loan credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At September 30, 2016, the interest rate that was being charged on the outstanding principal amount was 2.0%. The term loan credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum ratio of funded debt to EBITDA (as defined in the term loan credit agreement) and an interest coverage ratio.

The proceeds from the funding of the term loan credit facility were used to pay a portion of the acquisition consideration for the Brightree acquisition, as well as to pay fees and expenses in connection with the acquisition, the amendment to the revolving credit agreement and the term loan credit agreement.

At September 30, 2016, there was $300.0 million outstanding under the term loan credit agreement.


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

(10)	Stock-Based Employee Compensation

We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the employee stock purchase plan (the “ESPP”) using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period. The fair value of performance restricted stock units which contain a market condition, are estimated using a Monte-Carlo simulation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.

We estimate the fair value stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions:


	Three Months Ended September 30,
	2016			2015
Stock options:
Weighted average grant date fair value	$	-		$	-
Weighted average risk-free interest rate		-			-
Expected option life in years		-			-
Dividend yield		-			-
Expected volatility		-			-
ESPP purchase rights:
Weighted average grant date fair value	$	11.88		$	14.22
Weighted average risk-free interest rate		0.4	%		0.1	%
Expected option life in years		6 months			6 months
Dividend yield		2.14	%		1.73	%
Expected volatility		23	%		26	%

(11)	Stockholders’ Equity

Common Stock. Since the inception of our share repurchase programs and through September 30, 2016, we have repurchased a total of 41.1 million shares at a cost of $1.5 billion. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. We have temporarily suspended our share repurchase program due to recent acquisitions. Accordingly, we did not repurchase any shares during the three months ended September 30, 2016. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. At September 30, 2016, 13.6 million additional shares can be repurchased under the approved share repurchase program.

Preferred Stock. In April 1997, the board of directors designated 2,000,000 shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at September 30, 2016 and June 30, 2016.

Stock Options and Restricted Stock Units. We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the “2009 Plan”). The options have expiration dates of seven years from the date of grant and the options and restricted stock units vest over one to four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant.

The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 43.7 million shares. The number of securities remaining available for future issuance under the 2009 Plan at September 30, 2016 is 12.1 million. The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any “full-value award,” which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, that may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant’s initial year of hiring, when up to 4.5 million shares of our common stock may be granted).

At September 30, 2016, there were $54.4 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.1 years. The aggregate intrinsic value of the stock-based compensation arrangements outstanding and exercisable at September 30, 2016 was $161.5 million and $37.0 million, respectively. The aggregate intrinsic value of the options exercised during the three months ended September 30, 2016 and 2015, was $8.8 million and $8.9 million, respectively.


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

The following table summarizes option activity during the three months ended September 30, 2016:


			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
Outstanding at beginning of period		1,924,229	$	38.70		3.2
Granted		-		-
Exercised		(221,629)		28.44
Forfeited		-		-
Outstanding at end of period		1,702,600	$	40.04		3.2
Exercise price of granted options	$	-
Options exercisable at end of period		1,195,037	$	33.81

The following table summarizes the activity of restricted stock units during the three months ended September 30, 2016:


		Weighted Average Grant- Date Fair Value		Weighted Average Remaining Contractual Term in Years
Outstanding at beginning of period	1,861,510	$	50.52		1.4
Granted	7,539		63.68
Vested	(10,279)		45.06
Forfeited	(17,010)		50.69
Outstanding at end of period	1,841,760	$	50.62		1.1

Employee Stock Purchase Plan (the “ESPP”). Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors’ compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year. At September 30, 2016, the number of shares remaining available for future issuance under the ESPP is 1.2 million shares.


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

(12)	Fair Value Measurements

In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The hierarchies of inputs are as follows:


•	Level 1:	Input prices quoted in an active market for identical financial assets or liabilities;

•	Level 2:	Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and

•	Level 3:	Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.

The following table summarizes our financial assets and liabilities, as at September 30, 2016 and June 30, 2016, using the valuation input hierarchy (in thousands):


	Level 1		Level 2		Level 3			Total
Balances at September 30, 2016
Foreign currency hedging instruments, net	$	-	$	612	$	-		$	612
Business acquisition contingent consideration	$	-	$	-	$	(10,454	)	$	(10,454	)
Balances at June 30, 2016
Foreign currency hedging instruments, net	$	-	$	4,185	$	-		$	4,185
Business acquisition contingent consideration	$	-	$	-	$	(10,450	)	$	(10,450	)

We determine the fair value of our financial assets and liabilities as follows:


•		Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.

•		Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones. Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.

The following is a reconciliation of changes in the fair value of contingent consideration for the three months ended September 30, 2016 and 2015 (in thousands):


	Three Months Ended September 30,
	2016			2015
Balance at the beginning of the period	$	(10,450	)	$	(1,584	)
Foreign currency translation adjustments		(4	)		70
Balance at the end of the period	$	(10,454	)	$	(1,514	)

We did not have any significant non-financial assets or liabilities measured at fair value on September 30, 2016 or June 30, 2016.


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

(13)	Legal Actions and Contingencies

Litigation

In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.

Contingent Obligations Under Recourse Provisions

We use independent leasing companies to provide financing to certain customers for the purchase of our products. In some cases, and within certain limits, we are liable to the leasing companies in the event of a customer default for unpaid installment receivables transferred to the leasing companies. The gross amount of receivables sold with recourse during the three months ended September 30, 2016 and 2015, amounted to $17.3 million and $16.1 million, respectively. The maximum potential amounts of contingent liability under these arrangements at September 30, 2016 and June 30, 2016 were $14.4 million, and $12.9 million, respectively. The recourse liability recognized by us at September 30, 2016 and June 30, 2016, in relation to these arrangements was $0.8 million and $0.7 million, respectively.

(14)	Derivative Instruments and Hedging Activities

We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments.

We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income. We do not enter into financial instruments for trading or speculative purposes.

We held foreign currency instruments with notional amounts totaling $651.0 million and $612.2 million at September 30, 2016 and June 30, 2016, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to September 30, 2019.

The following table summarizes the amount and location of our derivative financial instruments as of September 30, 2016 and June 30, 2016 (in thousands):


	September 30, 2016			June 30, 2016			Balance Sheet Caption
Foreign currency hedging instruments	$	364		$	2,346			Other assets - current
Foreign currency hedging instruments		2,504			2,082			Other assets - non current
Foreign currency hedging instruments		(2,256	)		(243	)		Accrued expenses
Foreign currency hedging instruments		-			-			Other long-term liabilities
	$	612		$	4,185

The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the three months ended September 30, 2016 and 2015, respectively (in thousands):


	Gain /(Loss) Recognized						Income Statement Caption
	Three Months Ended September 30,
	2016			2015
Foreign currency hedging instruments	$	6,000		$	(39,353	)	Other, net
Other foreign-currency-denominated transactions		(5,199	)		37,081		Other, net
	$	801		$	(2,272	)

We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

(15)	Business Combinations

Brightree

On April 4, 2016 we completed the acquisition of Brightree LLC (“Brightree”), a provider of cloud-based clinical and business management software for the post-acute care industry, for a total purchase consideration paid of $804 million. This acquisition has been accounted for as a business combination using purchase accounting and included in our consolidated financial statements from April 4, 2016. The acquisition was funded through cash on-hand, funds available from our revolving credit facility and a new $300 million senior unsecured one-year term loan credit facility.

We have not completed the purchase price allocation in relation to this acquisition as certain appraisals associated with the valuation of intangible assets are not yet complete. We do not believe that the completion of this work will materially modify the preliminary purchase price allocation. We expect to complete our purchase price allocation during the quarter ending December 31, 2016. The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. The goodwill recognized as part of these acquisitions, which is deductible for tax purposes, mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future. The preliminary fair values of assets acquired and liabilities assumed, and the estimated useful lives of intangible assets acquired are as follows (in thousands):


	Brightree			Intangible assets - useful life
Current assets	$	13,868
Property, plant and equipment		1,045
Tradenames		28,700		10 years
In-process research and development		4,100		n/a
Developed technology		114,700		5 to 6 years
Customer relationships		51,000		10 to 15 years
Goodwill		604,438
Assets acquired	$	817,851

Current liabilities		(9,399	)
Deferred revenue		(4,571	)
Deferred tax liabilities		-
Total liabilities assumed	$	(13,970	)
Net assets acquired	$	803,881


PART I – FINANCIAL INFORMATION		Item 1

RESMED INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

Other Acquisitions

On October 2, 2015 we completed the acquisition of 100% of the shares in Curative Medical Technology Inc., a leading provider of non-invasive ventilation and sleep-disordered breathing medical devices and accessories in China. Curative Medical has its manufacturing base in Suzhou, China, offices in Beijing, Germany and the United States, and a distributor network throughout China and in other select markets.

On November 6, 2015 we completed the acquisition of 100% of the shares in Maribo Medico A/S, a distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders in Denmark and the Nordics.

On November 30, 2015 we completed the acquisition of 100% of the shares in Bennett Precision Tooling Pty Ltd, an Australian based company that designs and manufactures tools specializing in applications for Liquid Silicon Rubber.

On January 29, 2016 we completed the acquisition of 100% of the shares in Inova Labs Inc. (“Inova Labs”), a medical device company specializing in the development and commercialization of innovative oxygen therapy products.

These acquisitions have been accounted for as business combinations using purchase accounting and are included in our consolidated financial statements from their respective acquisition dates. The acquisitions, individually and collectively, are not considered a material business combination and accordingly pro forma information is not provided. The acquisitions were funded through cash on-hand and by drawing on our existing credit facility.

Except for the purchase price allocation associated with the Inova Labs acquisition, we have completed the purchase price allocation in relation to all these acquisitions. We expect to complete our purchase price allocation for Inova Labs during the quarter ending December 31, 2016. We do not believe that the completion of this work will materially modify the preliminary purchase price allocation for Inova Labs. The cost of the acquisitions was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. The goodwill recognized as part of these acquisitions, which is not deductible for tax purposes, mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future.

The fair values of assets acquired and liabilities assumed, and the estimated useful lives of intangible assets acquired are as follows (in thousands):


	All Other			Intangible assets - useful life
Current assets	$	51,261
Property, plant and equipment		5,294
Tradenames		17,400		7 years
Non-compete		1,400		5 years
Developed technology		20,515		5 years
Customer relationships		37,303		5 to 8 years
Goodwill		192,325
Assets acquired	$	325,498

Current liabilities		(21,147	)
Debt assumed		(21,201	)
Deferred revenue		(4,283	)
Deferred tax liabilities		(19,207	)
Total liabilities assumed	$	(65,838	)
Net assets acquired	$	259,660


PART I – FINANCIAL INFORMATION		Item 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Special Note Regarding Forward-Looking Statements

This report contains or may contain certain forward-looking statements and information that are based on the beliefs of our management as well as estimates and assumptions made by, and information currently available to, our management. All statements other than statements regarding historical facts are forward-looking statements. The words “believe,” “expect,” “intend,” “anticipate,” “will continue,” “will,” “estimate,” “plan,” “future” and other similar expressions, and negative statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding the development and approval of new products and product applications, market expansion, pending litigation, pending or consummated acquisitions and the development of new markets for our products, such as cardiovascular and stroke markets. These forward-looking statements are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements reflect the views of our management at the time the statements are made and are subject to a number of risks, uncertainties, estimates and assumptions, including, without limitation, and in addition to those identified in the text surrounding such statements, those identified in our annual report on Form 10-K for the fiscal year ended June 30, 2016 and elsewhere in this report.

In addition, important factors to consider in evaluating such forward-looking statements include changes or developments in healthcare reform, social, economic, market, legal or regulatory circumstances, changes in our business or growth strategy or an inability to execute our strategy due to changes in our industry or the economy generally, the emergence of new or growing competitors, the actions or omissions of third parties, including suppliers, customers, competitors and governmental authorities and various other factors. If any one or more of these risks or uncertainties materialize, or underlying estimates or assumptions prove incorrect, actual results may vary significantly from those expressed in our forward-looking statements, and there can be no assurance that the forward-looking statements contained in this report will in fact occur.

Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described in our annual report on Form 10-K for the fiscal year ended June 30, 2016, in addition to the other cautionary statements and risks described elsewhere in this report and in our other filings with the Securities and Exchange Commission (“SEC”), including our subsequent reports on Forms 10-Q and 8-K. These risks and uncertainties are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or uncertainties actually occurs with material adverse effects on us, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock will likely decline and you may lose all or part of your investment.


PART I – FINANCIAL INFORMATION		Item 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

The following is an overview of our results of operations for the three months ended September 30, 2016. Management’s discussion and analysis of financial condition and results of operations is intended to help the reader understand the results of operations and financial condition of ResMed Inc. Management’s discussion and analysis is provided as a supplement to, and should be read in conjunction with, the selected financial data and condensed consolidated financial statements and notes, included in this report.

We are a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders including sleep disordered breathing (“SDB”), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Our products and solutions are designed to improve patient quality of life, reduce the impact of chronic disease and lower healthcare costs as global healthcare systems continue to drive a shift in care from hospitals to the home and lower cost settings. Our cloud-based software digital health applications, along with our devices are designed to provide connected care to improve patient outcomes and efficiencies for our customers. During the three months ended September 30, 2016, we continued our efforts to build awareness of the consequences of untreated SDB, and to grow our business in this market.

Since the development of continuous positive airway pressure therapy, we have expanded our business by developing or acquiring a number of products and solutions for a broader range of respiratory disorders including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators and cloud-based software informatics solutions to manage patient outcomes and customer and provider business processes. Our growth has been fueled by geographic expansion, our research and product development efforts, acquisitions and an increasing awareness of SDB and respiratory conditions like chronic obstructive pulmonary disease as significant health concerns. During the three months ended September 30, 2016, we invested $34.4 million on research and development activities with a continued focus on the development and commercialization of new, innovative products and solutions that improve patient outcomes, create efficiencies for our customers and help physicians and providers better manage chronic disease and lower healthcare costs.

During the three months ended September 30, 2016, our net revenue increased by 13% compared to the three months ended September 30, 2015. Gross margin was 57.8% for the three months ended September 30, 2016 compared to 58.0% for the three months ended September 30, 2015. Diluted earnings per share for the three months ended September 30, 2016 was $0.54 per share, compared to $0.58 per share for the three months ended September 30, 2015.

At September 30, 2016, our cash and cash equivalents totaled $781.7 million, our total assets were $3.3 billion and our stockholders’ equity was $1.8 billion.

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis”, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.


PART I – FINANCIAL INFORMATION		Item 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Net Revenue

Net revenue for the three months ended September 30, 2016 increased to $465.4 million from $411.6 million for the three months ended September 30, 2015, an increase of $53.8 million or 13% (also a 13% increase on a constant currency basis). Net revenue for the three months ended September 30, 2016 includes revenue of $33.1 million from Brightree’s operations. Excluding revenue attributable to Brightree, net revenue for the three months ended September 30, 2016 was $432.4 million, an increase of $20.7 million or 5% compared to the three months ended September 30, 2015 (also a 5% increase on a constant currency basis). The increase in net revenue was attributable to an increase in unit sales of our devices and accessories, partially offset by a decline in average selling prices. Movements in international currencies against the U.S. dollar negatively impacted net revenues by approximately $1.6 million for the three months ended September 30, 2016.

Net revenue in North and Latin America for the three months ended September 30, 2016 increased to $301.0 million from $254.1 million for the three months ended September 30, 2015, an increase of $46.9 million or 18%. Excluding revenue attributable to Brightree, net revenue in North and Latin America increased for the three months ended September 30, 2016 to $267.9 million, an increase of $13.8 million or 5%. The increase in net revenue in North and Latin America, excluding revenue attributable to Brightree, is primarily due to an increase in unit sales of our devices and accessories, partially offset by a decline in average selling prices.

Net revenue in markets outside North and Latin America increased for the three months ended September 30, 2016 to $164.5 million from $157.5 million for the three months ended September 30, 2015, an increase of $7.0 million or 4% (a 5% increase on a constant currency basis). The constant currency increase in sales outside North and Latin America predominantly reflects an increase in unit sales of our devices, masks and accessories, partially offset by a decline in average selling prices.

Net revenue from devices for the three months ended September 30, 2016 increased to $259.2 million from $239.6 million for the three months ended September 30, 2015, an increase of $19.4 million or 8%, including an increase of 10% in North and Latin America and an increase of 6% outside North and Latin America (a 6% increase on a constant currency basis). Net revenue from masks and other accessories for the three months ended September 30, 2016 increased to $173.2 million from $172.0 million for the three months ended September 30, 2015, an increase of 1%, with revenue in North and Latin America remaining consistent with the prior year and an increase of 2% outside North and Latin America (a 4% increase on a constant currency basis). Excluding the impact of foreign currency movements, device sales for the three months ended September 30, 2016 increased by 8%, and masks and accessories sales increased by 1%, compared to the three months ended September 30, 2015.

The following table summarizes the percentage movements in our net revenue, excluding revenue attributable to Brightree, for the three months ended September 30, 2016 compared to the three months ended September 30, 2015:


	North and Latin America			Markets outside North and Latin America			Total			Markets outside North and Latin America (Constant Currency)*			Total (Constant Currency)*
Devices		10	%		6	%		8	%		6	%	8%
Masks and other accessories		0	%		2	%		1	%		4	%	1%
Total		5	%		4	%		5	%		5	%	5%

*	Constant currency numbers exclude the impact of movements in international currencies.

Gross Profit

Gross profit increased for the three months ended September 30, 2016 to $269.2 million from $238.6 million for the three months ended September 30, 2015, an increase of $30.6 million or 13%. Gross profit as a percentage of net revenue for the three months ended September 30, 2016 was 57.8%, which included a field safety notification expense of $5.1 million relating to the replacement of the potential faulty battery in our Astral ventilation device. Excluding the field safety notification expense, the gross profit as a percentage of net revenue for the three months ended September 30, 2016 was 58.9%, which was an increase from 58.0% for the three months ended September 30, 2015. The increase in gross margins was primarily due to manufacturing and procurement efficiencies and an incremental contribution from the Brightree acquisition, partly offset by an unfavorable product mix as sales of our lower margin products represented a higher proportion of our sales and declines in our average selling prices.


PART I – FINANCIAL INFORMATION		Item 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased for the three months ended September 30, 2016 to $128.9 million from $111.1 million for the three months ended September 30, 2015, an increase of $17.8 million or 16%. Selling, general and administrative expenses were unfavorably impacted by the movement of international currencies against the U.S. dollar, which increased our expenses by approximately $0.8 million, as reported in U.S. dollars. Excluding the impact of foreign currency movements, selling, general and administrative expenses for the three months ended September 30, 2016 increased by 15% compared to the three months ended September 30, 2015. Selling, general and administrative expenses, as a percentage of net revenue, were 27.7% for the three months ended September 30, 2016, compared to 27.0% for the three months ended September 30, 2015.

The constant currency increase in selling, general and administrative expenses was primarily due to additional expenses associated with the consolidation of recent acquisitions, an increase in the number of additional personnel to support our commercial activities and increased legal expenses. Excluding the incremental selling, general and administrative expenses attributed to our recent acquisitions, selling, general and administrative for the quarter increased by 6% in constant currency terms.

Research and Development Expenses

Research and development expenses increased for the three months ended September 30, 2016 to $34.4 million from $27.2 million for the three months ended September 30, 2015, an increase of $7.3 million, or 27%. Research and development expenses were unfavorably impacted by the movement of international currencies against the U.S. dollar, which increased our expenses by approximately $1.4 million for the three months ended September 30, 2016, as reported in U.S. dollars. Excluding the impact of foreign currency movements, research and development expenses increased by 21% compared to the three months ended September 30, 2015. Research and development expenses, as a percentage of net revenue, were 7.4% for the three months ended September 30, 2016, compared to 6.6% for the three months ended September 30, 2015.

The increase in research and development expenses in constant currency terms was primarily due to additional expenses associated with the consolidation of recent acquisitions, an increase in the number of research and development personnel and increases in materials and tooling costs incurred to facilitate development of new products and additional expenses associated with the consolidation of recent acquisitions. Excluding the incremental research and development expenses attributed to our recent acquisitions, research and development expenses for the quarter increased by 8% in constant currency terms.

Amortization of Acquired Intangible Assets

Amortization of acquired intangible assets for the three months ended September 30, 2016 totaled $11.7 million, compared to $2.3 million for the three months ended September 30, 2015. The increase in amortization expense was attributable to our recent acquisitions, in particular Brightree, Curative Medical and Inova Labs.

Total Other (Loss) Income, Net

Total other (loss) income, net for the three months ended September 30, 2016 was a loss of $1.2 million, compared to income of $1.4 million, for the three months ended September 30, 2015. The loss was attributable to an increase in interest expense due to higher borrowings and lower interest income resulting from lower interest rates on cash balances held which were partially offset by foreign currency hedging gains due to the appreciation of the Australian dollar against the U.S. dollar and Euro.

Income Taxes

Our effective income tax rate for the three months ended September 30, 2016 was approximately 18.1% as compared to approximately 16.6% for the three months ended September 30, 2015. Our effective income tax rate is affected by the geographic mix of our taxable income, including the lower taxes associated with our Singapore and Malaysia manufacturing operations. Our Singapore and Malaysia operations operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2020. As of September 30, 2016, we have not provided for U.S. income taxes for the undistributed earnings of our foreign subsidiaries. We intend these earnings to be permanently reinvested outside the United States.

Net Income and Earnings per Share

As a result of the factors above, our net income for the three months ended September 30, 2016 was $76.1 million compared to net income of $82.9 million for the three months ended September 30, 2015, a decrease of 8% over the three months ended September 30, 2015.

Our diluted earnings per share for the three months ended September 30, 2016 were $0.54 per diluted share, compared to $0.58 for the three months ended September 30, 2015, a decrease of 7% over the three months ended September 30, 2015.


PART I – FINANCIAL INFORMATION		Item 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Liquidity and Capital Resources

As of September 30, 2016 and June 30, 2016, we had cash and cash equivalents of $781.7 million and $731.4 million, respectively. Working capital was $854.3 million and $781.7 million, at September 30, 2016 and June 30, 2016, respectively.

As of September 30, 2016 and June 30, 2016, our cash and cash equivalent balances held within the United States amounted to $31.8 million and $40.9 million, respectively. Our remaining cash and cash equivalent balances at September 30, 2016 and June 30, 2016, of $749.9 million and $690.5 million, respectively, were held by our non-U.S. subsidiaries and would be subject to tax if repatriated. If these funds were needed for our operations in the United States, we would be required to accrue and pay United States taxes to repatriate these funds. However, we intend to permanently reinvest these funds outside of the United States and our current plans do not demonstrate a need to repatriate them to fund our United States operations. Our cash and cash equivalent balances are held at highly rated financial institutions.

Inventories at September 30, 2016 were $253.8 million, an increase of $29.4 million or 13% from the June 30, 2016 balance of $224.5 million. The increase in inventories was mainly to support the increase in unit sales.

Accounts receivable at September 30, 2016 were $347.1 million, a decrease of $34.9 million or 9% compared to the June 30, 2016 balance of $382.1 million. Accounts receivable days outstanding of 66 days at September 30, 2016 were higher than the 63 days at June 30, 2016. Our allowance for doubtful accounts as a percentage of total accounts receivable at September 30, 2016 was 3.2%, compared to 3.2% at June 30, 2016.

During the three months ended September 30, 2016, we generated cash of $86.2 million from operations compared to $124.6 million for the three months ended September 30, 2015. The lower level of cash generated from operations during the three months ended September 30, 2016, was primarily driven by the increase in our inventories and the timing of our corporate income tax payments. Movements in foreign currency exchange rates during the three months ended September 30, 2016 had the effect of increasing our cash and cash equivalents by $17.2 million, as reported in U.S. dollars. We have temporarily suspended our share repurchase program due to recent acquisitions. As a result, we did not repurchase any shares during the three months ended September 30, 2016. During the three months ended September 30, 2016 and 2015, we also paid dividends totaling $46.4 million and $42.1 million, respectively.

Capital expenditures for the three months ended September 30, 2016 and 2015 amounted to $14.6 million and $16.4 million, respectively. The capital expenditures for the three months ended September 30, 2016 primarily reflected investment in computer hardware and software, production tooling, equipment and machinery, and rental and loan equipment. At September 30, 2016, our balance sheet reflects net property, plant and equipment of $390.8 million compared to $384.3 million at June 30, 2016.

Details of contractual obligations at September 30, 2016 are as follows:


			Payments Due by September 30,
In $000’s	Total		2017		2018		2019		2020		2021		Thereafter
Short-term debt	$	300,000	$	300,000	$	-	$	-	$	-	$	-	$	-
Interest on Short-Term Debt		3,095		3,095		-		-		-		-		-
Long Term Debt		875,000		-		-		875,000		-		-		-
Interest on Long Term Debt		37,419		17,963		17,963		1,493		-		-		-
Operating Leases		62,126		18,776		15,026		9,046		5,097		4,001		10,180
Capital Leases		791		338		256		86		111		-		-
Purchase Obligations		169,300		169,300		-		-		-		-		-
Total	$	1,447,731	$	509,472	$	33,245	$	885,625	$	5,208	$	4,001	$	10,180

Details of other commercial commitments at September 30, 2016 are as follows:
			Amount of Commitment Expiration Per Period
In $000’s	Total		2017		2018		2019		2020		2021		Thereafter
Standby Letter of Credit	$	15,421	$	3,793	$	6,890	$	-	$	-	$	-	$	4,738
Guarantees*		14,700		700		-		-		65		142		13,793
Total	$	30,121	$	4,493	$	6,890	$	-	$	65	$	142	$	18,531

*	The above guarantees mainly relate to requirements under contractual obligations with insurance companies transacting with our German subsidiaries and guarantees provided under our facility leasing obligations.


PART I – FINANCIAL INFORMATION		Item 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Credit Facility

Our obligations under the revolving credit agreement (as amended) are unsecured but are guaranteed by certain of our direct and indirect U. S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree, Brightree Services LLC, Brightree Home Health & Hospice LLC and Strategic AR LLC, under an unconditional guaranty. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio.

At September 30, 2016, we were in compliance with the debt covenants under the revolving credit agreement and there was $875.0 million outstanding under the revolving credit facility.

Term Loan

At September 30, 2016, we were in compliance with the debt covenants under the term loan credit agreement and there was $300.0 million outstanding under the term loan credit agreement. We plan to refinance the facility prior to the maturity date of the term loan agreement, based on our funding needs at that time.

We expect to satisfy all of our liquidity requirements through a combination of cash on hand, cash generated from operations and debt facilities.

Common Stock

We have temporarily suspended our share repurchase program due to recent acquisitions. Accordingly, we did not repurchase any shares during the three months ended September 30, 2016. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. During the three months ended September 30, 2015, we repurchased 1.2 million shares at a cost of $62.0 million.

As of September 30, 2016, we have repurchased a total of 41.1 million shares at a cost of $1.5 billion. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. At September 30, 2016, 13.6 million additional shares can be repurchased under the current share repurchase program.


PART I – FINANCIAL INFORMATION		Item 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Critical Accounting Principles and Estimates

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, goodwill, potentially impaired assets, intangible assets, income taxes and contingencies.

We state these accounting policies in the notes to the financial statements and at relevant sections in this discussion and analysis. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.

For a full discussion of our critical accounting policies, see our Annual Report on Form 10-K for the year ended June 30, 2016.

Recently Issued Accounting Pronouncements

See note 1 to the condensed consolidated financial statements for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial positions and cash flows.

Off-Balance Sheet Arrangements

As of September 30, 2016, we are not involved in any significant off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC.


PART I – FINANCIAL INFORMATION		Item 3

RESMED INC. AND SUBSIDIARIES

Quantitative and Qualitative Disclosures About Market Risk

Foreign Currency Market Risk

Our reporting currency is the U.S. dollar, although the financial statements of our non-U.S. subsidiaries are maintained in their respective local currencies. We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollar. We have significant foreign currency exposure through our Australian and Singapore manufacturing activities and our international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures predominantly denominated in euros, Australian dollars and Singapore dollars. Under this program, increases or decreases in our foreign-currency-denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not enter into financial instruments for trading or speculative purposes. The foreign currency derivatives portfolio is recorded in the condensed consolidated balance sheets at fair value and included in other assets or other liabilities. All movements in the fair value of the foreign currency derivatives are recorded within other income, net, on our condensed consolidated statements of income.

The table below provides information (in U.S. dollars) on our significant foreign-currency-denominated balances by legal entity functional currency as of September 30, 2016 (in thousands):


	Australian Dollar (AUD)			U.S. Dollar (USD)			Euro (EUR)			Canadian Dollar (CAD)			Great Britain Pound (GBP)			Chinese Yuan (CNY)
AUD Functional:
Assets		-			274,166			169,109			-			-			8,641
Liabilities		-			(36,135	)		(86,196	)		(753	)		(10,235	)		(264	)
Forward Contracts		-			(242,000	)		(77,510	)		-			10,372			(4,496	)
Net Total		-			(3,969	)		5,403			(753	)		137			3,881
USD Functional:
Assets		-			-			12			13,947			4,235			-
Liability		(4,547	)		-			(70	)		(1,467	)		(5,980	)		-
Forward Contracts		-			-			-			(11,435	)		-			-
Net Total		(4,547	)		-			(58	)		1,045			(1,745	)		-
EURO Functional:
Assets		3,222			911			-			-			3,006			-
Liability		(2	)		(3,002	)		-			-			(30	)		-
Forward Contracts		-			-			-			-			(3,890	)		-
Net Total		3,220			(2,091	)		-			-			(914	)		-
GBP Functional:
Assets		-			847			82,750			-			-			-
Liability		-			(440	)		(80,867	)		-			-			-
Forward Contracts		-			-			-			-			-			-
Net Total		-			407			1,883			-			-			-
SGD Functional :
Assets		888			236,745			69,892			-			-			343
Liability		(2,576	)		(82,369	)		(34,057	)		-			-			(742	)
Forward Contracts		-			(153,000	)		(35,947	)		-			-			-
Net Total		(1,688	)		1,376			(112	)		-			-			(399	)


PART I – FINANCIAL INFORMATION		Item 3

RESMED INC. AND SUBSIDIARIES

Quantitative and Qualitative Disclosures About Market Risk

The table below provides information about our foreign currency derivative financial instruments and presents the information in U.S. dollar equivalents. The table summarizes information on instruments and transactions that are sensitive to foreign currency exchange rates, including foreign currency call options, collars and forward contracts held at September 30, 2016. The table presents the notional amounts and weighted average exchange rates by contractual maturity dates for our foreign currency derivative financial instruments, including the forward contracts used to hedge our foreign currency denominated assets and liabilities. These notional amounts generally are used to calculate payments to be exchanged under the contracts (in thousands, except exchange rates).


									Fair Value Assets / (Liabilities)
Foreign Exchange Contracts	Year 1		Year 2		Year 3		Total		September 30, 2016		June 30, 2016
Receive AUD/Pay USD
Contract amount		242,000		-		-		242,000		(1,386)		1,262
Ave. contractual exchange rate		AUD 1 = USD 0.7669						AUD 1 = USD 0.7669
Receive AUD/Pay Euro
Contract amount		122,440		44,930		22,470		189,840		2,284		2,325
Ave. contractual exchange rate		AUD 1 = Euro 0.6914		AUD 1 = Euro 0.6700		AUD 1 = Euro 0.6643		AUD 1 = Euro 0.6830
Receive SGD/Pay Euro
Contract amount		35,947		-		-		35,947		(157)		35
Ave. contractual exchange rate		SGD 1 = Euro 0.6518						SGD 1 = Euro 0.6518
Receive SGD/Pay USD
Contract amount		153,000		-		-		153,000		(312)		792
Ave. contractual exchange rate		SGD 1 = USD 0.7356						SGD 1 = USD 0.7356
Receive GBP/Pay AUD
Contract amount		10,372		-		-		10,372		10		(120)
Ave. contractual exchange rate		AUD 1 = GBP 0.5855						AUD 1 = GBP 0.5855
Receive EUR/Pay GBP
Contract amount		3,890		-		-		3,890		-		11
Ave. contractual exchange rate		EUR 1 = GBP 0.8664						EUR 1 = GBP 0.8664
Receive AUD/Pay CNY
Contract amount		4,496		-		-		4,496		94		(24)
Ave. contractual exchange rate		AUD 1 = CNY 5.0030						AUD 1 = CNY 5.0030
Receive USD/Pay CAD
Contract amount		11,435		-		-		11,435		79		(96)
Ave. contractual exchange rate		USD 1 = CAD 1.3028						USD 1 = CAD 1.3028

Interest Rate Risk

We are exposed to risk associated with changes in interest rates affecting the return on our cash and cash equivalents and debt. At September 30, 2016, we held cash and cash equivalents of $781.7 million principally comprised of bank term deposits and at-call accounts and are invested at both short-term fixed interest rates and variable interest rates. At September 30, 2016, we had total borrowings of $1,175.0 million, comprising a revolving credit balance of $875.0 million and a term loan credit balance of $300.0 million, which are subject to variable interest rates. A hypothetical 10% change in interest rates during the three months ended September 30, 2016, would not have had a material impact on pretax income. We have no interest rate hedging agreements.


PART I – FINANCIAL INFORMATION		Item 4

RESMED INC. AND SUBSIDIARIES

Controls and Procedures

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports made pursuant to the Securities Exchange Act of 1934, as amended (the Exchange Act), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2016.

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.


PART II – OTHER INFORMATION		Item 1-6

RESMED INC. AND SUBSIDIARIES

Item 1

Legal Proceedings

We are involved in various legal proceedings and claims. Litigation is inherently uncertain. Accordingly, we cannot predict the outcome of these matters. But we do not expect the outcome of these matters to have a material adverse effect on our consolidated financial statements when taken as a whole.

BMC and 3B litigation. ResMed is engaged in disputes with Chinese manufacturer BMC Medical Co., Ltd and its US distributor, 3B Medical, Inc. in several global forums. In 2013, we filed actions in the US and Germany against BMC and 3B to stop the infringement of several ResMed patents. In 2014, the US International Trade Commission ruled that certain BMC masks infringed ResMed’s patents and should be excluded from importation or sale in the US. BMC appealed the Commission’s ruling. At the request of the ITC and ResMed, the appeals court remanded the case to the Commission. The Commission has suspended the exclusion order during the pendency of the remand. A companion case in the US District Court for the Southern District of California remains stayed pending a final decision in the International Trade Commission proceedings.

In 2013, we initiated proceedings in Germany against BMC involving certain devices and mask assemblies we accused of patent infringement. In April 2016, ResMed and BMC settled the case against BMC’s infringing mask assemblies when BMC agreed not to sell infringing products in Germany. In May 2016, ResMed settled its infringement action against BMC’s flow generators in Germany. Additional infringement proceedings against BMC flow generators are currently stayed while a validity decision on the same patent is on appeal.

In 2015, BMC’s U.S. distributor, 3B Medical, Inc., filed suit in the US District Court for the Middle District of Florida against ResMed Inc. and ResMed Corp. for alleged federal and state antitrust violations. 3B subsequently named three ResMed customers as additional defendants. 3B alleges that in addition to enforcing its patents, ResMed has entered into exclusive dealing arrangements with customers, tied sales of masks to sales of devices, and spread false information about 3B. 3B seeks treble damages and an injunction.

In February 2016, BMC filed patent infringement suits in Shanghai, China against ResMed’s distribution subsidiary in China. BMC asserts that ResMed’s S9 devices infringe two BMC patents. ResMed has filed petitions to invalidate the BMC patents in the China Patent Review Board, and is defending the infringement proceedings in court. These proceedings are pending.

In May 2016, the International Trade Commission initiated a second investigation of patent infringement by BMC and 3B, based on alleged infringement of ResMed patents by BMC’s RESmart and Luna flow generators. A companion case in the US District Court for the Southern District of California remains stayed pending a final decision in the International Trade Commission proceedings.

Administrative subpoena. In July 2016, we received a federal administrative subpoena from the Office of Inspector General (“OIG”) of the Department of Health and Human Services. The subpoena contains a request for documents and other materials that relate primarily to industry offerings of patient resupply software to home medical equipment providers. We are cooperating with the OIG to respond to its requests for documents and information.

Fisher & Paykel Healthcare patent litigation. ResMed and Fisher & Paykel Healthcare are engaged in patent disputes in several global forums.

In August 2016, Fisher & Paykel HealthCare, or FPH, sued ResMed for patent infringement in US District Court for the Southern District of California, accusing ResMed’s Air 10 flow generators, ClimateLine heated tubing, and the Swift FX and Swift LT masks of infringing FPH’s patents. ResMed denied infringement, has asserted that the patents are invalid, and filed counterclaims for patent infringement against FPH’s Simplus, Eson and Eson 2 masks. In August 2016, ResMed requested, and the US International Trade Commission later instituted, an investigation of patent infringement against the same FPH masks.

Related court cases are now pending in New Zealand, Germany, and the United Kingdom. In August, the Munich district court issued preliminary injunctions temporarily prohibiting sales of FPH’s Simplus, Eson and Eson 2 masks in Germany.

Both ResMed and FPH have also filed proceedings in patent offices in the United States, Germany and Europe to invalidate many of the patents being asserted against the other party.


PART II – OTHER INFORMATION		Item 1-6

RESMED INC. AND SUBSIDIARIES

Item 1A

Risk Factors

The discussion of our business and operations should be read together with the risk factors contained in our annual report on Form 10-K for the fiscal year ended June 30, 2016 which was filed with the SEC and describe the various risks and uncertainties to which we are or may become subject. As of September 30, 2016, there have been no further material changes to such risk factors.

Item 2

Unregistered Sales of Equity Securities and Use of Proceeds

Purchases of equity securities. On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program.

We have temporarily suspended our share repurchase program due to recent acquisitions. As a result, we did not repurchase any shares during the three months ended September 30, 2016. However, there is no expiration date for this program, and we may, at any time, elect to resume the share repurchase program as the circumstances allow. Since the inception of the share buyback programs, we have repurchased 41.1 million shares at a total cost of $1.5 billion.

Item 3

Defaults Upon Senior Securities

None

Item 4

Mine Safety Disclosures

None

Item 5

Other Information

None


PART II – OTHER INFORMATION		Item 1-6

RESMED INC. AND SUBSIDIARIES

Item 6

Exhibits

Exhibits (numbered in accordance with Item 601 of Regulation S-K)



3.1		First Restated Certificate of Incorporation of ResMed Inc., as amended. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Report on Form 10-Q for the quarter ended September 30, 2013)

3.2		Fifth Amended and Restated Bylaws of ResMed Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K/A filed on September 17, 2012)

31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following financial statements from ResMed Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed on October 27, 2016, formatted in XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Income, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Cash Flows, (v) the Notes to the Condensed Consolidated Financial Statements.


PART II – OTHER INFORMATION		Signatures

Signatures

We have authorized the persons whose signatures appear below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

October 27, 2016

ResMed Inc.

/s/ MICHAEL J. FARRELL

Michael J. Farrell

Chief executive officer

(Principal Executive Officer)

/s/ BRETT A. SANDERCOCK

Brett A. Sandercock

Chief financial officer

(Principal Financial Officer)

EX-31.1 2 d265875dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

RESMED INC. AND SUBSIDIARIES

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Michael J. Farrell, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of ResMed Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

October 27, 2016

/s/ MICHAEL J. FARRELL

Michael J. Farrell

Chief executive officer

(Principal Executive Officer)

EX-31.2 3 d265875dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

RESMED INC. AND SUBSIDIARIES

CERTIFICATION OF CHIEF FINANCIAL OFFICER

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Brett A. Sandercock, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of ResMed Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

October 27, 2016

/s/ BRETT A. SANDERCOCK

Brett A. Sandercock

Chief financial officer

(Principal Financial Officer)

EX-32 4 d265875dex32.htm EX-32 EX-32

Exhibit 32

RESMED INC. AND SUBSIDIARIES

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of ResMed Inc., a Delaware corporation (the “Company”), hereby certifies, to his knowledge, that:

(i)	the accompanying Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

October 27, 2016

/s/ MICHAEL J. FARRELL

Michael J. Farrell

Chief executive officer

(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to ResMed Inc. and will be retained by ResMed Inc. and furnished to the Securities and Exchange Commission or its staff upon request. These certifications will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor will these certifications be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates them by reference.

RESMED INC. AND SUBSIDIARIES

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(i)	the accompanying Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

October 27, 2016

/s/ BRETT A. SANDERCOCK

Brett A. Sandercock

Chief financial officer

(Principal Financial Officer)

EX-101.INS 5 rmd-20160930.xml XBRL INSTANCE DOCUMENT 0000943819 2015-07-01 2016-06-30 0000943819 rmd:EmployeeStockPurchasePlanMember 2016-09-30 0000943819 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0000943819 rmd:EmployeeStockPurchasePlanPurchaseRightsMember 2016-07-01 2016-09-30 0000943819 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0000943819 rmd:EmployeeStockPurchasePlanPurchaseRightsMember 2015-07-01 2015-09-30 0000943819 rmd:ResmedInc2009IncentiveAwardPlanMember 2016-07-01 2016-09-30 0000943819 us-gaap:RestrictedStockUnitsRSUMember 2015-07-01 2016-06-30 0000943819 us-gaap:RestrictedStockUnitsRSUMember 2016-09-30 0000943819 us-gaap:RestrictedStockUnitsRSUMember 2016-06-30 0000943819 us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2016-09-30 0000943819 rmd:ResmedInc2009IncentiveAwardPlanMember us-gaap:MinimumMember 2016-07-01 2016-09-30 0000943819 rmd:ResmedInc2009IncentiveAwardPlanMember us-gaap:MaximumMember 2016-07-01 2016-09-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember 2016-07-01 2016-09-30 0000943819 us-gaap:VehiclesMember 2016-09-30 0000943819 us-gaap:MachineryAndEquipmentMember 2016-09-30 0000943819 us-gaap:LeaseholdImprovementsMember 2016-09-30 0000943819 us-gaap:LandMember 2016-09-30 0000943819 us-gaap:FurnitureAndFixturesMember 2016-09-30 0000943819 us-gaap:ComputerEquipmentMember 2016-09-30 0000943819 us-gaap:BuildingMember 2016-09-30 0000943819 rmd:ClinicalDemonstrationAndRentalEquipmentMember 2016-09-30 0000943819 us-gaap:VehiclesMember 2016-06-30 0000943819 us-gaap:MachineryAndEquipmentMember 2016-06-30 0000943819 us-gaap:LeaseholdImprovementsMember 2016-06-30 0000943819 us-gaap:LandMember 2016-06-30 0000943819 us-gaap:FurnitureAndFixturesMember 2016-06-30 0000943819 us-gaap:ComputerEquipmentMember 2016-06-30 0000943819 us-gaap:BuildingMember 2016-06-30 0000943819 rmd:ClinicalDemonstrationAndRentalEquipmentMember 2016-06-30 0000943819 us-gaap:SeriesAPreferredStockMember 2016-09-30 0000943819 us-gaap:SeriesAPreferredStockMember 2016-06-30 0000943819 us-gaap:SeriesAPreferredStockMember 1997-04-30 0000943819 us-gaap:GuaranteeOfIndebtednessOfOthersMember 2016-09-30 0000943819 us-gaap:GuaranteeOfIndebtednessOfOthersMember 2016-06-30 0000943819 rmd:BrightreeLlcMember us-gaap:RevolvingCreditFacilityMember rmd:UnionBankNAndHsbcBankUsaMember 2016-04-04 0000943819 rmd:BrightreeLlcMember rmd:TermLoanCreditAgreementMember 2016-04-04 0000943819 us-gaap:RevolvingCreditFacilityMember rmd:UnionBankNAndHsbcBankUsaMember 2016-04-03 0000943819 us-gaap:LetterOfCreditMember rmd:UnionBankNAndHsbcBankUsaMember 2013-10-31 0000943819 us-gaap:RevolvingCreditFacilityMember rmd:UnionBankNAndHsbcBankUsaMember 2016-07-01 2016-09-30 0000943819 rmd:BrightreeLlcMember rmd:TermLoanCreditAgreementMember 2016-07-01 2016-09-30 0000943819 rmd:UnionBankNAndHsbcBankUsaMember us-gaap:MinimumMember 2016-07-01 2016-09-30 0000943819 rmd:UnionBankNAndHsbcBankUsaMember us-gaap:MaximumMember 2016-07-01 2016-09-30 0000943819 rmd:BrightreeLlcMember 2015-07-01 2016-06-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember 2015-07-01 2016-06-30 0000943819 us-gaap:NondesignatedMember 2016-07-01 2016-09-30 0000943819 us-gaap:NondesignatedMember 2015-07-01 2015-09-30 0000943819 us-gaap:MinimumMember 2016-07-01 2016-09-30 0000943819 us-gaap:MaximumMember 2016-07-01 2016-09-30 0000943819 us-gaap:InProcessResearchAndDevelopmentMember 2016-09-30 0000943819 us-gaap:InProcessResearchAndDevelopmentMember 2016-06-30 0000943819 us-gaap:TradeNamesMember 2016-09-30 0000943819 us-gaap:PatentsMember 2016-09-30 0000943819 us-gaap:CustomerRelationshipsMember 2016-09-30 0000943819 rmd:IntangiblesAndNonCompeteAgreementsMember 2016-09-30 0000943819 rmd:DevelopedOrCoreProductTechnologyMember 2016-09-30 0000943819 us-gaap:TradeNamesMember 2016-06-30 0000943819 us-gaap:PatentsMember 2016-06-30 0000943819 us-gaap:CustomerRelationshipsMember 2016-06-30 0000943819 rmd:IntangiblesAndNonCompeteAgreementsMember 2016-06-30 0000943819 rmd:DevelopedOrCoreProductTechnologyMember 2016-06-30 0000943819 rmd:AccountingStandardsUpdate201609Member 2016-07-01 2016-09-30 0000943819 rmd:AccountingStandardsUpdate201609Member 2015-07-01 2015-09-30 0000943819 us-gaap:ForeignExchangeContractMember 2016-07-01 2016-09-30 0000943819 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember rmd:OtherIncomeExpenseNetMember 2016-07-01 2016-09-30 0000943819 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember rmd:OtherIncomeExpenseNetMember 2015-07-01 2015-09-30 0000943819 us-gaap:ForeignExchangeContractMember 2016-09-30 0000943819 us-gaap:ForeignExchangeContractMember 2016-06-30 0000943819 rmd:AccruedExpensesMember us-gaap:ForeignExchangeContractMember 2016-09-30 0000943819 rmd:AccruedExpensesMember us-gaap:ForeignExchangeContractMember 2016-06-30 0000943819 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember 2016-09-30 0000943819 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2016-09-30 0000943819 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember 2016-06-30 0000943819 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2016-06-30 0000943819 us-gaap:AccountingStandardsUpdate201503Member 2016-06-30 0000943819 rmd:BrightreeLlcMember rmd:TermLoanCreditAgreementMember 2016-04-04 2016-04-04 0000943819 us-gaap:RevolvingCreditFacilityMember rmd:UnionBankNAndHsbcBankUsaMember 2016-09-30 0000943819 rmd:BrightreeLlcMember rmd:TermLoanCreditAgreementMember 2016-09-30 0000943819 rmd:BrightreeLlcMember rmd:TermLoanCreditAgreementMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-07-01 2016-09-30 0000943819 rmd:BrightreeLlcMember rmd:TermLoanCreditAgreementMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-07-01 2016-09-30 0000943819 rmd:UnionBankNAndHsbcBankUsaMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-07-01 2016-09-30 0000943819 rmd:UnionBankNAndHsbcBankUsaMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-07-01 2016-09-30 0000943819 rmd:EmployeeStockPurchasePlanMember us-gaap:MaximumMember 2016-09-30 0000943819 2015-09-30 0000943819 2015-06-30 0000943819 rmd:BrightreeLlcMember us-gaap:TradeNamesMember 2016-06-30 0000943819 rmd:BrightreeLlcMember us-gaap:InProcessResearchAndDevelopmentMember 2016-06-30 0000943819 rmd:BrightreeLlcMember us-gaap:DevelopedTechnologyRightsMember 2016-06-30 0000943819 rmd:BrightreeLlcMember us-gaap:CustomerRelationshipsMember 2016-06-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember us-gaap:TradeNamesMember 2016-06-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember us-gaap:NoncompeteAgreementsMember 2016-06-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember us-gaap:DevelopedTechnologyRightsMember 2016-06-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember us-gaap:CustomerRelationshipsMember 2016-06-30 0000943819 rmd:BrightreeLlcMember 2016-06-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember 2016-06-30 0000943819 us-gaap:FairValueInputsLevel3Member 2016-09-30 0000943819 us-gaap:FairValueInputsLevel2Member 2016-09-30 0000943819 us-gaap:FairValueInputsLevel1Member 2016-09-30 0000943819 us-gaap:FairValueInputsLevel3Member 2016-06-30 0000943819 us-gaap:FairValueInputsLevel2Member 2016-06-30 0000943819 us-gaap:FairValueInputsLevel1Member 2016-06-30 0000943819 rmd:BrightreeLlcMember 2016-04-04 2016-04-04 0000943819 rmd:MariboMedicoSMember 2016-09-30 0000943819 rmd:InovaLabsMember 2016-09-30 0000943819 rmd:CurativeMedicalTechnologyIncMember 2016-09-30 0000943819 rmd:BennettPrecisionToolingPtyLtdMember 2016-09-30 0000943819 rmd:MariboMedicoSMember 2016-07-01 2016-09-30 0000943819 rmd:InovaLabsMember 2016-07-01 2016-09-30 0000943819 rmd:CurativeMedicalTechnologyIncMember 2016-07-01 2016-09-30 0000943819 rmd:BrightreeLlcMember 2016-07-01 2016-09-30 0000943819 rmd:BennettPrecisionToolingPtyLtdMember 2016-07-01 2016-09-30 0000943819 rmd:BrightreeLlcMember us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2015-07-01 2016-06-30 0000943819 rmd:BrightreeLlcMember us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2015-07-01 2016-06-30 0000943819 rmd:BrightreeLlcMember us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2015-07-01 2016-06-30 0000943819 rmd:BrightreeLlcMember us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2015-07-01 2016-06-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2015-07-01 2016-06-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2015-07-01 2016-06-30 0000943819 rmd:BrightreeLlcMember us-gaap:TradeNamesMember 2015-07-01 2016-06-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember us-gaap:TradeNamesMember 2015-07-01 2016-06-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember us-gaap:NoncompeteAgreementsMember 2015-07-01 2016-06-30 0000943819 rmd:AllOtherBusinessesAcquisitionMember us-gaap:DevelopedTechnologyRightsMember 2015-07-01 2016-06-30 0000943819 rmd:BrightreeLlcMember us-gaap:RevolvingCreditFacilityMember rmd:UnionBankNAndHsbcBankUsaMember 2016-04-04 2016-04-04 0000943819 2016-09-30 0000943819 2016-06-30 0000943819 us-gaap:GuaranteeOfIndebtednessOfOthersMember 2016-07-01 2016-09-30 0000943819 us-gaap:GuaranteeOfIndebtednessOfOthersMember 2015-07-01 2015-09-30 0000943819 rmd:EmployeeStockPurchasePlanMember 2016-07-01 2016-09-30 0000943819 rmd:ResmedInc2009IncentiveAwardPlanMember 2016-09-30 0000943819 rmd:OtherForeignCurrencyDenominatedTransactionsMember us-gaap:NondesignatedMember rmd:OtherIncomeExpenseNetMember 2016-07-01 2016-09-30 0000943819 rmd:OtherForeignCurrencyDenominatedTransactionsMember us-gaap:NondesignatedMember rmd:OtherIncomeExpenseNetMember 2015-07-01 2015-09-30 0000943819 rmd:EmployeeStockPurchasePlanMember us-gaap:MinimumMember 2016-07-01 2016-09-30 0000943819 rmd:EmployeeStockPurchasePlanMember us-gaap:MaximumMember 2016-07-01 2016-09-30 0000943819 2015-07-01 2015-09-30 0000943819 2016-10-20 0000943819 2016-07-01 2016-09-30 iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares false --06-30 Q1 2017 2016-09-30 10-Q 0000943819 140965500 Large Accelerated Filer RESMED INC rmd 2307000 11741000 -70000 4000 P27M P3M 37081000 -5199000 3000000 4500000 <div> <div style="margin-left:0pt;margin-right:0pt;"> Organization and Basis of Presentation <p style="margin:0pt 0pt 0pt 26.95pt;line-height:50%;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> <p style="margin:0pt 0pt 0pt 26.95pt;text-indent:0.05pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group.  Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea.  Our manufacturing operations are located in Australia, Singapore, France, Malaysia and the United States.  Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. <p style="margin:0pt 0pt 0pt 26.95pt;line-height:50%;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> <p style="margin:0pt 0pt 0pt 26.95pt;text-indent:0.05pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods.  The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2017. <p style="margin:0pt 0pt 0pt 26.95pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt"> The condensed consolidated financial statements for the three months ended September 30, 2016 and 2015 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2016. </div> </div> 0.85 0.85 16100000 17300000 2.8 300000000 300000000 300000000

92571000

80489000

382086000

347137000

39166000

38807000

156805000

153969000

414426000

427424000

-222658000

-192935000

P5Y

P7Y

P10Y

P8Y

P5Y

P15Y

P10Y

P6Y

P5Y

1303238000

1321522000

12555000

11293000

98697

264672

3256705000

3322264000

1419719000

1474852000

1836986000

1847412000

2015-11-30

2016-04-04

2015-10-02

2016-01-29

2015-11-06

1.00

804000000

10450000

10454000

<div> <div style="margin-left:0pt;margin-right:0pt;"> (15)    Business Combinations Brightree On April 4, 2016 we completed the acquisition of Brightree LLC (“Brightree”), a provider of cloud-based clinical and business management software for the post-acute care industry, for a total purchase consideration paid of $804 million.  This acquisition has been accounted for as a business combination using purchase accounting and included in our consolidated financial statements from April 4, 2016.  The acquisition was funded through cash on-hand, funds available from our revolving credit facility and a new $300 million senior unsecured one-year term loan credit facility. We have not completed the purchase price allocation in relation to this acquisition as certain appraisals associated with the valuation of intangible assets are not yet complete.  We do not believe that the completion of this work will materially modify the preliminary purchase price allocation.  We expect to complete our purchase price allocation during the quarter ending December 31, 2016.  The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. The goodwill recognized as part of these acquisitions, which is deductible for tax purposes, mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future. The preliminary fair values of assets acquired and liabilities assumed, and the estimated useful lives of intangible assets acquired are as follows (in thousands): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="bottom" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="bottom" style="width:49.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Brightree </td> <td valign="middle" style="width:25.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Intangible assets - useful life </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Current assets </td> <td valign="middle" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"> $ </td> <td valign="middle" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">13,868  </td> <td valign="middle" style="width:25.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Property, plant and equipment </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,045  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Tradenames </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">28,700  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> 10 years </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> In-process research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,100  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> n/a </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Developed technology </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">114,700  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> 5 to 6 years </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Customer relationships </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">51,000  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> 10 to 15 years </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">604,438  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Assets acquired </td> <td valign="middle" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"> $ </td> <td valign="middle" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">817,851  </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Current liabilities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(9,399) </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Deferred revenue </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(4,571) </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Deferred tax liabilities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">  - </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Total liabilities assumed </td> <td valign="middle" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"> $ </td> <td valign="middle" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(13,970) </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Net assets acquired </td> <td valign="middle" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"> $ </td> <td valign="middle" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">803,881  </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> </table></div> Other Acquisitions On October 2, 2015 we completed the acquisition of 100% of the shares in Curative Medical Technology Inc., a leading provider of non-invasive ventilation and sleep-disordered breathing medical devices and accessories in China.  Curative Medical has its manufacturing base in Suzhou, China, offices in Beijing, Germany and the United States, and a distributor network throughout China and in other select markets.  On November 6, 2015 we completed the acquisition of 100% of the shares in Maribo Medico A/S, a distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders in Denmark and the Nordics. On November 30, 2015 we completed the acquisition of 100% of the shares in Bennett Precision Tooling Pty Ltd, an Australian based company that designs and manufactures tools specializing in applications for Liquid Silicon Rubber. On January 29, 2016 we completed the acquisition of 100% of the shares in Inova Labs Inc. (“Inova Labs”), a medical device company specializing in the development and commercialization of innovative oxygen therapy products. These acquisitions have been accounted for as business combinations using purchase accounting and are included in our consolidated financial statements from their respective acquisition dates. The acquisitions, individually and collectively, are not considered a material business combination and accordingly pro forma information is not provided.  The acquisitions were funded through cash on-hand and by drawing on our existing credit facility.  Except for the purchase price allocation associated with the Inova Labs acquisition, we have completed the purchase price allocation in relation to all these acquisitions. We expect to complete our purchase price allocation for Inova Labs during the quarter ending December 31, 2016.  We do not believe that the completion of this work will materially modify the preliminary purchase price allocation for Inova Labs. The cost of the acquisitions was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. The goodwill recognized as part of these acquisitions, which is not deductible for tax purposes, mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future. The fair values of assets acquired and liabilities assumed, and the estimated useful lives of intangible assets acquired are as follows (in thousands): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="bottom" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="bottom" style="width:49.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> All Other </td> <td valign="middle" style="width:25.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Intangible assets - useful life </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Current assets </td> <td valign="middle" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"> $ </td> <td valign="middle" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">51,261  </td> <td valign="middle" style="width:25.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Property, plant and equipment </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">5,294  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Tradenames </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">17,400  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> 7 years </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Non-compete </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,400  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> 5 years </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Developed technology </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">20,515  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> 5 years </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Customer relationships </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">37,303  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> 5 to 8 years </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">192,325  </td> <td valign="middle" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Assets acquired </td> <td valign="middle" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"> $ </td> <td valign="middle" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">325,498  </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Current liabilities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(21,147) </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Debt assumed </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(21,201) </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Deferred revenue </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(4,283) </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Deferred tax liabilities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> <td valign="middle" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(19,207) </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Total liabilities assumed </td> <td valign="middle" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"> $ </td> <td valign="middle" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(65,838) </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> </td> <td valign="middle" style="width:49.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;"> Net assets acquired </td> <td valign="middle" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"> $ </td> <td valign="middle" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">259,660  </td> <td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.00pt;padding:0pt;">   </td> </tr> </table></div> </div> </div>

325498000

817851000

51261000

13868000

21147000

9399000

4283000

4571000

19207000

21201000

37303000

20515000

1400000

17400000

51000000

114700000

4100000

28700000

65838000

13970000

259660000

803881000

5294000

1045000

717249000

822053000

731434000

781658000

104804000

50224000

0.30

0.33

0.004

350000000

181747157

181974343

140660923

140888109

25000

563000

564000

-39191000

105830000

25600000

30182000

33815000

36573000

<div> <div style="margin-left:0pt;margin-right:0pt;"> (5)      Cost-Method Investments The aggregate carrying amount of our cost-method investments at September 30, 2016 and June 30, 2016, was $36.6 million and $33.8 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets.  We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered.  We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values that can be market supported and unobservable inputs including future cash flows.  We have determined that the fair value of our cost-method investments exceed their carrying values. The following table shows a reconciliation of the changes in our cost-method investments during the three months ended September 30, 2016 and 2015 (in thousands): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:52.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="bottom" style="width:52.76%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="4" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Three Months Ended September 30, </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="bottom" style="width:52.76%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2016 </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2015 </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.76%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Balance at the beginning of the period </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">33,815  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">25,600  </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.76%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Investments </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">2,758  </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,582  </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.76%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Balance at the end of the period </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">36,573  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">30,182  </td> </tr> </table></div> </div> </div>

173028000

196266000

<div> <div style="margin-left:0pt;margin-right:0pt;"> (9)      Debt Debt at September 30, 2016 and June 30, 2016 consisted of the following (in thousands): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="top" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> September 30, 2016 </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> June 30, 2016 </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Short-term debt </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">300,000  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">300,000  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Deferred borrowing costs </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(375) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(562) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Short-term debt, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">299,625  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">299,438  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Long-term debt </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">875,000  </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">875,000  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Deferred borrowing costs </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(1,489) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(1,668) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Long-term debt, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">873,511  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">873,332  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Total debt </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,173,136  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,172,770  </td> </tr> </table></div> Credit Facility On October 31, 2013, we entered into a revolving credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger, providing for a revolving credit facility of $700 million, with an uncommitted option to increase the revolving credit facility by an additional $300 million. On April 4, 2016, in connection with our acquisition of Brightree LLC (“Brightree”), we entered into a first amendment to the revolving credit agreement to increase the size of the revolving credit facility from $700 million to $1 billion, with an uncommitted option to increase the revolving credit facility by an additional $300 million, and to make other modifications to provide for the acquisition of Brightree. The credit facility terminates on October 31, 2018, when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At September 30, 2016, the interest rate that was being charged on the outstanding principal amount was 2.0%.  A commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility. The credit facility also includes a $25 million sublimit for letters of credit. Our obligations under the revolving credit agreement are unsecured but are guaranteed by certain of our direct and indirect U. S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree, Brightree Services LLC, Brightree Home Health & Hospice LLC and Strategic AR LLC, under an unconditional guaranty. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio. At September 30, 2016, there was $875.0 million outstanding under the revolving credit facility. Term Loan On April 4, 2016, in connection with the Brightree acquisition, we also entered into a credit agreement (the “term loan credit agreement”) providing a $300 million senior unsecured one-year term loan credit facility. Our obligations under the term loan credit agreement are unsecured but are guaranteed by certain of our direct and indirect U.S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree, Brightree Services LLC, Brightree Home Health & Hospice LLC and Strategic AR LLC, under an unconditional guaranty. The term loan credit facility terminates on April 3, 2017, when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the term loan credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At September 30, 2016, the interest rate that was being charged on the outstanding principal amount was 2.0%. The term loan credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum ratio of funded debt to EBITDA (as defined in the term loan credit agreement) and an interest coverage ratio. The proceeds from the funding of the term loan credit facility were used to pay a portion of the acquisition consideration for the Brightree acquisition, as well as to pay fees and expenses in connection with the acquisition, the amendment to the revolving credit agreement and the term loan credit agreement. At September 30, 2016, there was $300.0 million outstanding under the term loan credit agreement. </div> </div>

0.020

0.010

0.020

0.010

875000000

0.020

P1Y

1172770000

1173136000

562000

600000

375000

1668000

1700000

1489000

50009000

47665000

40281000

45736000

55496000

62926000

9061000

8920000

18403000

27775000

612200000

651000000

2346000

2082000

364000

2504000

243000

2256000

4185000

612000

<div> <div style="margin-left:0pt;margin-right:0pt;"> (14)    Derivative Instruments and Hedging Activities We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations.  We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows.  The terms of such foreign currency hedging contracts generally do not exceed three years.  The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars.  Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments.   We do not designate these foreign currency contracts as hedges.  We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income.  We do not enter into financial instruments for trading or speculative purposes. We held foreign currency instruments with notional amounts totaling $651.0 million and $612.2 million at September 30, 2016 and June 30, 2016, respectively, to hedge foreign currency fluctuations.  These contracts mature at various dates prior to September 30, 2019.  The following table summarizes the amount and location of our derivative financial instruments as of September 30, 2016 and June 30, 2016 (in thousands): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="top" style="width:31.96%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> September 30, 2016 </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> June 30, 2016 </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Balance Sheet Caption </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Foreign currency hedging instruments </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">364  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">2,346  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Other assets - current </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Foreign currency hedging instruments </td> <td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">2,504  </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">2,082  </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Other assets - non current </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Foreign currency hedging instruments </td> <td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(2,256) </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(243) </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accrued expenses </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Foreign currency hedging instruments </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Other long-term liabilities </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">612  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,185  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> </table></div> The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the three months ended September 30, 2016 and 2015, respectively (in thousands): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="4" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Gain /(Loss) Recognized </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Income Statement Caption </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="4" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Three Months Ended September 30, </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2016 </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2015 </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Foreign currency hedging instruments </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">6,000  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(39,353) </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Other, net </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Other foreign-currency-denominated transactions </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(5,199) </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">37,081  </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Other, net </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">801  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(2,272) </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> </table></div> We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments.  We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties. </div> </div>

-39353000

6000000

P3Y

<div> <div style="margin-left:0pt;margin-right:0pt;"> (10)    Stock-Based Employee Compensation We measure the compensation expense of all stock-based awards at fair value on the grant date.  We estimate the fair value of stock options and purchase rights granted under the employee stock purchase plan (the “ESPP”) using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period.  The fair value of performance restricted stock units which contain a market condition, are estimated using a Monte-Carlo simulation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest. We estimate the fair value stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions: <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="top" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="top" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="4" valign="middle" style="width:35.08%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Three Months Ended September 30, </td> </tr> <tr> <td valign="middle" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:17.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2016 </td> <td colspan="2" valign="middle" style="width:17.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2015 </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Stock options: </td> <td valign="middle" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="top" style="width:15.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="top" style="width:15.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Weighted average grant date fair value </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Weighted average risk-free interest rate </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Expected option life in years </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Dividend yield </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Expected volatility </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="bottom" style="width:59.82%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> ESPP purchase rights: </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Weighted average grant date fair value </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 11.88 </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 14.22 </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Weighted average risk-free interest rate </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 0.4% </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 0.1% </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Expected option life in years </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 6 months </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 6 months </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Dividend yield </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2.14% </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 1.73% </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Expected volatility </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 23% </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 26% </td> </tr> </table></div> </div> </div>

0.59

0.54

0.58

0.54

<div> <div style="margin-left:0pt;margin-right:0pt;"> (2)      Earnings Per Share <p style="margin:0pt 0pt 0pt 27pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:-27pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units. <p style="margin:0pt 0pt 0pt 27pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:-27pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> Stock options and restricted stock units of 264,672 and 98,697, for the three months ended September 30, 2016 and 2015, respectively, were not included in the computation of diluted earnings per share as the effect would have been anti-dilutive. <p style="margin:0pt 0pt 0pt 27pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:-27pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> Basic and diluted earnings per share for the three months ended September 30, 2016 and 2015 are calculated as follows (in thousands except per share data): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="4" valign="middle" style="width:28.28%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Three Months Ended September 30, </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:14.14%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2016 </td> <td colspan="2" valign="middle" style="width:14.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2015 </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Numerator: </td> <td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Net Income </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">76,107  </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">82,917  </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Denominator: </td> <td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Basic weighted-average common shares outstanding </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">140,785  </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">140,309  </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Effect of dilutive securities: </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Stock options and restricted stock units </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,305  </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,971  </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Diluted weighted average shares </td> <td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">142,090  </td> <td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">142,280  </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Basic earnings per share </td> <td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">0.54  </td> <td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">0.59  </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Diluted earnings per share </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">0.54  </td> <td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">0.58  </td> </tr> </table></div> </div> </div>

-61463000

17198000

54400000

P2Y1M6D

2500000

<div> <div style="margin-left:0pt;margin-right:0pt;"> (12)     Fair Value Measurements In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The hierarchies of inputs are as follows: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;"></td><td valign="top" align="left" style="width: 20.00pt; display: inline;"> · </td><td style="width:52pt;"></td><td align="left" valign="top"> Level 1:Input prices quoted in an active market for identical financial assets or liabilities;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;"></td><td valign="top" align="left" style="width: 20.00pt; display: inline;"> · </td><td style="width:52pt;"></td><td align="left" valign="top"> Level 2:Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;"></td><td valign="top" align="left" style="width: 20.00pt; display: inline;"> · </td><td style="width:52pt;"></td><td align="left" valign="top"> Level 3:Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market. </td></tr></table></div> The following table summarizes our financial assets and liabilities, as at September 30, 2016 and June 30, 2016, using the valuation input hierarchy (in thousands): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="top" style="width:52.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="top" style="width:52.80%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="top" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Level 1 </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Level 2 </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Level 3 </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.80%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Balances at September 30, 2016 </td> <td valign="top" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Foreign currency hedging instruments, net </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">612  </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">612  </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Business acquisition contingent consideration </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(10,454) </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(10,454) </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.80%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Balances at June 30, 2016 </td> <td valign="bottom" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Foreign currency hedging instruments, net </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,185  </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,185  </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Business acquisition contingent consideration </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(10,450) </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(10,450) </td> </tr> </table></div> We determine the fair value of our financial assets and liabilities as follows: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> · </td><td style="width:0pt;"></td><td align="left" valign="top"> Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> · </td><td style="width:0pt;"></td><td align="left" valign="top"> Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones.  Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.</td></tr></table></div> The following is a reconciliation of changes in the fair value of contingent consideration for the three months ended September 30, 2016 and 2015 (in thousands): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="bottom" style="width:65.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="bottom" style="width:65.04%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="4" valign="middle" style="width:29.86%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Three Months Ended September 30, </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="bottom" style="width:65.04%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2016 </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2015 </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:65.04%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Balance at the beginning of the period </td> <td valign="middle" style="width:01.86%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:13.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(10,450) </td> <td valign="middle" style="width:01.86%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:13.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(1,584) </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:65.04%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Foreign currency translation adjustments </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(4) </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">70  </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:65.04%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Balance at the end of the period </td> <td valign="middle" style="width:01.86%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:13.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(10,454) </td> <td valign="middle" style="width:01.86%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:13.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(1,514) </td> </tr> </table></div> We did not have any significant non-financial assets or liabilities measured at fair value on September 30, 2016 or June 30, 2016. </div> </div>

1584000

1514000

10450000

10454000

63825000

1899000

26783000

53551000

3832000

72493000

2013000

29905000

56762000

5733000

202050000

3089000

118528000

4100000

74034000

47897000

203041000

3133000

119293000

4100000

78388000

48624000

299808000

138225000

1190000

91745000

4100000

20483000

44065000

289673000

130548000

1120000

89388000

4100000

21626000

42891000

P15Y

P2Y

4185000

612000

-2272000

801000

264261000

262818000

1059245000

1062758000

192325000

604438000

457000

<div> <div style="margin-left:0pt;margin-right:0pt;"> (6)     Goodwill <p style="margin:6pt -0.3pt 0pt 28.35pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> Changes in the carrying amount of goodwill for the three months ended September 30, 2016, and 2015 were as follows (in thousands): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="bottom" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="4" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Three Months Ended September 30, </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="bottom" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2016 </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2015 </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Balance at the beginning of the period </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,059,245  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">264,261  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Other adjustments, net </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">457  </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Foreign currency translation adjustments </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">3,056  </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(1,443) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Balance at the end of the period </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,062,758  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">262,818  </td> </tr> </table></div> . </div> </div>

-1443000

3056000

457000

238619000

269184000

99444000

92925000

18118000

28261000

16527000

16818000

1127000

-18707000

-30498000

-36207000

17194000

28073000

3526000

19115000

<div> <div style="margin-left:0pt;margin-right:0pt;"> (7)     Other Intangible Assets Other intangible assets were comprised of the following as of September 30, 2016 and June 30, 2016 (in thousands): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="top" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> September 30, 2016 </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> June 30, 2016 </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Developed/core product technology </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">203,041  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">202,050  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(72,493) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(63,825) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Developed/core product technology, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">130,548  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">138,225  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Trade names </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">48,624  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">47,897  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(5,733) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(3,832) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Trade names, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">42,891  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">44,065  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Non-compete agreements </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">3,133  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">3,089  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(2,013) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(1,899) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Non compete agreements, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,120  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,190  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Customer relationships </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">119,293  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">118,528  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(29,905) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(26,783) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Customer relationships, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">89,388  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">91,745  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> In-process research and development </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,100  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,100  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> In-process research and development, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,100  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,100  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Patents </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">78,388  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">74,034  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:15.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(56,762) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:15.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(53,551) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Patents, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">21,626  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">20,483  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Total other intangibles, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">289,673  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">299,808  </td> </tr> </table></div> Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, and we amortize them over the estimated useful life of the assets, generally between two and fifteen years. There are no expected residual values related to these intangible assets. In-process research and development is amortized over the estimated useful life of the assets, once the research and development efforts are completed. At least on an annual basis, we evaluate the in-process research and development balances for impairment. </div> </div>

3422000

-2493000

1247000

6401000

<div> <div style="margin-left:0pt;margin-right:0pt;"> (3)      Inventories Inventories were comprised of the following at September 30, 2016 and June 30, 2016 (in thousands): <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="middle" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:52.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.16%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> September 30, 2016 </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> June 30, 2016 </td> </tr> <tr> <td valign="middle" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.16%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Raw materials </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">65,416  </td> <td valign="middle" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">67,121  </td> </tr> <tr> <td valign="middle" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.16%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Work in progress </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,859  </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">3,939  </td> </tr> <tr> <td valign="middle" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.16%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Finished goods </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">183,553  </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">153,396  </td> </tr> <tr> <td valign="middle" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.16%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Total inventories </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">253,828  </td> <td valign="middle" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">224,456  </td> </tr> </table></div> </div> </div>

153396000

183553000

224456000

253828000

67121000

65416000

3939000

4859000

1561874000

1549696000

3256705000

3322264000

637989000

620555000

923885000

929141000

0.0025

0.0015

2017-04-03

2018-10-31

25000000

700000000

300000000

1000000000

873332000

873511000

700000

800000

12900000

14400000

104408000

-40048000

-62749000

-13169000

124608000

86243000

82917000

76107000

<div> <div style="margin-left:0pt;margin-right:0pt;"> New Accounting Pronouncements <p style="margin:0pt 0pt 0pt 26.95pt;line-height:50%;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> <p style="margin:0pt 0pt 0pt 26.95pt;text-indent:0.05pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> In May, 2014, the FASB issued Accounting Standards Update (ASU), ASU No. 2014-09, “Revenue from Contracts with Customers”, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the company beginning in the first quarter of fiscal year 2019. Early application is not permitted. We are currently assessing the impact on our financial condition, results of operations and cash flows as a result of the adoption of ASU 2014-09, however, we do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures. <p style="margin:0pt 0pt 0pt 26.95pt;text-indent:0.05pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt"> <p style="margin:0pt 0pt 0pt 26.95pt;text-indent:0.05pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> In April, 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable International Financial Reporting Standards (IFRS) by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The new standard was effective for us beginning in the first quarter of fiscal 2017. As a result of the adoption, we reclassified debt issuance costs of $0.6 million and $1.7 million, from other assets to short-term debt and long-term debt, respectively, in our consolidated balance sheet as of June 30, 2016. The adoption of this guidance did not impact our consolidated statements of earnings, comprehensive income, stockholders’ equity, or cash flows.    <p style="margin:0pt 0pt 0pt 26.95pt;text-indent:0.05pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt"> <p style="margin:0pt 0pt 0pt 26.95pt;text-indent:0.05pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this guidance more closely align the measurement of inventory in GAAP with the measurement of inventory in IFRS.  The new standard is effective for us beginning in the first quarter of fiscal 2018.  We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures. <p style="margin:0pt 0pt 0pt 26.95pt;text-indent:0.05pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> <p style="margin:0pt 0pt 0pt 26.95pt;text-indent:0.05pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> In February 2016, the FASB issued ASU No. 2016-02, “Leases”. Under the new guidance, lessees are required to recognize lease assets and liabilities on the balance sheet for leases classified as operating leases under current GAAP. This ASU is effective for the company beginning July 1, 2019. We are currently evaluating the impact of this standard on our consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting”, which requires companies to recognize additional tax benefits or expenses related to the vesting or settlement of employee share-based awards (the difference between the actual benefit for tax purposes and the tax benefit initially recognized for financial reporting purposes) as income tax benefit or expense in earnings, rather than in additional paid-in capital, in the reporting period in which they occur. This ASU also requires companies to classify cash flows resulting from employee share-based payments, including the additional tax benefits or expenses related to the vesting or settlement of share-based awards, as cash flows from operating activities rather than financing activities. The new standard is effective for annual reporting periods beginning after December 15, 2016, with early adoption permitted. We elected to early adopt this ASU during the fourth quarter of fiscal year 2016 and are therefore required to report the impacts as though the ASU had been adopted on July 1, 2015.  Accordingly, we recognized a reduction in income tax expense and an increase in operating cash flows related to the vesting or settlement of employee share-based awards of $2.5 million in each of the three month periods ended September 30, 2016 and September 30, 2015. </div> </div>

742000

1891000

1419000

-1221000

140594000

175038000

98025000

94146000

38161000

41258000

-122108000

29723000

1211000

974000

-2003000

1272000

39341000

-9710000

57857000

42079000

46378000

3090000

2423000

2471000

4582000

2758000

16403000

14560000

0.01

2000000

81743000

92229000

4352000

6330000

200000000

25000000

9823000

8883000

15043000

17578000

2039000

2855000

1790000

5243000

<div> <div style="margin-left:0pt;margin-right:0pt;"> (4)      Property, Plant and Equipment Property, plant and equipment were comprised of the following as of September 30, 2016 and June 30, 2016 (in thousands):  <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> September 30, 2016 </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> June 30, 2016 </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Machinery and equipment </td> <td valign="middle" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">197,075  </td> <td valign="middle" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">197,485  </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Computer equipment </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">163,787  </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">154,105  </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Furniture and fixtures </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">44,363  </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">40,776  </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Vehicles </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">7,477  </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">9,060  </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Clinical, demonstration and rental equipment </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">83,152  </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">79,641  </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Leasehold improvements </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">34,126  </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">33,795  </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Land </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">55,194  </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">54,338  </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Buildings </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">233,047  </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">229,502  </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">818,221  </td> <td valign="middle" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">798,702  </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accumulated depreciation and amortization </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(427,424) </td> <td valign="middle" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(414,426) </td> </tr> <tr> <td valign="middle" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:53.44%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Property, plant and equipment, net </td> <td valign="middle" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">390,797  </td> <td valign="middle" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">384,276  </td> </tr> </table></div> </div> </div>

798702000

79641000

229502000

154105000

40776000

54338000

33795000

197485000

9060000

818221000

83152000

233047000

163787000

44363000

55194000

34126000

197075000

7477000

384276000

390797000

8000

25000000

27192000

34446000

2160299000

2190028000

411647000

465450000

<div> <div style="margin-left:0pt;margin-right:0pt;"> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="top" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> September 30, 2016 </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> June 30, 2016 </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Developed/core product technology </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">203,041  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">202,050  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(72,493) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(63,825) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Developed/core product technology, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">130,548  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">138,225  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Trade names </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">48,624  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">47,897  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(5,733) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(3,832) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Trade names, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">42,891  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">44,065  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Non-compete agreements </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">3,133  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">3,089  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(2,013) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(1,899) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Non compete agreements, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,120  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,190  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Customer relationships </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">119,293  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">118,528  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(29,905) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(26,783) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Customer relationships, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">89,388  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">91,745  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> In-process research and development </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,100  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,100  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> In-process research and development, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,100  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">4,100  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Patents </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">78,388  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">74,034  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt;"> Accumulated amortization </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:15.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(56,762) </td> <td valign="middle" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:15.00pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(53,551) </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Patents, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">21,626  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">20,483  </td> </tr> <tr> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:52.24%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Total other intangibles, net </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">289,673  </td> <td valign="middle" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">299,808  </td> </tr> </table></div> </div> </div>

<div> <div style="margin-left:0pt;margin-right:0pt;"> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="top" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="top" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="4" valign="middle" style="width:35.08%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Three Months Ended September 30, </td> </tr> <tr> <td valign="middle" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:17.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2016 </td> <td colspan="2" valign="middle" style="width:17.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2015 </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Stock options: </td> <td valign="middle" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="top" style="width:15.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="top" style="width:15.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Weighted average grant date fair value </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Weighted average risk-free interest rate </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Expected option life in years </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Dividend yield </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Expected volatility </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> - </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="bottom" style="width:59.82%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> ESPP purchase rights: </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Weighted average grant date fair value </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 11.88 </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 14.22 </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Weighted average risk-free interest rate </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 0.4% </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 0.1% </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Expected option life in years </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 6 months </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 6 months </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Dividend yield </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 2.14% </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 1.73% </td> </tr> <tr> <td valign="bottom" style="width:05.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:59.82%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Expected volatility </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 23% </td> <td valign="middle" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 26% </td> </tr> </table></div> </div> </div>

111095000

128851000

12383000

12049000

P4Y

P1Y

17010

50.69

7539

63.68

1861510

1841760

50.52

50.62

P1Y4M24D

P1Y1M6D

10279

45.06

P7Y

0.0173

0.0214

P6M

0.26

0.23

0.001

0.004

43700000

1200000

12100000

37000000

33.81

8900000

8800000

14.22

11.88

161500000

1924229

1702600

38.70

40.04

P3Y2M12D

28.44

1195037

299438000

299625000

691000

-147000

1694831000

1772568000

<div> <div style="margin-left:0pt;margin-right:0pt;"> (11)    Stockholders’ Equity Common Stock.    Since the inception of our share repurchase programs and through September 30, 2016, we have repurchased a total of 41.1 million shares at a cost of $1.5 billion.  Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. We have temporarily suspended our share repurchase program due to recent acquisitions.  Accordingly, we did not repurchase any shares during the three months ended September 30, 2016. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors.  At September 30, 2016, 13.6 million additional shares can be repurchased under the approved share repurchase program. Preferred Stock.    In April 1997, the board of directors designated 2,000,000 shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at September 30, 2016 and June 30, 2016. Stock Options and Restricted Stock Units.    We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the “2009 Plan”).  The options have expiration dates of seven years from the date of grant and the options and restricted stock units vest over one to four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant. The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 43.7 million shares. The number of securities remaining available for future issuance under the 2009 Plan at September 30, 2016 is 12.1 million.  The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any “full-value award,” which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards.  The maximum number of shares, that may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant’s initial year of hiring, when up to 4.5 million shares of our common stock may be granted). At September 30, 2016, there were $54.4 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.1 years.  The aggregate intrinsic value of the stock-based compensation arrangements outstanding and exercisable at September 30, 2016 was $161.5 million and $37.0 million, respectively.  The aggregate intrinsic value of the options exercised during the three months ended September 30, 2016 and 2015, was $8.8 million and $8.9 million, respectively.  The following table summarizes option activity during the three months ended September 30, 2016: <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.50pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.50pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.50pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.50pt;padding:0pt;"> Weighted Average Exercise Price </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.50pt;padding:0pt;"> Weighted Average Remaining Contractual Term in Years </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Outstanding at beginning of period </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,924,229  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">38.70  </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 3.2 </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Granted </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Exercised </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(221,629) </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">28.44  </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Forfeited </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Outstanding at end of period </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,702,600  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">40.04  </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 3.2 </td> </tr> <tr> <td valign="top" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Exercise price of granted options </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">  - </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="top" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Options exercisable at end of period </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,195,037  </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">33.81  </td> <td valign="top" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> </table></div> The following table summarizes the activity of restricted stock units during the three months ended September 30, 2016: <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.50pt;padding:0pt;"> </td> <td valign="top" style="width:31.96%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.50pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.50pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.50pt;padding:0pt;"> Weighted Average Grant-Date Fair Value </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.50pt;padding:0pt;"> Weighted Average Remaining Contractual Term in Years </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Outstanding at beginning of period </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,861,510  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">50.52  </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 1.4 </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Granted </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">7,539  </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">63.68  </td> <td valign="top" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Vested </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(10,279) </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">45.06  </td> <td valign="top" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Forfeited </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">(17,010) </td> <td valign="middle" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">50.69  </td> <td valign="top" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:05.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> </td> <td valign="middle" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> Outstanding at end of period </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">   </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">1,841,760  </td> <td valign="middle" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;"> $ </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;font-family:Times New Roman;font-size:8pt;text-align:right;" nowrap="nowrap">50.62  </td> <td valign="middle" style="width:19.94%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:11.25pt;padding:0pt;"> 1.1 </td> </tr> </table></div> Employee Stock Purchase Plan (the “ESPP”).  Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors’ compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year.  At September 30, 2016, the number of shares remaining available for future issuance under the ESPP is 1.2 million shares. </div> </div>

221629

13600000

41086234

1546611000

1971000

1305000

142280000

142090000

140309000

140785000

EX-101.SCH 6 rmd-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements Of Income link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements Of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Inventories (Schedule Of Inventories) (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Property, Plant And Equipment (Components Of Property, Plant And Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Other Intangible Assets (Schedule Of Other Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Debt (Schedule Of Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 41403 - Disclosure - Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 41502 - Disclosure - Business Combinations (Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives) (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Summary Of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Property, Plant And Equipment link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Cost-Method Investments link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Product Warranties link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Stock-Based Employee Compensation link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Legal Actions And Contingencies link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Derivative Instruments And Hedging Activities link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - Summary Of Significant Accounting Policies (Policy) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Property, Plant And Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Cost-Method Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Product Warranties (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Stock-Based Employee Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Derivative Instruments And Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Earnings Per Share (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Cost-Method Investments (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Goodwill (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Other Intangible Assets (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Debt (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Stock-Based Employee Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Stock-Based Employee Compensation (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Stockholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Stockholders' Equity (Schedule Of Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Legal Actions And Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Derivative Instruments And Hedging Activities (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 41402 - Disclosure - Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Business Combinations (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rmd-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 rmd-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 rmd-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document And Entity Information [Abstract] Statement [Table] Statement [Line Items] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Trading Symbol Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Condensed Consolidated Balance Sheets [Abstract] Assets [Abstract] Assets Current assets: Cash and cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of $12,276 and $10,971 at June 30, 2015 and June 30, 2014, respectively Accounts receivable, net of allowance for doubtful accounts of $11,293 and $12,555 at September 30, 2016 and June 30, 2016, respectively Inventories, net (note 5) Total inventories Inventories (note 3) Other current assets Prepaid expenses and other current assets Assets, Current Total current assets Non-current assets: Property, plant and equipment, net (note 6) Property, plant and equipment, net Property, plant and equipment, net (note 4) Goodwill Balance at the end of the period Balance at the beginning of the period Goodwill (note 6) Finite-Lived Intangible Assets, Net Other intangible assets, net (note 7) Total other intangibles, net Deferred income taxes Deferred income taxes Other assets Other assets Assets, Noncurrent Total non-current assets Assets, Total Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Current liabilities: Accounts payable Accrued Liabilities Current Accrued expenses Deferred revenue, current Deferred revenue Accrued Income Taxes, Current Income taxes payable Short-term debt Short-term debt (note 9) Short-term debt, net Liabilities, Current Total current liabilities Non-current liabilities: Deferred revenue, noncurrent Deferred revenue Non-current deferred tax liability Deferred income taxes Other Liabilities, Noncurrent Other long-term liabilities Long-term debt Long-term debt (note 9) Long-term debt, net Liabilities, Noncurrent Total non-current liabilities Liabilities, Total Total liabilities Commitments and Contingencies Commitments and contingencies (note 13) Stockholders' equity Abstract Stockholders' equity: (note 11) Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued Common stock, $0.004 par value, 350,000,000 shares authorized; 181,080,475 issued and 139,994,241 outstanding at December 31, 2015 and 179,660,939 issued and 140,474,705 outstanding at June 30, 2015 Common stock, $0.004 par value, 350,000,000 shares authorized; 181,974,343 issued and 140,888,109 outstanding at September 30, 2016 and 181,747,157 issued and 140,660,923 outstanding at June 30, 2016 Additional Paid In Capital Common Stock Additional paid-in capital Retained earnings Treasury stock, at cost, 41,086,234 shares at December 31, 2015, and 39,186,234 shares at June 30, 2015 Treasury stock, at cost, 41,086,234 shares at September 30, 2016, and June 30, 2016 Total cost of shares repurchased pursuant to the repurchase program Accumulated other comprehensive income Accumulated other comprehensive loss Stockholders' Equity Total stockholders' equity Liabilities and Stockholders' Equity Total liabilities and stockholders' equity Accounts receivable, allowance for doubtful accounts Preferred stock, par value Preferred stock at par value Preferred stock, shares authorized Preferred stock, shares issued Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares held Total number of shares repurchased pursuant to the repurchase program Condensed Consolidated Statements Of Income [Abstract] Sales Revenue Net Net revenue Cost of sales Cost of sales (excluding amortization of acquired intangible assets) Gross Profit Gross profit Operating expenses: Selling, general and administrative Research and development The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. Amortization of acquired intangible assets 1 Amortization of acquired intangible assets Operating Expenses Total operating expenses Operating Income (Loss) Income from operations Other (loss) income, net: Interest Income (Expense), Net Interest (expense) income, net Other Nonoperating Income (Expense) Other, net Nonoperating Income (Expense) Total other (loss) income, net Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Cumulative Effects of Changes in Accounting Principles, Noncontrolling Interest Income before income taxes Income Tax Expense Benefit Income taxes Net income Net income Net income Basic earnings per share Basic earnings per share Diluted earnings per share (note 2-k) Diluted earnings per share Diluted earnings per share (note 2) Common Stock, Dividends, Per Share, Declared Dividend declared per share Weighted average shares used to calculate basic earnings per share Basic shares outstanding (000's) Basic weighted-average common shares outstanding Diluted shares outstanding (000's) Diluted shares outstanding (000's) Diluted weighted average shares Condensed Consolidated Statements Of Comprehensive Income [Abstract] Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation gain (loss) adjustments Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Condensed Consolidated Statements Of Cash Flows [Abstract] Cash flows from operating activities: Depreciation and amortization Stock-based compensation costs Changes in operating assets and liabilities, net of effect of acquisitions: Increase (Decrease) in Accounts Receivables Accounts receivable Inventories, net Inventories Prepaid expenses, net deferred income taxes and other current assets Prepaid expenses, net deferred income taxes and other current assets Accounts payable, accrued expenses and other liabilities Net cash provided by operating activities Net cash provided by operating activities Cash flows from investing activities: Purchases of property plant and equipment Purchases of property, plant and equipment Patent registration costs Patent registration costs Business acquisitions, net of cash acquired Business acquisitions, net of cash acquired Purchase of cost-method investments Investments in cost-method investments Investments Proceeds from exercise of foreign currency options Proceeds (Payments) on maturity of foreign currency contracts Net cash used in investing activities Net cash used in investing activities Cash flows from financing activities: Proceeds from issuance of common stock, net Purchases of treasury stock Purchases of treasury stock Proceeds from Issuance of Long-term Debt Proceeds from borrowings, net of borrowing costs Repayment of borrowings Repayment of borrowings Payments of Dividends Dividends paid Net cash -used in/provided by financing activities Net cash (used in) from financing activities Effect of exchange rate changes on cash Net increase in cash and cash equivalents Net increase in cash and cash equivalents Supplemental disclosure of cash flow information: Income Taxes Paid, Net Income taxes paid, net of refunds Interest paid Interest paid Noncash or Part Noncash Acquisition, Value of Assets Acquired Fair value of assets acquired, excluding cash Goodwill on acquisition Goodwill Goodwill on acquisition Noncash or Part Noncash Acquisition, Deferred Payments Deferred payments Payments To Acquire Businesses Gross Total cash component of purchase price Summary Of Significant Accounting Policies [Abstract] Summary of Significant Accounting Policies [Text Block] Summary Of Significant Accounting Policies Earnings Per Share [Abstract] Earnings Per Share [Text Block] Earnings Per Share Inventories [Abstract] Inventories [Text Block] Inventories Property, Plant And Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property, Plant And Equipment Cost-Method Investments [Abstract] Cost-method Investments, Description [Text Block] Cost-Method Investments Goodwill And Other Intangible Asset [Abstract] Goodwill Disclosure [Text Block] Goodwill Intangible Assets Disclosure [Text Block] Other Intangible Assets Product Warranties [Abstract] Product Warranty Disclosure [Text Block] Product Warranties Debt [Abstract] Debt Disclosure [Text Block] Debt Stock-Based Employee Compensation [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Employee Compensation Stockholders' Equity [Abstract] Stockholders Equity Note Disclosure Text Block Stockholders' Equity Fair Value Measurements [Abstract] Fair Value Measurements [Text Block] Fair Value Measurements Legal Actions And Contingencies [Abstract] Legal Actions and Contingencies [Text block] Legal Actions And Contingencies Derivative Instruments And Hedging Activities [Abstract] Derivative Instruments and Hedging Activities [Text Block] Derivative Instruments And Hedging Activities Business Combinations [Abstract] Business Combination Disclosure [Text Block] Business Combinations Organization And Basis Of Presentation [Policy Text Bock] Organization And Basis Of Presentation [Policy Text Bock] Organization And Basis Of Presentation New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block] Schedule Of Basic And Diluted Earnings Per Share Schedule of Inventory, Current [Table Text Block] Schedule Of Inventories Property, Plant and Equipment [text bock] Components Of Property, Plant And Equipment Schedule of Cost Method Investments [Table Text Block] Schedule Of Reconciliation Of Changes In Cost-Method Investments Schedule of Goodwill [Table Text Block] Schedule Of Changes In Carrying Amount Of Goodwill Other Intangible Assets [Text Block] Schedule Of Other Intangible Assets Schedule of Product Warranty Liability [Table Text Block] Schedule Of Changes In Liability For Warranty Costs Schedule of Debt [Table Text Block] Schedule Of Debt Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule Of Option Activity Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule Of Activity Of Restricted Stock Units Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary Of Financial Assets And Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Summary Of Amount And Location Of Derivative Financial Instruments Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block] Summary Of Gains (Losses) Associated With Derivative Financial Instruments Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Debt Issuance Costs, Current, Net Deferred borrowing costs Debt issuance costs, short-term debt Debt Issuance Costs, Noncurrent, Net Deferred borrowing costs Debt issuance costs, long-term debt Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Tax benefits Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Stock options and restricted stock units not included in the computation of diluted earnings per share Income Amounts Attributable to Parent, Disclosures [Abstract] Numerator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Denominator: Earnings Per Share, Diluted, Other Disclosures [Abstract] Effect of dilutive securities: Weighted Average Number Diluted Shares Outstanding Adjustment Stock options and restricted stock units Inventory, Raw Materials, Net of Reserves Raw materials Inventory, Work in Process, Net of Reserves Work in progress Inventory, Finished Goods, Net of Reserves Finished goods Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment by Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Machinery And Equipment [Member] Machinery And Equipment [Member] Computer Equipment [Member] Computer Equipment [Member] Furniture And Fixtures [Member] Furniture And Fixtures [Member] Vehicles [Member] Vehicles [Member] Clinical, Demonstration and Rental Equipment [Member] Clinical Demonstration And Rental Equipment [Member] Clinical, Demonstration And Rental Equipment [Member] EX-101.PRE 10 rmd-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Sep. 30, 2016	Oct. 20, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Trading Symbol	rmd
Entity Registrant Name	RESMED INC
Entity Central Index Key	0000943819
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		140,965,500

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 781,658	$ 731,434
Accounts receivable, net of allowance for doubtful accounts of $11,293 and $12,555 at September 30, 2016 and June 30, 2016, respectively	347,137	382,086
Inventories (note 3)	253,828	224,456
Prepaid expenses and other current assets	92,229	81,743
Total current assets	1,474,852	1,419,719
Non-current assets:
Property, plant and equipment, net (note 4)	390,797	384,276
Goodwill (note 6)	1,062,758	1,059,245
Other intangible assets, net (note 7)	289,673	299,808
Deferred income taxes	62,926	55,496
Other assets	41,258	38,161
Total non-current assets	1,847,412	1,836,986
Total assets	3,322,264	3,256,705
Current liabilities:
Accounts payable	80,489	92,571
Accrued expenses	153,969	156,805
Deferred revenue	47,665	50,009
Income taxes payable	38,807	39,166
Short-term debt (note 9)	299,625	299,438
Total current liabilities	620,555	637,989
Non-current liabilities:
Deferred revenue	45,736	40,281
Deferred income taxes	8,920	9,061
Other long-term liabilities	974	1,211
Long-term debt (note 9)	873,511	873,332
Total non-current liabilities	929,141	923,885
Total liabilities	1,549,696	1,561,874
Commitments and contingencies (note 13)
Stockholders' equity: (note 11)
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued
Common stock, $0.004 par value, 350,000,000 shares authorized; 181,974,343 issued and 140,888,109 outstanding at September 30, 2016 and 181,747,157 issued and 140,660,923 outstanding at June 30, 2016	564	563
Additional paid-in capital	1,321,522	1,303,238
Retained earnings	2,190,028	2,160,299
Treasury stock, at cost, 41,086,234 shares at September 30, 2016, and June 30, 2016	(1,546,611)	(1,546,611)
Accumulated other comprehensive loss	(192,935)	(222,658)
Total stockholders' equity	1,772,568	1,694,831
Total liabilities and stockholders' equity	$ 3,322,264	$ 3,256,705

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Condensed Consolidated Balance Sheets [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 11,293	$ 12,555
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.004	$ 0.004
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	181,974,343	181,747,157
Common stock, shares outstanding	140,888,109	140,660,923
Treasury stock, shares held	41,086,234	41,086,234

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Condensed Consolidated Statements Of Income [Abstract]
Net revenue	$ 465,450	$ 411,647
Cost of sales (excluding amortization of acquired intangible assets)	196,266	173,028
Gross profit	269,184	238,619
Operating expenses:
Selling, general and administrative	128,851	111,095
Research and development	34,446	27,192
Amortization of acquired intangible assets	11,741	2,307
Total operating expenses	175,038	140,594
Income from operations	94,146	98,025
Other (loss) income, net:
Interest (expense) income, net	(2,493)	3,422
Other, net	1,272	(2,003)
Total other (loss) income, net	(1,221)	1,419
Income before income taxes	92,925	99,444
Income taxes	16,818	16,527
Net income	$ 76,107	$ 82,917
Basic earnings per share	$ 0.54	$ 0.59
Diluted earnings per share (note 2)	0.54	0.58
Dividend declared per share	$ 0.33	$ 0.30
Basic shares outstanding (000's)	140,785	140,309
Diluted shares outstanding (000's)	142,090	142,280

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 76,107	$ 82,917
Other comprehensive income (loss):
Foreign currency translation gain (loss) adjustments	29,723	(122,108)
Comprehensive income (loss)	$ 105,830	$ (39,191)

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income	$ 76,107	$ 82,917
Depreciation and amortization	27,775	18,403
Stock-based compensation costs	12,049	12,383
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	36,207	30,498
Inventories	(28,073)	(17,194)
Prepaid expenses, net deferred income taxes and other current assets	(19,115)	(3,526)
Accounts payable, accrued expenses and other liabilities	(18,707)	1,127
Net cash provided by operating activities	86,243	124,608
Cash flows from investing activities:
Purchases of property, plant and equipment	(14,560)	(16,403)
Patent registration costs	(2,471)	(2,423)
Business acquisitions, net of cash acquired	(3,090)
Investments in cost-method investments	(2,758)	(4,582)
Proceeds (Payments) on maturity of foreign currency contracts	9,710	(39,341)
Net cash used in investing activities	(13,169)	(62,749)
Cash flows from financing activities:
Proceeds from issuance of common stock, net	6,330	4,352
Purchases of treasury stock		(57,857)
Proceeds from borrowings, net of borrowing costs	25,000	200,000
Repayment of borrowings	(25,000)	(8)
Dividends paid	(46,378)	(42,079)
Net cash (used in) from financing activities	(40,048)	104,408
Effect of exchange rate changes on cash	17,198	(61,463)
Net increase in cash and cash equivalents	50,224	104,804
Cash and cash equivalents at beginning of period	731,434	717,249
Cash and cash equivalents at end of period	781,658	822,053
Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds	28,261	18,118
Interest paid	6,401	1,247
Fair value of assets acquired, excluding cash	1,891
Goodwill on acquisition	457
Deferred payments	742
Total cash component of purchase price	$ 3,090

XML 17 R7.htm IDEA: XBRL DOCUMENT

Summary Of Significant Accounting Policies	3 Months Ended
Summary Of Significant Accounting Policies	Sep. 30, 2016
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	(1) Summary of Significant Accounting Policies Organization and Basis of Presentation ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, France, Malaysia and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2017. The condensed consolidated financial statements for the three months ended September 30, 2016 and 2015 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2016. New Accounting Pronouncements In May, 2014, the FASB issued Accounting Standards Update (ASU), ASU No. 2014-09, “Revenue from Contracts with Customers”, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the company beginning in the first quarter of fiscal year 2019. Early application is not permitted. We are currently assessing the impact on our financial condition, results of operations and cash flows as a result of the adoption of ASU 2014-09, however, we do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures. In April, 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable International Financial Reporting Standards (IFRS) by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The new standard was effective for us beginning in the first quarter of fiscal 2017. As a result of the adoption, we reclassified debt issuance costs of $0.6 million and $1.7 million, from other assets to short-term debt and long-term debt, respectively, in our consolidated balance sheet as of June 30, 2016. The adoption of this guidance did not impact our consolidated statements of earnings, comprehensive income, stockholders’ equity, or cash flows. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this guidance more closely align the measurement of inventory in GAAP with the measurement of inventory in IFRS. The new standard is effective for us beginning in the first quarter of fiscal 2018. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU No. 2016-02, “Leases”. Under the new guidance, lessees are required to recognize lease assets and liabilities on the balance sheet for leases classified as operating leases under current GAAP. This ASU is effective for the company beginning July 1, 2019. We are currently evaluating the impact of this standard on our consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting”, which requires companies to recognize additional tax benefits or expenses related to the vesting or settlement of employee share-based awards (the difference between the actual benefit for tax purposes and the tax benefit initially recognized for financial reporting purposes) as income tax benefit or expense in earnings, rather than in additional paid-in capital, in the reporting period in which they occur. This ASU also requires companies to classify cash flows resulting from employee share-based payments, including the additional tax benefits or expenses related to the vesting or settlement of share-based awards, as cash flows from operating activities rather than financing activities. The new standard is effective for annual reporting periods beginning after December 15, 2016, with early adoption permitted. We elected to early adopt this ASU during the fourth quarter of fiscal year 2016 and are therefore required to report the impacts as though the ASU had been adopted on July 1, 2015. Accordingly, we recognized a reduction in income tax expense and an increase in operating cash flows related to the vesting or settlement of employee share-based awards of $2.5 million in each of the three month periods ended September 30, 2016 and September 30, 2015.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Earnings Per Share

3 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Earnings Per Share

(2) Earnings Per Share

Basic and diluted earnings per share for the three months ended September 30, 2016 and 2015 are calculated as follows (in thousands except per share data):


	Three Months Ended September 30,
	2016		2015
Numerator:
Net Income	$	76,107	$	82,917
Denominator:
Basic weighted-average common shares outstanding		140,785		140,309
Effect of dilutive securities:
Stock options and restricted stock units		1,305		1,971
Diluted weighted average shares		142,090		142,280
Basic earnings per share	$	0.54	$	0.59
Diluted earnings per share	$	0.54	$	0.58

XML 19 R9.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Sep. 30, 2016

Inventories [Abstract]

Inventories

(3) Inventories

Inventories were comprised of the following at September 30, 2016 and June 30, 2016 (in thousands):


	September 30, 2016		June 30, 2016
Raw materials	$	65,416	$	67,121
Work in progress		4,859		3,939
Finished goods		183,553		153,396
Total inventories	$	253,828	$	224,456

XML 20 R10.htm IDEA: XBRL DOCUMENT

Property, Plant And Equipment

3 Months Ended

Sep. 30, 2016

Property, Plant And Equipment [Abstract]

Property, Plant And Equipment

(4) Property, Plant and Equipment

Property, plant and equipment were comprised of the following as of September 30, 2016 and June 30, 2016 (in thousands):


	September 30, 2016		June 30, 2016
Machinery and equipment	$	197,075	$	197,485
Computer equipment		163,787		154,105
Furniture and fixtures		44,363		40,776
Vehicles		7,477		9,060
Clinical, demonstration and rental equipment		83,152		79,641
Leasehold improvements		34,126		33,795
Land		55,194		54,338
Buildings		233,047		229,502
		818,221		798,702
Accumulated depreciation and amortization		(427,424)		(414,426)
Property, plant and equipment, net	$	390,797	$	384,276

XML 21 R11.htm IDEA: XBRL DOCUMENT

Cost-Method Investments

3 Months Ended

Sep. 30, 2016

Cost-Method Investments [Abstract]

Cost-Method Investments

(5) Cost-Method Investments

The following table shows a reconciliation of the changes in our cost-method investments during the three months ended September 30, 2016 and 2015 (in thousands):


	Three Months Ended September 30,
	2016		2015
Balance at the beginning of the period	$	33,815	$	25,600
Investments		2,758		4,582
Balance at the end of the period	$	36,573	$	30,182

XML 22 R12.htm IDEA: XBRL DOCUMENT

Goodwill

3 Months Ended

Sep. 30, 2016

Goodwill And Other Intangible Asset [Abstract]

Goodwill

(6) Goodwill

Changes in the carrying amount of goodwill for the three months ended September 30, 2016, and 2015 were as follows (in thousands):


	Three Months Ended September 30,
	2016		2015
Balance at the beginning of the period	$	1,059,245	$	264,261
Other adjustments, net		457		-
Foreign currency translation adjustments		3,056		(1,443)
Balance at the end of the period	$	1,062,758	$	262,818

XML 23 R13.htm IDEA: XBRL DOCUMENT

Other Intangible Assets

3 Months Ended

Sep. 30, 2016

Goodwill And Other Intangible Asset [Abstract]

Other Intangible Assets

(7) Other Intangible Assets

Other intangible assets were comprised of the following as of September 30, 2016 and June 30, 2016 (in thousands):


	September 30, 2016		June 30, 2016
Developed/core product technology	$	203,041	$	202,050
Accumulated amortization		(72,493)		(63,825)
Developed/core product technology, net		130,548		138,225
Trade names		48,624		47,897
Accumulated amortization		(5,733)		(3,832)
Trade names, net		42,891		44,065
Non-compete agreements		3,133		3,089
Accumulated amortization		(2,013)		(1,899)
Non compete agreements, net		1,120		1,190
Customer relationships		119,293		118,528
Accumulated amortization		(29,905)		(26,783)
Customer relationships, net		89,388		91,745
In-process research and development		4,100		4,100
Accumulated amortization		-		-
In-process research and development, net		4,100		4,100
Patents		78,388		74,034
Accumulated amortization		(56,762)		(53,551)
Patents, net		21,626		20,483
Total other intangibles, net	$	289,673	$	299,808

XML 24 R14.htm IDEA: XBRL DOCUMENT

Product Warranties

3 Months Ended

Sep. 30, 2016

Product Warranties [Abstract]

Product Warranties

(8) Product Warranties


	Three Months Ended September 30,
	2016		2015
Balance at the beginning of the period	$	15,043	$	9,823
Warranty accruals for the period		5,243		1,790
Warranty costs incurred for the period		(2,855)		(2,039)
Foreign currency translation adjustments		147		(691)
Balance at the end of the period	$	17,578	$	8,883

XML 25 R15.htm IDEA: XBRL DOCUMENT

Debt

3 Months Ended

Sep. 30, 2016

Debt [Abstract]

Debt

(9) Debt

Debt at September 30, 2016 and June 30, 2016 consisted of the following (in thousands):


	September 30, 2016		June 30, 2016
Short-term debt	$	300,000	$	300,000
Deferred borrowing costs		(375)		(562)
Short-term debt, net		299,625		299,438

Long-term debt		875,000		875,000
Deferred borrowing costs		(1,489)		(1,668)
Long-term debt, net		873,511		873,332
Total debt	$	1,173,136	$	1,172,770

Credit Facility

At September 30, 2016, there was $875.0 million outstanding under the revolving credit facility.

Term Loan

At September 30, 2016, there was $300.0 million outstanding under the term loan credit agreement.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Stock-Based Employee Compensation

3 Months Ended

Sep. 30, 2016

Stock-Based Employee Compensation [Abstract]

Stock-Based Employee Compensation

(10) Stock-Based Employee Compensation

We estimate the fair value stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions:


	Three Months Ended September 30,
	2016		2015
Stock options:
Weighted average grant date fair value	$	-	$	-
Weighted average risk-free interest rate		-		-
Expected option life in years		-		-
Dividend yield		-		-
Expected volatility		-		-

ESPP purchase rights:
Weighted average grant date fair value	$	11.88	$	14.22
Weighted average risk-free interest rate		0.4%		0.1%
Expected option life in years		6 months		6 months
Dividend yield		2.14%		1.73%
Expected volatility		23%		26%

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Sep. 30, 2016

Stockholders' Equity [Abstract]

Stockholders' Equity

(11) Stockholders’ Equity

Common Stock. Since the inception of our share repurchase programs and through September 30, 2016, we have repurchased a total of 41.1 million shares at a cost of $1.5 billion. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. We have temporarily suspended our share repurchase program due to recent acquisitions. Accordingly, we did not repurchase any shares during the three months ended September 30, 2016. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. At September 30, 2016, 13.6 million additional shares can be repurchased under the approved share repurchase program.

Preferred Stock. In April 1997, the board of directors designated 2,000,000 shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at September 30, 2016 and June 30, 2016.

Stock Options and Restricted Stock Units. We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the “2009 Plan”). The options have expiration dates of seven years from the date of grant and the options and restricted stock units vest over one to four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant.

The following table summarizes option activity during the three months ended September 30, 2016:


			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
Outstanding at beginning of period		1,924,229	$	38.70	3.2
Granted		-		-
Exercised		(221,629)		28.44
Forfeited		-		-
Outstanding at end of period		1,702,600	$	40.04	3.2
Exercise price of granted options	$	-
Options exercisable at end of period		1,195,037	$	33.81

The following table summarizes the activity of restricted stock units during the three months ended September 30, 2016:


		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Term in Years
Outstanding at beginning of period	1,861,510	$	50.52	1.4
Granted	7,539		63.68
Vested	(10,279)		45.06
Forfeited	(17,010)		50.69
Outstanding at end of period	1,841,760	$	50.62	1.1

Employee Stock Purchase Plan (the “ESPP”). Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors’ compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year. At September 30, 2016, the number of shares remaining available for future issuance under the ESPP is 1.2 million shares.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Sep. 30, 2016

Fair Value Measurements [Abstract]

Fair Value Measurements

(12) Fair Value Measurements

The hierarchies of inputs are as follows:

Level 1:Input prices quoted in an active market for identical financial assets or liabilities;

Level 2:Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and

Level 3:Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.

The following table summarizes our financial assets and liabilities, as at September 30, 2016 and June 30, 2016, using the valuation input hierarchy (in thousands):


		Level 1		Level 2		Level 3		Total
Balances at September 30, 2016
Foreign currency hedging instruments, net	$	-	$	612	$	-	$	612
Business acquisition contingent consideration	$	-	$	-	$	(10,454)	$	(10,454)
Balances at June 30, 2016
Foreign currency hedging instruments, net	$	-	$	4,185	$	-	$	4,185
Business acquisition contingent consideration	$	-	$	-	$	(10,450)	$	(10,450)

We determine the fair value of our financial assets and liabilities as follows:

Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.

Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones. Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.

The following is a reconciliation of changes in the fair value of contingent consideration for the three months ended September 30, 2016 and 2015 (in thousands):


	Three Months Ended September 30,
		2016		2015
Balance at the beginning of the period	$	(10,450)	$	(1,584)
Foreign currency translation adjustments		(4)		70
Balance at the end of the period	$	(10,454)	$	(1,514)

We did not have any significant non-financial assets or liabilities measured at fair value on September 30, 2016 or June 30, 2016.

XML 29 R19.htm IDEA: XBRL DOCUMENT

Legal Actions And Contingencies	3 Months Ended
Legal Actions And Contingencies	Sep. 30, 2016
Legal Actions And Contingencies [Abstract]
Legal Actions And Contingencies	(13) Legal Actions and Contingencies Litigation In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole. Contingent Obligations Under Recourse Provisions We use independent leasing companies to provide financing to certain customers for the purchase of our products. In some cases, and within certain limits, we are liable to the leasing companies in the event of a customer default for unpaid installment receivables transferred to the leasing companies. The gross amount of receivables sold with recourse during the three months ended September 30, 2016 and 2015, amounted to $17.3 million and $16.1 million, respectively. The maximum potential amounts of contingent liability under these arrangements at September 30, 2016 and June 30, 2016 were $14.4 million, and $12.9 million, respectively. The recourse liability recognized by us at September 30, 2016 and June 30, 2016, in relation to these arrangements was $0.8 million and $0.7 million, respectively.

XML 30 R20.htm IDEA: XBRL DOCUMENT

Derivative Instruments And Hedging Activities

3 Months Ended

Sep. 30, 2016

Derivative Instruments And Hedging Activities [Abstract]

Derivative Instruments And Hedging Activities

(14) Derivative Instruments and Hedging Activities

The following table summarizes the amount and location of our derivative financial instruments as of September 30, 2016 and June 30, 2016 (in thousands):


	September 30, 2016		June 30, 2016		Balance Sheet Caption
Foreign currency hedging instruments	$	364	$	2,346		Other assets - current
Foreign currency hedging instruments		2,504		2,082		Other assets - non current
Foreign currency hedging instruments		(2,256)		(243)		Accrued expenses
Foreign currency hedging instruments		-		-		Other long-term liabilities
	$	612	$	4,185


	Gain /(Loss) Recognized				Income Statement Caption
	Three Months Ended September 30,
	2016		2015
Foreign currency hedging instruments	$	6,000	$	(39,353)		Other, net
Other foreign-currency-denominated transactions		(5,199)		37,081		Other, net
	$	801	$	(2,272)

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

XML 31 R21.htm IDEA: XBRL DOCUMENT

Business Combinations

3 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

Business Combinations

(15) Business Combinations

Brightree


		Brightree	Intangible assets - useful life
Current assets	$	13,868
Property, plant and equipment		1,045
Tradenames		28,700	10 years
In-process research and development		4,100	n/a
Developed technology		114,700	5 to 6 years
Customer relationships		51,000	10 to 15 years
Goodwill		604,438
Assets acquired	$	817,851
Current liabilities		(9,399)
Deferred revenue		(4,571)
Deferred tax liabilities		-
Total liabilities assumed	$	(13,970)
Net assets acquired	$	803,881

Other Acquisitions

The fair values of assets acquired and liabilities assumed, and the estimated useful lives of intangible assets acquired are as follows (in thousands):


		All Other	Intangible assets - useful life
Current assets	$	51,261
Property, plant and equipment		5,294
Tradenames		17,400	7 years
Non-compete		1,400	5 years
Developed technology		20,515	5 years
Customer relationships		37,303	5 to 8 years
Goodwill		192,325
Assets acquired	$	325,498
Current liabilities		(21,147)
Debt assumed		(21,201)
Deferred revenue		(4,283)
Deferred tax liabilities		(19,207)
Total liabilities assumed	$	(65,838)
Net assets acquired	$	259,660

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 32 R22.htm IDEA: XBRL DOCUMENT

Summary Of Significant Accounting Policies (Policy)	3 Months Ended
Summary Of Significant Accounting Policies (Policy)	Sep. 30, 2016
Summary Of Significant Accounting Policies [Abstract]
Organization And Basis Of Presentation	Organization and Basis of Presentation ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, France, Malaysia and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2017. The condensed consolidated financial statements for the three months ended September 30, 2016 and 2015 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2016.
New Accounting Pronouncements	New Accounting Pronouncements In May, 2014, the FASB issued Accounting Standards Update (ASU), ASU No. 2014-09, “Revenue from Contracts with Customers”, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the company beginning in the first quarter of fiscal year 2019. Early application is not permitted. We are currently assessing the impact on our financial condition, results of operations and cash flows as a result of the adoption of ASU 2014-09, however, we do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures. In April, 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable International Financial Reporting Standards (IFRS) by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The new standard was effective for us beginning in the first quarter of fiscal 2017. As a result of the adoption, we reclassified debt issuance costs of $0.6 million and $1.7 million, from other assets to short-term debt and long-term debt, respectively, in our consolidated balance sheet as of June 30, 2016. The adoption of this guidance did not impact our consolidated statements of earnings, comprehensive income, stockholders’ equity, or cash flows. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this guidance more closely align the measurement of inventory in GAAP with the measurement of inventory in IFRS. The new standard is effective for us beginning in the first quarter of fiscal 2018. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU No. 2016-02, “Leases”. Under the new guidance, lessees are required to recognize lease assets and liabilities on the balance sheet for leases classified as operating leases under current GAAP. This ASU is effective for the company beginning July 1, 2019. We are currently evaluating the impact of this standard on our consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting”, which requires companies to recognize additional tax benefits or expenses related to the vesting or settlement of employee share-based awards (the difference between the actual benefit for tax purposes and the tax benefit initially recognized for financial reporting purposes) as income tax benefit or expense in earnings, rather than in additional paid-in capital, in the reporting period in which they occur. This ASU also requires companies to classify cash flows resulting from employee share-based payments, including the additional tax benefits or expenses related to the vesting or settlement of share-based awards, as cash flows from operating activities rather than financing activities. The new standard is effective for annual reporting periods beginning after December 15, 2016, with early adoption permitted. We elected to early adopt this ASU during the fourth quarter of fiscal year 2016 and are therefore required to report the impacts as though the ASU had been adopted on July 1, 2015. Accordingly, we recognized a reduction in income tax expense and an increase in operating cash flows related to the vesting or settlement of employee share-based awards of $2.5 million in each of the three month periods ended September 30, 2016 and September 30, 2015.

XML 33 R23.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Tables)

3 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Schedule Of Basic And Diluted Earnings Per Share


	Three Months Ended September 30,
	2016		2015
Numerator:
Net Income	$	76,107	$	82,917
Denominator:
Basic weighted-average common shares outstanding		140,785		140,309
Effect of dilutive securities:
Stock options and restricted stock units		1,305		1,971
Diluted weighted average shares		142,090		142,280
Basic earnings per share	$	0.54	$	0.59
Diluted earnings per share	$	0.54	$	0.58

XML 34 R24.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

3 Months Ended

Sep. 30, 2016

Inventories [Abstract]

Schedule Of Inventories


	September 30, 2016		June 30, 2016
Raw materials	$	65,416	$	67,121
Work in progress		4,859		3,939
Finished goods		183,553		153,396
Total inventories	$	253,828	$	224,456

XML 35 R25.htm IDEA: XBRL DOCUMENT

Property, Plant And Equipment (Tables)

3 Months Ended

Sep. 30, 2016

Property, Plant And Equipment [Abstract]

Components Of Property, Plant And Equipment


	September 30, 2016		June 30, 2016
Machinery and equipment	$	197,075	$	197,485
Computer equipment		163,787		154,105
Furniture and fixtures		44,363		40,776
Vehicles		7,477		9,060
Clinical, demonstration and rental equipment		83,152		79,641
Leasehold improvements		34,126		33,795
Land		55,194		54,338
Buildings		233,047		229,502
		818,221		798,702
Accumulated depreciation and amortization		(427,424)		(414,426)
Property, plant and equipment, net	$	390,797	$	384,276

XML 36 R26.htm IDEA: XBRL DOCUMENT

Cost-Method Investments (Tables)

3 Months Ended

Sep. 30, 2016

Cost-Method Investments [Abstract]

Schedule Of Reconciliation Of Changes In Cost-Method Investments


	Three Months Ended September 30,
	2016		2015
Balance at the beginning of the period	$	33,815	$	25,600
Investments		2,758		4,582
Balance at the end of the period	$	36,573	$	30,182

XML 37 R27.htm IDEA: XBRL DOCUMENT

Goodwill (Tables)

3 Months Ended

Sep. 30, 2016

Goodwill And Other Intangible Asset [Abstract]

Schedule Of Changes In Carrying Amount Of Goodwill


	Three Months Ended September 30,
	2016		2015
Balance at the beginning of the period	$	1,059,245	$	264,261
Other adjustments, net		457		-
Foreign currency translation adjustments		3,056		(1,443)
Balance at the end of the period	$	1,062,758	$	262,818

XML 38 R28.htm IDEA: XBRL DOCUMENT

Other Intangible Assets (Tables)

3 Months Ended

Sep. 30, 2016

Goodwill And Other Intangible Asset [Abstract]

Schedule Of Other Intangible Assets


	September 30, 2016		June 30, 2016
Developed/core product technology	$	203,041	$	202,050
Accumulated amortization		(72,493)		(63,825)
Developed/core product technology, net		130,548		138,225
Trade names		48,624		47,897
Accumulated amortization		(5,733)		(3,832)
Trade names, net		42,891		44,065
Non-compete agreements		3,133		3,089
Accumulated amortization		(2,013)		(1,899)
Non compete agreements, net		1,120		1,190
Customer relationships		119,293		118,528
Accumulated amortization		(29,905)		(26,783)
Customer relationships, net		89,388		91,745
In-process research and development		4,100		4,100
Accumulated amortization		-		-
In-process research and development, net		4,100		4,100
Patents		78,388		74,034
Accumulated amortization		(56,762)		(53,551)
Patents, net		21,626		20,483
Total other intangibles, net	$	289,673	$	299,808

XML 39 R29.htm IDEA: XBRL DOCUMENT

Product Warranties (Tables)

3 Months Ended

Sep. 30, 2016

Product Warranties [Abstract]

Schedule Of Changes In Liability For Warranty Costs


	Three Months Ended September 30,
	2016		2015
Balance at the beginning of the period	$	15,043	$	9,823
Warranty accruals for the period		5,243		1,790
Warranty costs incurred for the period		(2,855)		(2,039)
Foreign currency translation adjustments		147		(691)
Balance at the end of the period	$	17,578	$	8,883

XML 40 R30.htm IDEA: XBRL DOCUMENT

Debt (Tables)

3 Months Ended

Sep. 30, 2016

Debt [Abstract]

Schedule Of Debt


	September 30, 2016		June 30, 2016
Short-term debt	$	300,000	$	300,000
Deferred borrowing costs		(375)		(562)
Short-term debt, net		299,625		299,438

Long-term debt		875,000		875,000
Deferred borrowing costs		(1,489)		(1,668)
Long-term debt, net		873,511		873,332
Total debt	$	1,173,136	$	1,172,770

XML 41 R31.htm IDEA: XBRL DOCUMENT

Stock-Based Employee Compensation (Tables)

3 Months Ended

Sep. 30, 2016

Stock-Based Employee Compensation [Abstract]

Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted


	Three Months Ended September 30,
	2016		2015
Stock options:
Weighted average grant date fair value	$	-	$	-
Weighted average risk-free interest rate		-		-
Expected option life in years		-		-
Dividend yield		-		-
Expected volatility		-		-

ESPP purchase rights:
Weighted average grant date fair value	$	11.88	$	14.22
Weighted average risk-free interest rate		0.4%		0.1%
Expected option life in years		6 months		6 months
Dividend yield		2.14%		1.73%
Expected volatility		23%		26%

XML 42 R32.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Sep. 30, 2016

Stockholders' Equity [Abstract]

Schedule Of Option Activity


			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
Outstanding at beginning of period		1,924,229	$	38.70	3.2
Granted		-		-
Exercised		(221,629)		28.44
Forfeited		-		-
Outstanding at end of period		1,702,600	$	40.04	3.2
Exercise price of granted options	$	-
Options exercisable at end of period		1,195,037	$	33.81

Schedule Of Activity Of Restricted Stock Units


		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Term in Years
Outstanding at beginning of period	1,861,510	$	50.52	1.4
Granted	7,539		63.68
Vested	(10,279)		45.06
Forfeited	(17,010)		50.69
Outstanding at end of period	1,841,760	$	50.62	1.1

XML 43 R33.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Sep. 30, 2016

Fair Value Measurements [Abstract]

Summary Of Financial Assets And Liabilities


		Level 1		Level 2		Level 3		Total
Balances at September 30, 2016
Foreign currency hedging instruments, net	$	-	$	612	$	-	$	612
Business acquisition contingent consideration	$	-	$	-	$	(10,454)	$	(10,454)
Balances at June 30, 2016
Foreign currency hedging instruments, net	$	-	$	4,185	$	-	$	4,185
Business acquisition contingent consideration	$	-	$	-	$	(10,450)	$	(10,450)

Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs


	Three Months Ended September 30,
		2016		2015
Balance at the beginning of the period	$	(10,450)	$	(1,584)
Foreign currency translation adjustments		(4)		70
Balance at the end of the period	$	(10,454)	$	(1,514)

XML 44 R34.htm IDEA: XBRL DOCUMENT

Derivative Instruments And Hedging Activities (Tables)

3 Months Ended

Sep. 30, 2016

Derivative Instruments And Hedging Activities [Abstract]

Summary Of Amount And Location Of Derivative Financial Instruments


	September 30, 2016		June 30, 2016		Balance Sheet Caption
Foreign currency hedging instruments	$	364	$	2,346		Other assets - current
Foreign currency hedging instruments		2,504		2,082		Other assets - non current
Foreign currency hedging instruments		(2,256)		(243)		Accrued expenses
Foreign currency hedging instruments		-		-		Other long-term liabilities
	$	612	$	4,185

Summary Of Gains (Losses) Associated With Derivative Financial Instruments


	Gain /(Loss) Recognized				Income Statement Caption
	Three Months Ended September 30,
	2016		2015
Foreign currency hedging instruments	$	6,000	$	(39,353)		Other, net
Other foreign-currency-denominated transactions		(5,199)		37,081		Other, net
	$	801	$	(2,272)

XML 45 R35.htm IDEA: XBRL DOCUMENT

Business Combinations (Tables)

3 Months Ended

Sep. 30, 2016

Brightree LLC [Member]

Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives


		Brightree	Intangible assets - useful life
Current assets	$	13,868
Property, plant and equipment		1,045
Tradenames		28,700	10 years
In-process research and development		4,100	n/a
Developed technology		114,700	5 to 6 years
Customer relationships		51,000	10 to 15 years
Goodwill		604,438
Assets acquired	$	817,851
Current liabilities		(9,399)
Deferred revenue		(4,571)
Deferred tax liabilities		-
Total liabilities assumed	$	(13,970)
Net assets acquired	$	803,881

All Other [Member]

Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives


		All Other	Intangible assets - useful life
Current assets	$	51,261
Property, plant and equipment		5,294
Tradenames		17,400	7 years
Non-compete		1,400	5 years
Developed technology		20,515	5 years
Customer relationships		37,303	5 to 8 years
Goodwill		192,325
Assets acquired	$	325,498
Current liabilities		(21,147)
Debt assumed		(21,201)
Deferred revenue		(4,283)
Deferred tax liabilities		(19,207)
Total liabilities assumed	$	(65,838)
Net assets acquired	$	259,660

XML 46 R36.htm IDEA: XBRL DOCUMENT

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs, short-term debt	$ 375		$ 562
Debt issuance costs, long-term debt	1,489		1,668
ASU 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs, short-term debt			600
Debt issuance costs, long-term debt			$ 1,700
ASU 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Tax benefits	$ 2,500	$ 2,500

XML 47 R37.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Narrative) (Details) - shares	3 Months Ended
Earnings Per Share (Narrative) (Details) - shares	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Stock options and restricted stock units not included in the computation of diluted earnings per share	264,672	98,697

XML 48 R38.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Net income	$ 76,107	$ 82,917
Denominator:
Basic weighted-average common shares outstanding	140,785	140,309
Effect of dilutive securities:
Stock options and restricted stock units	1,305	1,971
Diluted weighted average shares	142,090	142,280
Basic earnings per share	$ 0.54	$ 0.59
Diluted earnings per share	$ 0.54	$ 0.58

XML 49 R39.htm IDEA: XBRL DOCUMENT

Inventories (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Inventories [Abstract]
Raw materials	$ 65,416	$ 67,121
Work in progress	4,859	3,939
Finished goods	183,553	153,396
Total inventories	$ 253,828	$ 224,456

XML 50 R40.htm IDEA: XBRL DOCUMENT

Property, Plant And Equipment (Components Of Property, Plant And Equipment) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 818,221	$ 798,702
Accumulated depreciation and amortization	(427,424)	(414,426)
Property, plant and equipment, net	390,797	384,276
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	197,075	197,485
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	163,787	154,105
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	44,363	40,776
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	7,477	9,060
Clinical, Demonstration And Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	83,152	79,641
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	34,126	33,795
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	55,194	54,338
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 233,047	$ 229,502

XML 51 R41.htm IDEA: XBRL DOCUMENT

Cost-Method Investments (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Jun. 30, 2015
Cost-Method Investments [Abstract]
Aggregate carrying amount of cost-method investments	$ 36,573	$ 33,815	$ 30,182	$ 25,600

XML 52 R42.htm IDEA: XBRL DOCUMENT

Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cost-Method Investments [Abstract]
Balance at the beginning of the period	$ 33,815	$ 25,600
Investments	2,758	4,582
Balance at the end of the period	$ 36,573	$ 30,182

XML 53 R43.htm IDEA: XBRL DOCUMENT

Goodwill (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Goodwill And Other Intangible Asset [Abstract]
Balance at the beginning of the period	$ 1,059,245	$ 264,261
Other adjustments, net	457
Foreign currency translation adjustments	3,056	(1,443)
Balance at the end of the period	$ 1,062,758	$ 262,818

XML 54 R44.htm IDEA: XBRL DOCUMENT

Other Intangible Assets (Narrative) (Details)	3 Months Ended
Other Intangible Assets (Narrative) (Details)	Sep. 30, 2016
Minimum [Member]
Goodwill [Line Items]
Intangible assets, estimated useful life	2 years
Maximum [Member]
Goodwill [Line Items]
Intangible assets, estimated useful life	15 years

XML 55 R45.htm IDEA: XBRL DOCUMENT

Other Intangible Assets (Schedule Of Other Intangible Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Total other intangibles, net	$ 289,673	$ 299,808
Developed/Core Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	203,041	202,050
Accumulated amortization	(72,493)	(63,825)
Total other intangibles, net	130,548	138,225
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	48,624	47,897
Accumulated amortization	(5,733)	(3,832)
Total other intangibles, net	42,891	44,065
Non Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	3,133	3,089
Accumulated amortization	(2,013)	(1,899)
Total other intangibles, net	1,120	1,190
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	119,293	118,528
Accumulated amortization	(29,905)	(26,783)
Total other intangibles, net	89,388	91,745
In-Process Research And Development [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	4,100	4,100
Total other intangibles, net	4,100	4,100
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	78,388	74,034
Accumulated amortization	(56,762)	(53,551)
Total other intangibles, net	$ 21,626	$ 20,483

XML 56 R46.htm IDEA: XBRL DOCUMENT

Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Product Warranties [Abstract]
Balance at the beginning of the period	$ 15,043	$ 9,823
Warranty accruals for the period	5,243	1,790
Warranty costs incurred for the period	(2,855)	(2,039)
Foreign currency translation adjustments	147	(691)
Balance at the end of the period	$ 17,578	$ 8,883

XML 57 R47.htm IDEA: XBRL DOCUMENT

Debt (Narrative) (Details) - USD ($) $ in Thousands		3 Months Ended
Debt (Narrative) (Details) - USD ($) $ in Thousands	Apr. 04, 2016	Sep. 30, 2016	Jun. 30, 2016	Apr. 03, 2016	Oct. 31, 2013
Debt Instrument [Line Items]
Outstanding under the revolving credit facility		$ 875,000	$ 875,000
Outstanding under the term loan credit agreement		$ 300,000	$ 300,000
Union Bank, N.A. and HSBC Bank USA [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 700,000
Credit facility termination date		Oct. 31, 2018
Interest rate on outstanding principal amount		2.00%
Union Bank, N.A. and HSBC Bank USA [Member] \| Letters Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 25,000
Minimum [Member] \| Union Bank, N.A. and HSBC Bank USA [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility		0.15%
Minimum [Member] \| Union Bank, N.A. and HSBC Bank USA [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus		1.00%
Maximum [Member] \| Union Bank, N.A. and HSBC Bank USA [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility		0.25%
Maximum [Member] \| Union Bank, N.A. and HSBC Bank USA [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus		2.00%
Brightree LLC [Member] \| Term Loan Credit Agreement [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 300,000
Credit facility term, years	1 year
Credit facility termination date		Apr. 03, 2017
Interest rate on outstanding principal amount		2.00%
Brightree LLC [Member] \| Union Bank, N.A. and HSBC Bank USA [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000
Uncommitted option to increase credit facility	$ 300,000
Brightree LLC [Member] \| Minimum [Member] \| Term Loan Credit Agreement [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus		1.00%
Brightree LLC [Member] \| Maximum [Member] \| Term Loan Credit Agreement [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus		2.00%

XML 58 R48.htm IDEA: XBRL DOCUMENT

Debt (Schedule Of Debt) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Debt [Abstract]
Short-term debt	$ 300,000	$ 300,000
Deferred borrowing costs	(375)	(562)
Short-term debt, net	299,625	299,438
Long-term debt	875,000	875,000
Deferred borrowing costs	(1,489)	(1,668)
Long-term debt, net	873,511	873,332
Total debt	$ 1,173,136	$ 1,172,770

XML 59 R49.htm IDEA: XBRL DOCUMENT

Stock-Based Employee Compensation (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details) - $ / shares	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value
Weighted average risk-free interest rate
Dividend yield
Expected volatility
ESPP Purchase Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value	$ 11.88	$ 14.22
Weighted average risk-free interest rate	0.40%	0.10%
Expected option life in years	6 months	6 months
Dividend yield	2.14%	1.73%
Expected volatility	23.00%	26.00%

XML 60 R50.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Narrative) (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) $ / shares shares	Apr. 30, 1997 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares repurchased pursuant to the repurchase program	41,086,234		41,086,234
Total cost of shares repurchased pursuant to the repurchase program \| $	$ 1,546,611		$ 1,546,611
Common shares repurchased	0
Additional shares that can be repurchased under the approved share repurchase program	13,600,000
Preferred stock, shares authorized	2,000,000		2,000,000
Preferred stock at par value \| $ / shares	$ 0.01		$ 0.01
Preferred stock, shares issued	0		0
Unrecognized compensation costs related to unvested stock-based compensation arrangements \| $	$ 54,400
Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements	2 years 1 month 6 days
Aggregate intrinsic value of the stock-based compensation arrangements outstanding \| $	$ 161,500
Aggregate intrinsic value of the stock-based compensation arrangements exercisable \| $	37,000
Aggregate intrinsic value of the options exercised \| $	$ 8,800	$ 8,900
Series A Junior Participating Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares authorized				2,000,000
Preferred stock at par value \| $ / shares				$ 0.01
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0
2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option expiration period	7 years
Common stock authorized for issuance	43,700,000
Reduction in the number of shares of common stock available for issuance	2.8
Number of securities remaining available for future issuance	12,100,000
Maximum number of shares subject to awards granted	3,000,000
Number of common stock shares granted in participant's initial year of hiring	4,500,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of securities remaining available for future issuance	1,200,000
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant	85.00%
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase	85.00%
Minimum [Member] \| 2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options and restricted stock units vesting period	1 year
Minimum [Member] \| Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock purchase program offering period	3 months
Maximum [Member] \| 2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options and restricted stock units vesting period	4 years
Maximum [Member] \| Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock purchase program offering period	27 months
Common stock shares subscribed \| $	$ 25

XML 61 R51.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Schedule Of Option Activity) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Stockholders' Equity [Abstract]
Options, Outstanding at beginning of period	1,924,229
Options, Granted
Options, Exercised	(221,629)
Options, Forfeited
Options, Outstanding at end of period	1,702,600	1,924,229
Options, Exercise price of granted options
Options exercisable at end of period	1,195,037
Weighted Average Exercise Price, Outstanding at beginning of period	$ 38.70
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised	28.44
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding at end of period	40.04	$ 38.70
Weighted Average Exercise Price, Options exercisable at end of period	$ 33.81
Weighted Average Remaining Contractual Term in Years, Outstanding	3 years 2 months 12 days	3 years 2 months 12 days

XML 62 R52.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Stock Units, Outstanding at beginning of period	1,861,510
Restricted Stock Units, Granted	7,539
Restricted Stock Units, Vested	(10,279)
Restricted Stock Units, Forfeited	(17,010)
Restricted Stock Units, Outstanding at end of period	1,841,760	1,861,510
Weighted Average Grant-Date Fair Value, Outstanding at beginning of period	$ 50.52
Weighted Average Grant-Date Fair Value, Granted	63.68
Weighted Average Grant-Date Fair Value, Vested	45.06
Weighted Average Grant-Date Fair Value, Forfeited	50.69
Weighted Average Grant-Date Fair Value, Outstanding at end of period	$ 50.62	$ 50.52
Weighted Average Remaining Contractual Term in Years, Outstanding	1 year 1 month 6 days	1 year 4 months 24 days

XML 63 R53.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	$ 612	$ 4,185
Business acquisition contingent consideration	(10,454)	(10,450)
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net
Business acquisition contingent consideration
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	612	4,185
Business acquisition contingent consideration
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net
Business acquisition contingent consideration	$ (10,454)	$ (10,450)

XML 64 R54.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair Value Measurements [Abstract]
Balance at the beginning of the period	$ (10,450)	$ (1,584)
Foreign currency translation adjustments	(4)	70
Balance at the end of the period	$ (10,454)	$ (1,514)

XML 65 R55.htm IDEA: XBRL DOCUMENT

Legal Actions And Contingencies (Narrative) (Details) - Contingent Obligations Under Recourse Provisions [Member] - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
Loss Contingencies [Line Items]
Receivables sold to leasing companies under debt factoring arrangements	$ 17.3	$ 16.1
Maximum potential contingent liability	14.4		$ 12.9
Recourse liability recognized	$ 0.8		$ 0.7

XML 66 R56.htm IDEA: XBRL DOCUMENT

Derivative Instruments And Hedging Activities (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Derivative [Line Items]
Notional amount of foreign currency hedging contracts held	$ 651.0	$ 612.2
Foreign Currency Hedging Instruments [Member]
Derivative [Line Items]
Terms of foreign currency hedging contracts, maximum	3 years

XML 67 R57.htm IDEA: XBRL DOCUMENT

Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) - Foreign Currency Hedging Instruments [Member] - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Derivatives, Fair Value [Line Items]
Net foreign currency hedging instruments	$ 612	$ 4,185
Other Assets - Current [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, assets	364	2,346
Other Assets - Non Current [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, assets	2,504	2,082
Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, liabilities	$ (2,256)	$ (243)

XML 68 R58.htm IDEA: XBRL DOCUMENT

Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) - Derivatives Not Designated As Hedging Instruments [Member] - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income	$ 801	$ (2,272)
Foreign Currency Hedging Instruments [Member] \| Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency hedging instruments	6,000	(39,353)
Other Foreign-Currency-Denominated Transactions [Member] \| Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other foreign-currency-denominated transactions	$ (5,199)	$ 37,081

XML 69 R59.htm IDEA: XBRL DOCUMENT

Business Combinations (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended
	Apr. 04, 2016	Sep. 30, 2016
Brightree LLC [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Apr. 04, 2016
Total purchase price of acquisition	$ 804
Brightree LLC [Member] \| Term Loan Credit Agreement [Member]
Business Combinations [Line Items]
Maximum borrowing capacity	$ 300
Credit facility term, years	1 year
Curative Medical Technology Inc [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Oct. 02, 2015
Percentage of outstanding shares acquired		100.00%
Maribo Medico A/S [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Nov. 06, 2015
Percentage of outstanding shares acquired		100.00%
Bennett Precision Tooling Pty Ltd [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Nov. 30, 2015
Percentage of outstanding shares acquired		100.00%
Inova Labs [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Jan. 29, 2016
Percentage of outstanding shares acquired		100.00%

XML 70 R60.htm IDEA: XBRL DOCUMENT

Business Combinations (Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Business Combinations [Line Items]
Goodwill	$ 457
Brightree LLC [Member]
Business Combinations [Line Items]
Current assets		$ 13,868
Property, plant and equipment		1,045
Goodwill		604,438
Assets acquired		817,851
Current liabilities		(9,399)
Deferred revenue		(4,571)
Total liabilities assumed		(13,970)
Net assets acquired		803,881
All Other [Member]
Business Combinations [Line Items]
Current assets		51,261
Property, plant and equipment		5,294
Goodwill		192,325
Assets acquired		325,498
Current liabilities		(21,147)
Debt assumed		(21,201)
Deferred revenue		(4,283)
Deferred tax liabilities		(19,207)
Total liabilities assumed		(65,838)
Net assets acquired		259,660
Trade Names [Member] \| Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets		$ 28,700
Intangible assets, useful life		10 years
Trade Names [Member] \| All Other [Member]
Business Combinations [Line Items]
Intangible assets		$ 17,400
Intangible assets, useful life		7 years
In-Process Research And Development [Member] \| Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets		$ 4,100
Non-Compete [Member] \| All Other [Member]
Business Combinations [Line Items]
Intangible assets		$ 1,400
Intangible assets, useful life		5 years
Developed Technology [Member] \| Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets		$ 114,700
Developed Technology [Member] \| All Other [Member]
Business Combinations [Line Items]
Intangible assets		$ 20,515
Intangible assets, useful life		5 years
Developed Technology [Member] \| Minimum [Member] \| Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets, useful life		5 years
Developed Technology [Member] \| Maximum [Member] \| Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets, useful life		6 years
Customer Relationships [Member] \| Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets		$ 51,000
Customer Relationships [Member] \| All Other [Member]
Business Combinations [Line Items]
Intangible assets		$ 37,303
Customer Relationships [Member] \| Minimum [Member] \| Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets, useful life		10 years
Customer Relationships [Member] \| Minimum [Member] \| All Other [Member]
Business Combinations [Line Items]
Intangible assets, useful life		5 years
Customer Relationships [Member] \| Maximum [Member] \| Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets, useful life		15 years
Customer Relationships [Member] \| Maximum [Member] \| All Other [Member]
Business Combinations [Line Items]
Intangible assets, useful life		8 years

EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( )FA6TF@:=\6!P( '4D 3 6T-O;G1E;G1?5'EP97-= M+GAM;,W:2V[;,! &X*L8VA86S9?[0)Q-TVT;(+D *XTMPJ)(D(SCW#Z4G 2M MX19)&P/_QK(\Y,Q((WTK7]P^!$JSO>N'M*JZG,,7QE+3D3.I]H&&$EG[Z$PN MIW'#@FFV9D-,+!9+UO@ATY#G>IL>"KU;5^RI/+;JBK1 M]*H*QQO_UIEUX]#"L/EMQWC^C]=R=!-WKK^*YMX>%=B=;4SCL7;&#J=&=>_C M]J?WV_=\3&B\JI;:>8AE8%,? J0/"=*' NE#@_2Q!.GC M(T@?GT#Z^ S2!U^@-((B*DQW8OG*\M M"_V/Z'D4X$G1H>)%]2-F Q+M*;V"^GH A3&^.R6:E((C-Z."N[_8_ )02P,$ M% @ F:%;22ON=IL3 @ <20 !H !X;"]? [+&Q8@-BIFIS]Z%> M5.X/1UU8.AL01OKF73U& T]]KM=?TJDMQZ'/W7',JQ_G4Y_7\^^;JBME7(>0 MMUTZM_EN&%,_W]T/T[DM\^5T"&.[?6\/*4A=-V&ZGE,]/_TY>_6ZVU33ZRY6 MJZ_M=$AE4WT?IO?^_*,B_%J@ M"LM!LAPDE"!=#E)*D"T'&27(EX.<$M0L!S64H/OEH'M*T,-RT ,EZ'$YZ)$2 M%&L@8\U)0EASM(Z Z\CQ.@*P(T?L",B.'+,C0#MRU(Z [@M';P%Z"T=O 7H+1V\!>@M';P%Z M"T=O 7H+1V\!>@M';P5Z*T=O!7HK1V\%>BMIKP1MEG#T5J"WAM';P-Z&T=O WH;1V\#>AM';P-Z&T=O!WH[1V\'>CM';P=Z.T=O!WH[1V\' M>COI725Z6SM';@=[.T=N!WL[1VX'>SM&[ 7HW'+V;*[USUTYI]U:F M8W_(MZ[Y;3@LNL([EX]3NGW*92ILN-*ZS"NE<#G>_-_L,O5G2/CKZZ+G3U!+ M P04 " "9H5M)N4!WUE\# #$#@ $ &1O8U!R;W!S+V%P<"YX;6R] M5TU3VS 0_2N:7 HS!8<0TI8)GN$C+9F!)M-0. MYDVA0)%>24])?WY5-7 =D M!>=0+LC2OM7NOK=KIR]-^W2L50K:2&D.<7-L];#I5>D$M/NI9I*93SN!*L6P!TD:==KL7P;,%F4!RD)9.6W'?W7*>IH(S:KF2 M\2UG6ADUM63PS$#TH]<&.0(]3X!EFMM5W"YLJENYS811 9=X5SREPD!A]6\S MM[E4BY3*550\W7#Y9'ZF=^J*6JBB-@\*[W.J(<%+-[R7F[G-]0KS% Y[.:=R M!DG5]NWANA;WH(W+]*ASV,:_L@3K_<(WT(3+V9AR;>+^TIXN@5FE7VA:VEU9 M2A1SI)O[.XS/M,@C->"69ZTEU9Q*VR*&_\''3JNXMMC-UR(U5L.[? U:9E5&86OY1M(V^W<\>M #.:CJFV_ZD4>4[K0O3: MK4KV:Q?D7"9D("W*D0QE<1625RU)N;I4V!?20$)P993@"^ .=D!T_-B)MEB0?6*C*9DPF>2(QW459$QE6$5O9@!U1*U8,@8 M-,E[SVLVE$LD1&D<.-[SER&W^DC&@JZ9^Y7QU/%8DZ"Q![=@YRHASKNQSM3O M_9M2R6\NA/=P9.<8^E!:G #\40 Y-P9J'&&82<8L>:!:8YAUV5S!HS_HB57L MZ>"".EX&BU2H%0!Q Q"IHC45SC%S)1(@^+K=-XI/K)W1Y%#L[]-A6'#H!S)7A-!KB\*"C,<38U"@Y[?*C5\ MAY-LV"*HW>.C=VLW?$N-B(.Y!H5YW'V_,+<4(*308_](]2GTNZ/$1;OO?ZWX M,!-\;2894C^:;E=VQ9@4!\U%WFTW$WF15#-,$>>6QJ@F4WRE&3)LUB:!V&HQ M@=A\K;6-GZ*]*LSO78&E7 2[L9JZVRE1S?NS^Z5!?Y9A-L"4L3;'G/B'>^TD M*/JP&>8',"59\U?AB?_K*CAQ3ORC((SYM /F&ULS9--3\,P#(;_"NJ]2]M)0U1=#X X,0F)(1"WD'A;6/.AQ%/7 M?T_F=2T#+KMQJVN_CU_'225<*:R')V\=>%00KO:Z,:$4;IYL$%W)6! ;T#Q, M8H6)R97UFF,,_9HY+K9\#:S(LAG3@%QRY.P 3-U 3.I*BE)XX&A]CY=BP+N= M;P@F!8,&-!@,+)_D+*E?S-;8UE1LU-=5=-SP@ LKU4J!O.W&LM^IV!G!ZW"4 M@QS:T]\_/5"&)7WE/JBAJFW;23NENCAPSMX6C\]T-JDR ;D1$%5!E=@YF">G MSJ_3N_OE0U(763Y+\RPMKI=%5N9%.;UY/TQVYF\TK/LA_JWCDT':+BILX,+= MDD;2AIKNUQ@=7DY< MV=KZ[ICZ$9V]JOH+4$L#!!0 ( )FA6TF97)PC$ 8 )PG 3 >&PO M=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$ M[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4 M\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6 M:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+ MTHMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3 M:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ M %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ W MQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYK ME']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6? MR"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^: M/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B" MP#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F M.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1 MN0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/ MPT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,K MD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5; M\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;Z MEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX# M7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1 M/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% M @ F:%;2>AD811A @ 0@P T !X;"]S='EL97,N>&ULS5=;:]LP%/XK M0AVCA1';"4G7U3:,0F"PE4+SL+NN'(8(AZ'/2[9FJ@"Q*+D*X+*#@(V_$PD.X-/E^Q^E4+?O@!TO M/EQY]5S(^K5F=0O7FT *A7SR#':+:WS/NL:!" J6/AE90 M(QPQ;#WN$"61) 9,$2-T;^&Y >K3U/@QPH6L<]L,XSPSM\\DLRB ;O,[/5W4 ML]>#61ZA]'!Y&@C]'"F%)5_K!]#8FWVN%\<%QU9D[?>*=R;1WILO!P'UH/-& M0B98=ID]V$*A3W&J=( DV=:,2N1&NE!*,&TD!&6"(VHHVXC&T+0QIO31O+O? MTP/N*@76Q]38A<"H:$V]$8W9'X-Z4YTAF^4>TB[>Q NJM$N@HU&>T_UG2C+. ML!5KH;5HGEZC]X[0ASYJ6<%62/*L_$4MR7+,)R77^9SQ>VN)ZJ M,M-J)RMM-5UIDRWHXF:JRLPE9[+2?G?7G*:=#GKV0SM;S@A);.7QOY?0_@+4$L#!!0 ( )FA6TG$QAFWT@0 # 3 / M>&PO=V]R:V)O;VLN>&ULE9A;;]LX$$;_"J&738'MVKHY%]0%FDO; $T3U$'Z M3$MT3(0BO225-/WU):4X^52/C>3)NIA'Y/#,D-('=_1@[-WCLQB(2MQ:JJV$=J/LO%X,K)"<2^- M=DNY[\62V]J*=)$4[-@QAL1!S)Z*^A=.%_ M.6*Z"\YZBMDG7;,S[0.%G>M^\D)H8A_"G\_K[L'V2(8#>UZG?:@0=&)T+;03 M-0M'SBA9AZC4[)@KKBO! )0!*'LK* =0#J#\U:"9#S]AR J %2\%50"J 10 M^5;0!$ 3 $TV0;.V:;A]9)<+-I.W6H9DY7$.J\JT80X!M ^@_4W0&;C*AOI@_>._[$KQM7;_MW(5 M)43;QJC;F(JE\^\OA%^:FL6>.!\)V)-T8"RA[!=CZ@>I%+9!.5/"SDN_#)$Z M#ZFK;V.FL4_.B>%C4K3MK5LH\"A'T:T*5=GR@2HK2I91U$;4TJ@YE\Y]NUOPCMD?74D*V MSUQ:=L-5*]B%X*ZU8F/*4+F4<.Z;N.4J>-ZM0YT\(9-\,%CHZJ] HH@I8>*I ML/*>QXH>IM-YVY7!GOE5U+=8L-#%C'#QN'52"^=B7.=2]ZLD M#$C#!Q9SYG M&:(&U9,0=#.CV5Y84)1P[Q"#DF:$I)#<9'O4-",TW9GG; ]1:'!&5DTRT]?= M0A0:G!$&KS.>'!+JFQ'Z;DE]JA^H<49HO%D"R!ZAPAFI\-Q3#7,4-B>$W5D4 M\A11J&Y.J4L4!;)/*&Y.B+NE.A#AS0<+/R'OSM3."T2AQSGA,9G:Y/A0XYPJ MQ+MR/,?%/T>-_1Y7BD-_A7BM'J?-7;0#8WBSLY.LV"'ZY0!1*G>_> M#PP8K+^!*!0[?^LNH1CCU@U5+UZ_3U@'#%&H>D%N<;>@^L$B"F4O"-E?"A$& MZF092DN(WCFB4/:"D'UK6=H=2#=*O0-$+0O2>@M&.5YYAB$+1"T+TG=6S.$04BEX0HM/5\WFL^&J! MHI?;:OH&ZGG B$+1RU?7]"=4B=N1$D4OWU+5^W*(*!2])$3?BOHA*J,K1*'H M)2'ZSFUD.7BC&[S2$:+O7&M*+.LEBEZ2HN]"[2,*;2])VW>A#A"%MI>$[5M6 MP+6CB$+;2\+V+:BUH_C^B[9/QD_?,UX^8=1B$4AU_,#CNL=47%7QJT_XZ=_C MBC*^ <3S"U.'9\?/-0E;M$J=A&N7^IOAW4>-GKS^SO/Q#U!+ P04 " "9 MH5M))0$F4% " #T!P & 'AL+W=OJ+W'.TBM7*E[C0+9?ZIF0G5^RC"/'CH M,)/B."KP0H%F1:!BSP , 8[8L>-_ 2=7$<& ")Q!9.S1PA[#]ABTQ\8>+^R) MM0"N(H4!"0A('/O& KB*+0Q(04#JV#,+X"I0"!,V(&'C^I&%&"6ID73C-H=H M T.V(&3K0JR3$'9)]OD"-'CE@"$XB5'D1K"/&*3!*Q0XUY&; MRCBR;J-)LUPU%(=9FB2A/:5@<N<'[H#-)?TI+_*> MW.@/PF]U)[PSD^JJ-Q?RE3%)U8C"%W7@*_4$SXV&7J6N;E2=CX_2V)"L?[ZQ M\T-?_ 502P,$% @ F:%;29]Z+$.0! T!8 !@ !X;"]W;W)KRBPV$-[5F(E M-E:VO)(2;_]])=GQ.C/#H!?KP^^0+TGQX9"+4]-^[[95U<]^[NM#=S_?]OWQ MKBBZQVVU+[O/S;$Z#/\\->V^[(?']KGHCFU5;J:@?5V@,;[8E[O#?+F8WGUM MEXOFI:]WA^IK.^M>]ONR_7=5U';M<< M9FWU=#__#>[6E$;)I/A[5YVZF_O9:/ZA:;Z/#W]N[N=F]%#5U6,_%E$.E]=J M7=7U6-)0\X]+H;_J' -O[]]*_WUJ[F#_H>RJ=5/_L]OTV\&MF<\VU5/Y4O?? MFM,?U:4-;BSPL:F[Z7?V^-+US?XM9#[;ES_/U]UANI[._T1S"=,#\!* UP"P M'P;0)8!80'%V-K7K2]F7RT7;G&;M>3".Y3CF<$=#SSV.+Z>.FOX;6M8-;U^7 M:!?%ZUC.1;(Z2_!6\EZQ5A3N*BF&^J\F4#6!4SS=QGL]GM1XFN+M;7Q@C3A+ MPB0Y3)(0P;O(6J+(""Q9W8U5W5CIAE6S.DO\335D Q SO59D$4W,](U3W3CI M)C$W3E2#;JB(]XTB0VM=QHU7W7CAA@QSXT4U"9%[7DM5A&!)]Q)4+T%Z >8E MB%K !AL=GP":#E* I/N)JI\H9@&A'I_4^"3;0ZP]27Y0R83$OSM%%BV&S$B/ MF-3(8J0?@18C.\YX#&)>JD*7T&8X QG:@?3DN">0WWE,/A"WI.A2BB9F'.GH M Y2./'>$HB:/"3TW)&7.V90;-1VE(%G*L;2Z:&XKLH!RS*2,!N9"QH\.4Y T M)4Y3D)R$.,Q3$.N4)B2?

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end

XML 72 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 135 238 1 false 48 0 false 4 false false R1.htm 00090 - Document - Document And Entity Information Sheet http://investor.resmed.com/2011-03-31/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://investor.resmed.com/2011-03-31/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://investor.resmed.com/2011-03-31/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements Of Income Sheet http://investor.resmed.com/2011-03-31/role/StatementCondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements Of Income Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements Of Comprehensive Income Sheet http://investor.resmed.com/2011-03-31/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements Of Comprehensive Income Statements 5 false false R6.htm 00500 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://investor.resmed.com/2011-03-31/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements Of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Summary Of Significant Accounting Policies Sheet http://investor.resmed.com/2011-03-31/role/DisclosureSummaryOfSignificantAccountingPolicies Summary Of Significant Accounting Policies Notes 7 false false R8.htm 10201 - Disclosure - Earnings Per Share Sheet http://investor.resmed.com/2011-03-31/role/DisclosureEarningsPerShare Earnings Per Share Notes 8 false false R9.htm 10301 - Disclosure - Inventories Sheet http://investor.resmed.com/2011-03-31/role/DisclosureInventories Inventories Notes 9 false false R10.htm 10401 - Disclosure - Property, Plant And Equipment Sheet http://investor.resmed.com/2011-03-31/role/DisclosurePropertyPlantAndEquipment Property, Plant And Equipment Notes 10 false false R11.htm 10501 - Disclosure - Cost-Method Investments Sheet http://investor.resmed.com/2011-03-31/role/DisclosureCostMethodInvestments Cost-Method Investments Notes 11 false false R12.htm 10601 - Disclosure - Goodwill Sheet http://investor.resmed.com/2011-03-31/role/DisclosureGoodwill Goodwill Notes 12 false false R13.htm 10701 - Disclosure - Other Intangible Assets Sheet http://investor.resmed.com/2011-03-31/role/DisclosureOtherIntangibleAssets Other Intangible Assets Notes 13 false false R14.htm 10801 - Disclosure - Product Warranties Sheet http://investor.resmed.com/2011-03-31/role/DisclosureProductWarranties Product Warranties Notes 14 false false R15.htm 10901 - Disclosure - Debt Sheet http://investor.resmed.com/2011-03-31/role/DisclosureDebt Debt Notes 15 false false R16.htm 11001 - Disclosure - Stock-Based Employee Compensation Sheet http://investor.resmed.com/2011-03-31/role/DisclosureStockBasedEmployeeCompensation Stock-Based Employee Compensation Notes 16 false false R17.htm 11101 - Disclosure - Stockholders' Equity Sheet http://investor.resmed.com/2011-03-31/role/DisclosureStockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 11201 - Disclosure - Fair Value Measurements Sheet http://investor.resmed.com/2011-03-31/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 18 false false R19.htm 11301 - Disclosure - Legal Actions And Contingencies Sheet http://investor.resmed.com/2011-03-31/role/DisclosureLegalActionsAndContingencies Legal Actions And Contingencies Notes 19 false false R20.htm 11401 - Disclosure - Derivative Instruments And Hedging Activities Sheet http://investor.resmed.com/2011-03-31/role/DisclosureDerivativeInstrumentsAndHedgingActivities Derivative Instruments And Hedging Activities Notes 20 false false R21.htm 11501 - Disclosure - Business Combinations Sheet http://investor.resmed.com/2011-03-31/role/DisclosureBusinessCombinations Business Combinations Notes 21 false false R22.htm 20102 - Disclosure - Summary Of Significant Accounting Policies (Policy) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy Summary Of Significant Accounting Policies (Policy) Policies http://investor.resmed.com/2011-03-31/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 30203 - Disclosure - Earnings Per Share (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureEarningsPerShareTables Earnings Per Share (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureEarningsPerShare 23 false false R24.htm 30303 - Disclosure - Inventories (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureInventoriesTables Inventories (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureInventories 24 false false R25.htm 30403 - Disclosure - Property, Plant And Equipment (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosurePropertyPlantAndEquipmentTables Property, Plant And Equipment (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosurePropertyPlantAndEquipment 25 false false R26.htm 30503 - Disclosure - Cost-Method Investments (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureCostMethodInvestmentsTables Cost-Method Investments (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureCostMethodInvestments 26 false false R27.htm 30603 - Disclosure - Goodwill (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureGoodwillTables Goodwill (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureGoodwill 27 false false R28.htm 30703 - Disclosure - Other Intangible Assets (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureOtherIntangibleAssetsTables Other Intangible Assets (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureOtherIntangibleAssets 28 false false R29.htm 30803 - Disclosure - Product Warranties (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureProductWarrantiesTables Product Warranties (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureProductWarranties 29 false false R30.htm 30903 - Disclosure - Debt (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureDebtTables Debt (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureDebt 30 false false R31.htm 31003 - Disclosure - Stock-Based Employee Compensation (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureStockBasedEmployeeCompensationTables Stock-Based Employee Compensation (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureStockBasedEmployeeCompensation 31 false false R32.htm 31103 - Disclosure - Stockholders' Equity (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureStockholdersEquity 32 false false R33.htm 31203 - Disclosure - Fair Value Measurements (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureFairValueMeasurements 33 false false R34.htm 31403 - Disclosure - Derivative Instruments And Hedging Activities (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables Derivative Instruments And Hedging Activities (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureDerivativeInstrumentsAndHedgingActivities 34 false false R35.htm 31503 - Disclosure - Business Combinations (Tables) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureBusinessCombinationsTables Business Combinations (Tables) Tables http://investor.resmed.com/2011-03-31/role/DisclosureBusinessCombinations 35 false false R36.htm 40101 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails Summary Of Significant Accounting Policies (Narrative) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy 36 false false R37.htm 40201 - Disclosure - Earnings Per Share (Narrative) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureEarningsPerShareNarrativeDetails Earnings Per Share (Narrative) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureEarningsPerShareTables 37 false false R38.htm 40202 - Disclosure - Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureEarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureEarningsPerShareTables 38 false false R39.htm 40301 - Disclosure - Inventories (Schedule Of Inventories) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureInventoriesScheduleOfInventoriesDetails Inventories (Schedule Of Inventories) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureInventoriesTables 39 false false R40.htm 40401 - Disclosure - Property, Plant And Equipment (Components Of Property, Plant And Equipment) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosurePropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails Property, Plant And Equipment (Components Of Property, Plant And Equipment) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosurePropertyPlantAndEquipmentTables 40 false false R41.htm 40501 - Disclosure - Cost-Method Investments (Narrative) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureCostMethodInvestmentsNarrativeDetails Cost-Method Investments (Narrative) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureCostMethodInvestmentsTables 41 false false R42.htm 40502 - Disclosure - Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureCostMethodInvestmentsScheduleOfReconciliationOfChangesInCostMethodInvestmentsDetails Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureCostMethodInvestmentsTables 42 false false R43.htm 40601 - Disclosure - Goodwill (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureGoodwillScheduleOfChangesInCarryingAmountOfGoodwillDetails Goodwill (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureGoodwillTables 43 false false R44.htm 40701 - Disclosure - Other Intangible Assets (Narrative) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureOtherIntangibleAssetsNarrativeDetails Other Intangible Assets (Narrative) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureOtherIntangibleAssetsTables 44 false false R45.htm 40702 - Disclosure - Other Intangible Assets (Schedule Of Other Intangible Assets) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureOtherIntangibleAssetsScheduleOfOtherIntangibleAssetsDetails Other Intangible Assets (Schedule Of Other Intangible Assets) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureOtherIntangibleAssetsTables 45 false false R46.htm 40801 - Disclosure - Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureProductWarrantiesTables 46 false false R47.htm 40901 - Disclosure - Debt (Narrative) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureDebtNarrativeDetails Debt (Narrative) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureDebtTables 47 false false R48.htm 40902 - Disclosure - Debt (Schedule Of Debt) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureDebtScheduleOfDebtDetails Debt (Schedule Of Debt) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureDebtTables 48 false false R49.htm 41002 - Disclosure - Stock-Based Employee Compensation (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureStockBasedEmployeeCompensationScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails Stock-Based Employee Compensation (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureStockBasedEmployeeCompensationTables 49 false false R50.htm 41101 - Disclosure - Stockholders' Equity (Narrative) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureStockholdersEquityNarrativeDetails Stockholders' Equity (Narrative) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureStockholdersEquityTables 50 false false R51.htm 41102 - Disclosure - Stockholders' Equity (Schedule Of Option Activity) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureStockholdersEquityScheduleOfOptionActivityDetails Stockholders' Equity (Schedule Of Option Activity) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureStockholdersEquityTables 51 false false R52.htm 41103 - Disclosure - Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureStockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureStockholdersEquityTables 52 false false R53.htm 41201 - Disclosure - Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesDetails Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureFairValueMeasurementsTables 53 false false R54.htm 41202 - Disclosure - Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureFairValueMeasurementsReconciliationForFairValueMeasurementsUsingSignificantUnobservableInputsDetails Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureFairValueMeasurementsTables 54 false false R55.htm 41301 - Disclosure - Legal Actions And Contingencies (Narrative) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureLegalActionsAndContingenciesNarrativeDetails Legal Actions And Contingencies (Narrative) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureLegalActionsAndContingencies 55 false false R56.htm 41401 - Disclosure - Derivative Instruments And Hedging Activities (Narrative) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesNarrativeDetails Derivative Instruments And Hedging Activities (Narrative) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables 56 false false R57.htm 41402 - Disclosure - Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummaryOfAmountAndLocationOfDerivativeFinancialInstrumentsDetails Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables 57 false false R58.htm 41403 - Disclosure - Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummaryOfGainsLossesAssociatedWithDerivativeFinancialInstrumentsDetails Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables 58 false false R59.htm 41501 - Disclosure - Business Combinations (Narrative) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureBusinessCombinationsNarrativeDetails Business Combinations (Narrative) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureBusinessCombinationsTables 59 false false R60.htm 41502 - Disclosure - Business Combinations (Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives) (Details) Sheet http://investor.resmed.com/2011-03-31/role/DisclosureBusinessCombinationsScheduleOfPreliminaryPurchasePriceAllocationAndPreliminaryEstimatedUsefulLivesDetails Business Combinations (Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives) (Details) Details http://investor.resmed.com/2011-03-31/role/DisclosureBusinessCombinationsTables 60 false false All Reports Book All Reports rmd-20160930.xml rmd-20160930.xsd rmd-20160930_cal.xml rmd-20160930_def.xml rmd-20160930_lab.xml rmd-20160930_pre.xml true true ZIP 77 0001193125-16-750066-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-16-750066-xbrl.zip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
(IYXG7]SP?'H7).0O7(DEO3";\D"Q ^7&8SY8*QU);?!4:5V]DXRDX MG!M$FS[*-RH2')>93 @*7H=.U]# !0YL\+(HD6#' 1;/!4F"UUT$V@$8@5;2 ML8 ,#^'YJ61&N$X,^XS8+Y5JD)!1&!R3/K4Y3"0YS$3@^&)*KU#\PHW=Y=C> MS[Z6\'FQEYX;)9X7E0-<$K(JI@>8!'@:+PZ0'C>"(A[='U ?2#D&E F##-Z4 M*AM-,F:4$Q;NJ?PC /M4URH$=[FR\C]%\#?-S4QF,T?>)M?>)(W;B 73'W#& MR!!&' @44(RWT#7( JA(2%O2&N$:J%2)J9^2,=S "QP+A1XB6*GA,/D?@2M- M_=3^OPT1#A9:.PQ^&5B I-G B#SV&?^SH%;P3%*K6FMIU:R' ')^.M%/)NL= M,TYD\J;\D%P6B3^$JS9I5V2F:SDWC..J$=AA>#Y>Z>:VR6:6@*Z]9\;OP0?A M19K?9-XAK].<>>B'BQO6/_IRO6@?*_OS"UOUY,J65.Z1@/ M4WI2QL-,J7D+GL]^HCT(K.X@I[[WKAF(M/L89NH0%OT$W>.7K(>'["%/A9_. M.,<022:Z&VRN[.R,ZJMKZ,V3SWI+3RR_;H?X7@BX[_/A;Q*P7=\) :TP:[AR M9Y?X9R3X[(G:#DX&+N)*B$ F/OM;R9_14OWDLU'KQ%38%/HI!>X&'O?O&1^> M>YQ[ST H\2L')B_!K[7VOGJTA1)S:]4<&T&Q_NY^:BA^XO[8T/9!0G^,D*[W M'O ( @_!9GM]+->97 K04"KTV^J HSJG _"Q<)Q T=HY1&-8=;R5_7 M:+;#'>77)]D0D/5%L*,U.MV- 9E:N>_,SX(N]8ZA=5I+X5DVUU90I=#31ENO MMS>'B@?2I'I#=D]?F,B$4%V]M4"GY?-L#DX*"G4ZV@*!4H!S;=,>:IZ=#77T M9JNC-9?!LSC1YO"DJ+-KUKNM!35;$YY@&#B8-EZR$=[C)DTY_.VP*,M*ENW= M<%SA\^H,_; !^N M)[_2MO!WN9?%K+,GQB')_"E8/W"N[?[K:7 1NUS>-/^5).OFE#E>&K_61%>1 M=P>MN&_:I2?JSIOTW^A:Z8E8B*M';CJ*#WFXD^D(+'4>KZ*[T17=#R+N1V#_ M\WK!\$U+D?Y 5ZKORLI;EL2?.C?4AD$NZ,CVJ9/8YMAN1:NNU8WZ7/[^YI09 M@)ABD:MNZ$W#V Y$Q_&>7S+A<:]Z8.(4R-]J-3M-(-S&N-66!=*?> MZLYOMJKIE\2:X1E.\G@(UY]2],E8;UHAKDN\_T;7/L7 MN>8L3[6J9I0!XRO7>Z+7M"=F&:I7C6X9T/M&N=WS)#N]NWFMU%H[0S%9 MC/A/#XO,KK 0F@E?Q!G&6N58VUJ@-ZHG]9KVNF5: X]"$\4K[!U&9;DO5D-U]$:<37<)@BL@_JR%D5Q MBR>VD+T_&P$Z\\W>;DJ>'0_LYAOM.; M[\FR@\C3OV+:D03Q!-GV0&NG5F_N$]'M#^/.'+Z-X<_/ =NWVCI- M",.+OKB]G^$U.93':AJ!!*1MS#EN\@<@8V;$J0'=,)V%E'3E*B]@^PX-:&<.;7I!+][G%(B MT6L%B3U_NGV-,_O<&Y(985O9\B()]S- V _D(7D_ZF]E4C$@GEL=R#9)^",@ M$9]"#.=!D'A\@(V8\G@8Z ($>FXS[%/L[C4:'@>AR6Z+3U! MID!C?V%/"GKP6=R>CAO;C-D4N*6F!+"(VA7UF&-#SA%VN0D;>@RCPS]A(QR M]=GC?P(,C@/^ WOJR%930\\"1H28 W8V-MGEX]546 5'V%('Z3)I>80F:C4U MK;#+'4[\[X!R "ANP'/)S*B_B;Y@1K?W3&!^M[R*.ZD9'/994F*#3X?IXEVJ?H"M$T*TD^*;)!>2:#T. M5"9@Q1RP($C >CIX^BD<:HFV3D;%AI/8N@G9;>H!?(> M&Z*Z(::)A9)GV_('0#/M[R>QZ?%E2&HGR?NFP&2$?WF M$-YLS6EV9.^)\3[H].G MBRV6I8R%J=948I$R[?2,:_1E1*AF+?(O/FY_M=< MJK(MZ36CIK44Z7=,^B&,[; YTNN=6J>A2'$TAM-97"R)WWXF1?-C\L5,_)? M85G'VZPQLN=-TE=OY*RC<2^ LCUN)QWX03WX/&7G^+;\YP3CEC^0)\Y-](CD MQ'/OFN3IS%AA*9["8;]!\;>,4SYD/)'%8O4>X^O:J\[&N47G]4W0'?KYP?JWRU\M4%]=5&I]+6 M-.6L<[NTI&]Z_F R@KP3,9V-4I&!B@Q*I\7[W%"KCKB'5P3C7< ,#W#+Y#XJ M)E?IO0H9"APR-"JZBAAR'#&X'Q;/82IGKYR]^NO'M! MO;NN-]2*0*[]>W/K!0'?V_10\V2,3;N:J%4)%:BH0.5 I87A%4F3EA+RCB05 MJJA0I:"A2E.O:"I2R7&DDL'>10:ABKY]P*1B%16K'#96R<[48>L Y26UJ@TZKL\RG!\$8HJA+]^>NSV_U)V4U^$K]UX8=I35O9==C;+>.0B;$B0: MV!8D+U?;!FK;8-Y)O^M6ZMWN>^6:S,+<8+NN M:\HO*[]\0+_57U8;V!DX9KS0IGB)?8C].P=K5[I=')<#Y=_T[07'Q]^ MQ'N!)U)OV4_)7U^[/+G>FA6( M^"(A1(8:V\5'JZ7CDF1'3&XXL3K;P\Q7G:_/9@ "0(G!I0#@VR77 2<^O83(]^899O4(?>3=E_DRC5K%4*) MPR@Z?C+BWA/PF^,H$*& <7BB M]] AMAA]TW9$=0X3 VJ@) ,O @O0XH_X MQQA&TUCLR39QC1 >IR8V%?6X'8$$#]):PNM/_EH =D#A#4A(0,:"/C7]@.,< M/2H8#G07_&?@!95PP I W9=3PB_GS/X#GJR07QF'=\<2#"3,3]=&!M[YU&>B M$D)' !&?VST(B3AQF?_L\3_A80B8'F%X/QQ>/@HC>]+N".8PTP>P^)^0+R5P M(,[A,%#-$.M8S=#WR@HF!?JM4?./MQ5YO0.WHA-Q^0R(=*''WPT M+5*7+9L^NIZ0?Z,V LOI(]J#5\P1/A>J+ RLL&\>'Q,XDF(CO M$-M@E*77,"5,F^HS'7MV+7YG+G@)WURPYD)X *P]Y[GH+[=^&-R[5NHH.0, MN,Y!&N!/]-B6Q!6=L3^@/@0( N1$Q)HA!!$C&!I>_@^."E/2T<@! MZR C?6D7KFT@%7AR&[X& &Z#'O"FMJW_S;TD*ZU--\8_0+0HF'RC*Y5VTP:0 M)5#:*]=[HN2:]H0,_,F[2)2 *A07%R1(W!4B] MAF>'C(>/T9@^MHMSR3#?>QD_,ODJ"-88\P\K,'WE>LN$Z_V B1D=$9#5 >][ M##@/F:$7N*A(:-(AV>L%$-_A#10@.CU(N\(7\$M(3P-N#J@<3+X5QW<@X " MZ006"U.T@,/KKEP$IW)L&,A%*02XX0L43_ AW!NBY-EA: CI'$ID4I?Q95$C M][,J#EFC[5HV),H!=9QQ).>.$P[@C"L2'M?S)0QV&)""%L%@'$%8AF&<)6/D MZ3XZ4A.0(D,*<\E_Y5.VD.-&:;JU-(6>AQ;,%8#3#UQ+6BN9U!*3B@&!!'\@ MYX7_>A 3<_J,%/5" K(7",[QLPGPVQ"*4Q/+?L89YKJY%]UC4M,O+R8;11D7 MB-!$UT8O5L^P/Y=,*U)&1O:Q]605\KC<6LPUT-'&A_ MW"86>S#"+_C"G/VI;>^B?V>@(&@S<)88.*DWJV%#TB8(985K68C/OR%" ;83 MYLIEN$MF1HF&GE',LM12 Z6MWV<@1:IQQP;7'\8V"-&$4DBCP^I.-@A7%7# MWG@34PAV;NA9(/4A4X%Q]A ,(@1KZQ(Q-,ZF)_PXW)DU?>!0HG=1HY: ()BF M]^@"]2QT="-@>32@F/)^$+'BZ_W \SB5!Y6)EQ1C),BCV*^GA95)F(5 M:Y$%P1SK!UA(_!0.!6A1]U$*^,*H'+\#000E?A;DG90Q+Q PJ'A_6G:R%TC$ M]EON -'W7*T29,R3K7!9$$),YCA10D,!O!T)-AI M_,?'<&#@HB;K=T*:AB4ZLP4L=!"=1#9J 1U37&: M%:4-*[HV.6=Z),S;HK1K9V=&%>G3DCXO_1T4Z3/#RGQ?93_.!%)Z[%.<^#D_QHI_?*-))FS/'(;+V>"NSE,+/E\,L'9)E5PL+ M3-7I(E0_7>\Y%34<0]2PQU.F16),;F.'_KL,5D:Y;^6^E?LNM/N^YQ14D0X+T_Q9^6KEJ^=] MM=ZN-#1-.>O<+BVU%XQ+R@'(F%&>SD2IP$ %!J53XOVI['?/K>(!#^:K>YM4 M9%#8R$ %!KD.##9MKZ$" Q48J,#@0)='Q8E.% M""I$4"&""A%4B)!-_9\ S&4[QK!-AQC8([7!H(*$H@8)]7:EKM55D%#B(,'W M-FT8-!FCHR*5?$FDBE0*>I!H?X;CUZAQ4T&"$W46L@Q77V>^R]$U*G5#+6*H M:D7EK@OFKLMQ\'=__OI,W5U9R 2M*(<+B^'PP=E7&MU.6H>OKJ=6[CV?["BK M>R^[&F6];Q#V#4CTF"U(7JXV#=2FP;R3?F?H%;W1?J]\F!NH MDWIYMG7*,;_JF!L5HU-7?CD?LJK\LO++JJPL \>,-_D5;SD[%]O51^2AB['K M_$[O0NZL%K1S(JW*1RL?K6K)MG#2]YY/G647FJJJ,E55=H159>]:S4JGWE'^ M7?EWY=^5?R^\?__._/G+QI5G5Y[]"#V[T>Q66JW4C?#VY^+S;YKVXN/#CWBU M_43J+?LI^>L2L$G\7[TU*Q!_!,*W^^/PJ^C#J8V*7+4MYCV"= S6=J1)E5Y? MG]_VEQ.T1S-HQOB'T\!0GT[T\(S\:L.0I!=)?OCE0R"JCY2.3L\# 0 *<>$- M>[8K>Y-II9G8689'5\R 7R8[);U/YVXR -9[=:[ MW9*2,][YO0TKLG(AO@VC4]\CN>=(4&3J;R#;C69[Y\[L$,2.)[JG+XD?OWNN M&9W:RX.DZUU#VYVA?HL$NR/^5QC -6WJY,\SPG0[(_@RM'='Y.D5\N'#DCCW M ^K&3:+V0?').("[[;-K^VD1L//Q-_J'QR\<"M/@V/$[<>/-VV3?S77SP79= MVYV7>).VBJVKV3IIN7X_Z;A^BWYI7=8:6E-O*M;FD;7H/,);=LX>(D*NABJFY8ZJ\5/$[7JJX+BO;BI>91>@'\Z!R45!Q,0=\,]$^:Z98)1;@X K8B]Z"S73U=;KW?;N1'4O%,22J3P(H]'LMEJ[HR6@F6\:;K(MK=4[G=TMQ>V4 M9.#B1XS[XQN'NCX\\06>E>X]%\+8-+J-G=%U)>I%I/8F1E-K[&YI:DWB7E"! M827^@T\\40>78<[\"\KYV'8?_TF=5_>2FF]BV=;;1F-VRW.M2;.!L[LVG!W# MT)KU0\$Y$;:WZ5G7&_7&H>FY!IP='>*JW#LB,D6DDDWF9!4S.,S'#PAD/;EXNT. M"0QCKHD!YXNP3UW;^73B\X"=I)3N#QG.\QIIUI]G25ED&JY\QOK+9"TF_#U; MNAI6!V/M;/0YK/:=*:9]J^+5:,<5K[:+GN&45.57ZQ:U:AM6M4Z ?*?7WR>J M?5_]ZYH]4H>$Y)'//II# M\!4!AS\F-K9!G1BAG1 2] M/YCIXXUSW O ##B3&0#YC-M%%X8 QZ 428#U*9D);\/;(?)^3@3@>,+G,D? MV"(YE$E=U_-)CY$1!,BVZ3.+/-O^@)@0$U,@VUC"U&..S9YP-.KCD#8G?0B\ M'9C<-[TA(W(=$4:J '!@QFTKH(XS)AZ'SX0^/G(P;#ZKD &%42@9P@=NP_O4 M>F)(!-;O([X $:(#3D2>YJ (3C\N\ "ZPQ?2$Q&?_LE@8+"1Y'G@.:Q&CDB, MBFL"EV$S\7#^!K/W!-@5X=>$,Z7' 6L*Q& M5L E 0?H'3AC9 B,&0B"]+?('1OYM6?X_W? M]':MOO4H!(340<>(4&8 4ZNF;S],!%,%'?D(W*3]Q)QQR*PA?;&'P9",/!]7 MO="C2J)N/>=B&[+4I 39,:>V/>ZA,@9)13L, B-0 4 N'R.G#K'%"GGY1P 1 MT.2;9P9JDP%S&K5&9@)3R4IBC%HW0Z!F)&:9N;J7\6&DRU,>\2S5JMKLZ"_-7W& +^^ MQ+H4X'I& -]0_H/?83)HR97P^,4T"ZK+ -2TQE((5\V7!8"I*)@9@/)7<1;X M X]+(Y^"<@MPU9O:?%'C*U-M ]-*8NT6IBLA@BUII'?T=J.M-]NOP!-.LRDL MZ],&8.FV&_7&1!7S9P-B"DW776M*8\<;P:B\+\Q M,-_6E?O$1!BT;55]831;"_YBR1R;@;$^W^J:WC%V!<;Z^E:O=_1Y*Y Y-=8 MH]5LSRO^9F!=7XSK:Q@S3"1VPBPI9!M1, ]$FVC8H/FVK4&R_Y" MW:F&RD,2VK/EZD.S,;?C5"W7>L3K)1?UYFB^ $5/?)E' N"BX&33EIA1U5EB M3R#YX[?$@+&9 MK:6M=[8/((*MS22PM6L-S*.R_<[(2-85VJ:LF6!/D$"@WDEAB77O2=:9OJYZ MH%(0.X<[A6'UF&ES,QAB)F+*G42J&\DJ&=$RBVA#<#7ABG%E+ MMQ 8# 'L8P]ZG-UX(7]P=P+B$0<*DJ]G $;\O=2\?#GT ?@"HQ$!Q5+I"[ MEM=XP(_48;P1Y%IR-TQN_4Y'CW140C#P',S%Y&[JB-M/ "N0>L +D5:X=H>T8"^0=$-VC=NI" J^@W"SOA<](8+1R..3,AJOA\/+ M#5Z0S3^!K#"[B5NMOWG/@ &O1#LD,Q84QI+TDYLO'#O*,#0-X78*$->-NQ:' MCT5 FL"ZWF2>*2 (9. F( E)%M$':=D/_(#++>L!P0:FRW>V@<^R?,=BH"E# M$&=K*DCK\QQ(R.2;B,BL>(NMMSF4J//T?M1=V83F$U'@IW&?WP,!P99TF2+Z/G< M>1;=3:XRV//-F.FZK&??IW_.=0T= ^O#S]K=!Y?MR M<;UF-'-]IU!F8=)2!BT/D[:]3"CW+-KM;;Z !20Q0/+&R1L^ ]*617=="NH? M\BJG>YFT?PN3]B^+27LJ-5)F\&C-8+ZNF"JN&30V,H.YNE&^@%805R8WTI2= M\FW/U]L5DV]-Y:&.V$.E6,\L1:BX/Q:=1U41T39CCP$(+F[U1/M#XNG6][8NA,E6X_,ZU_86J]7.N!W4M[7JJ2]Z-*>^M+O M4DB[T:RTM#=O)U:!52Z\=OXVBE5<-U:3=YVE7/B)BKM M9F>',9$2XE)O$N=#B!N59L=0H4XA'&D1UY#RL6)[L$4DYEK%7#XZ^@V2HJP? M[4;!,E] :E6:[7J.%Y"4O!=D!:D@\JY5]-1Q5?@1CSY,6!"U 8A_778BIZK5 MZLL.Y22[K._TJ,Z&)W4V/904TR:<)L..;&NVSB3ML6)KE=1?M MNF;,7=8Q.]OFH*3MG])M&?("K#5!N60]/\\W-N3WV)KJFG&8KAFY%8AWW?<+ MI-Y(J#9LT['UY&@+-F!*:[1XQ<0V3#J3=P" >3,]BY%O=UMRZ4W6SQ)@[7[# MV*?!%GB4.DH;IV=8YXZ/KM.KH0RG+#5U4*^XIRP-=>CI8.?-U%&_0YTWZRC2 M*ZD_+M(KJ<_Q*TL!M76> M53IU#(.32W6%21%W449<5(.8J#9\?%\!1&MUMI&=EUGE&BK$3Y@*+R;R2^:.0>148J<"HI(%1MARZ]MS'Z<)00?:] ME%O)]V&+?.30G79SQ\5!2HR5&.=%C%7$DPM_JB*>O'-H5=%/06(?M85P:*]1 MC!V$=WJET>FJJA\EOD45WU:KH^I^\NQ)5:R3=P[-KN[(LA]5]7,\CN(H2B4Z M[7JEJ>NJZD>)B>\^GSEYWMH[05QSG@>%B M>!2]HH-/T>LM%1XID3\>D3&S377H[XM*/V!6>6[9.OU+0=VQ_G&/GT3-\ACW=[ M#4AZ-L]Q]8=+?IB^)YO&Z;+16+U"GO$.+0"(6?"J[Q%*.'ORG">YQQ>* 7WD MC.%U'15"1;0%R#B\:OL#XC 7+)JHP-NF$Z#_P![PGDO.J?MGA7ROG=7D:]0: MVJXM?+R3XHG!F'*\/SR8%,:@%J&<4_<1QQ5R@Q'1B$:7;=P=Y@.8 MNV1W#9 M0@3X//[ZV]WYA9R2_+P[@VGES1<0QYX)X9FV_"3!$&/7LDWY.81!OKT$C 7_ MDI;:%3+BWI,M*=+W^#+"]B/]0IS^U@;[#S+@2$@E::E+ M?TAD/;E_WJY34I M!'@$I.:,"B;[UZ\>M3?&(="I1\3X6WTZ1VWQ+.,&\G0VXK9#&F'7.I0![*_O M,E-"*I'P D#=_'=@"PD%HGHN/1'(%+F^OB#O(A6$$2X^3GZ:?GGY\?TR*>W; M7 #S0"PM%$TDRU)J3(1W@7"(37P)P&HB]KDWW)Y4R-VM!XE9AYAL#Y&^/3R] MW8KK]CC6,Z1Z:&< G2']$^0&<.%DZ%EV/S(G G\+59Y)A4=L5TE^;6NP,KQ MY!X G6<&;H#8+O7!&P'HVYN*6;_3R<"Z/@\82(OC@-"-*,308(E5YE.[Z5#PK5EMT:=$9"2RL]6Y])1[;U3%I- M;^9$MC1(= \A7$3^%%H]?#QP P$2,_)X;,.76('0BLR;!NH(+XJ*83R:@3LS MFMG%$"+H.?80X057M1!;U]:Y_.B R9!*^U+X7HC /6#V8Q2F3)W9*\$RY2C[ M@IF!+/L,PF\> PK9D<_PJS$Q&?>I+94"HWS+YA#X1]XW^O"S1NYJ*&L"$B'* M0;&2B>(M$]]@J N/CR!)C#Y]\WR0R'MF#ES/\1Y1%Z]<$WX_M[EEL^C#E>L] M47)->Z(2_QS'5HD_P4WP)]N$(2#32'[_FS>$_\>H W&KE 7\#[X5(WA:IB6( MQAUFJ^S1-LG9;3A"$*6C,M)U)Y%J1)=90S E)M[*"(02Q 19 9SH)WWQ%QX M988>,4'[$'F!-X*!)X])>&#>*2,CY\8@'K7E\$M>ES9M9@H*C[_8PV X9_B0 MB7W$S@I;(X,-_W)^=7]Y1MZ!([08C"ESKZ3YFR#X/H9NXGT1[NG@RIKD!=/M MK8!&_;N[.9Z \L5"9AV]\Z[68MPWP]&6B^8GTGX42^94AIRQ8K MZ_=86'@-F:@RB3G!-)-U];?705'CI_%'8EU(+F[*7&%NA7,AC'B'8R172V65 M*BYK+#P[LWR:6(C.(@O)?#K#SG-OLIY=KW M01< )';%;@3 M3<<@D7/[%LGM:- D:* Q#XS\#=4Q&/W&0LUA[V $17P8472 M,S.._")%S8;<#(6Y9_]/)91"J\$/[ M07] BCW<>P_=A[H6?HC&?K@&JO_HAX6=<5WGV8LM'OC0>I 5>U@]]_W,M7X3 M/1/__BGH-\F+R1BW6!DG7XJ_^19ZO+GGDL#./'X-:8'G7J& ]6"&'_T^+GC@ M8S).#8$8)TZ97P#R$\&ZEZ&_@NFLR+<%WHHIQ4#_[S!S!MG"5AZ*; MW,%;:@\;\+^Q/9S\?0B)^GRC_VL5YOCF(GK8] 0#9R"TO/<(_[[PACU!:DVH( M5U-?7"O8 *ZOU.;_I$X &>C<^VL%->?400]]-V ,LH/P$.A,_/(#=RXB'Q6: MF;GD;CKK-#^[M<6?,Z- P,3L1_?+BSG U:T+@(Q3<\7BP:*$U1OSIN]M] ]* ML*D].1C-M,Y\@K4GFBU9B"J"D-5;C6+1*PZID1+(6@Y8-@1C.5V=^,8NNF_WM N*%WY@.IMT#/ -5% ML=@#JA"6983I%$2!*^S,>L0-%EP+EY']DGJ%-,'O9ZR$2%9%P-^SY2EA&S6L M_X@^AWW19OK/O5G5THY+6FS7 DQ.255^M;>JE7=ZX_VR$_K+_IJ2GB1H'S8P M"JE/IN3?MMRG5>MBN0\"7HWZQS6UO^>W_"?+4J=VGNN@3=D5Z=&5/&]>?!V2,M7[2'L"8 MW L>!Z3G12V>5DT GX%^01]P#;@$?R+?E6GAO!NWZQ+4P?+_4526*);VOHA! M90);#]IBP"QL"#4/["#2J!%'!@\)4AH^!1RL+A9)3AX,.Q6%:@BC/%-N23N' M-EG6.^)(+)Z@&K]7!7/CA2<6K$1A,)41984XTR42.?(L&4PJ!@2[A2]',:YZ MEBT91& .5J,WA?21N4 WQQD#5XGK^< N+"7=OI0;N,VV/U1%\%#5:G0?/2"> MK%.UQ0+O;,D'!K@"Q4V)(] 3MZEEA>R$^/9PA%J%I=>K9!=KKZ=\PPIO& RT M#[4HDLDWM649#C^C"D0 -8*Z,NE\!6SDZ,6C#W@J"'1F <2U!2H$LV_+G>BX M#8R0AY!&E/NV))#7[V/6U!N31UDA+YOH>4),FYO$5+:GOFC[JW@)F=#+HX5IZ;V)#7DM7JJ)6RJYN-7>R8O/DE5E4\SX:I MG'0,LF>O5%)P0'X$!$P9OK>*5+%-1@$(C_@FS%8"+EF)SVE8\L^)&#$S<$(" M@.\"&X;<.$8=/9+0<, %HM74:]KV M84-B^M[=2X#JF/H30 $@?^ECS\.N)X(AXF6H"OFQCW./WT,=B >^FY'">\ M9U5V5X<48 AXP',B.D(E-]'"B"[J9AR?,Y\N,2SW+U3ZJG5DG[R3GA4D$WX2 M[T]+3?64XI58RXIN#]"TOY_$5BEDF@D)>'2GPJ<3[41^%I"?Q)^C]Z,[ 4S, M+4:"G<9_? P'!MRT&@S^<7[-;!;?#2XSTM/>E;/E94;I+J4 G#.^)V=VY,EU M70NW=1%]X_LI]#?%:5:4-KRJHJ[7NGN^B:HHS)N?*^NKUO ^%Z4W!R$]Q#\- M17HE]<=%>B7U2NJ/C_0H]5G?XJY('W[>^A;4?2<.9;MB,[/D *B_5F:PZ^L& M#\^@W5Z^#%A X@X$-T[>\!AXZK2DY#_D=8^+RU4;Z8WBXX'Y.+.^J%A81!9& MA:]$5KZ2"RJ+9U*Q4D4AY8I"4BQ1;JM^1\:BKZN*OA(;.MFS;GG:NV/6[?O& MZO VY/VQQ*TI6DYU?2C4J]T5*R MGF$TO-N5@@T6-?,HQD5*2.2)SJA*FE2C6,E7&4GQPMW\%4VHA&3/"A%CK&$J(2R/$>ZZ*.+K\P?5.:1RB"/U7(6P;%F'7^^,BM%LO5=AEQ+>(@IOHZY$M^BBJS*&C".8J+W? MY.I#E2<4+PHM8)Z0C]K#$B4*^_-9;[$N?S4A)0NW\J$[!ZS*(5,F5972**51 M2J.4)B?!>J5*EX<7@1#XKD0PES:O5V4PJ< M-\^CZM[WZ9^R7GINZ;LL6E&RKF0]/[+>J.B=II+V4N<4N13D(O)@+BD(/V*_ MS8DEBNZV_NGG7V_!V@W?AU0;OL9#/PPLTHZ[N MZS7%E4W7!_)>$\;($. ;",)<; V_HE,NWDDZVQQ:MU MR\UA'S_50E$U#CT^TBNI5U)_?*174J_:Y9:*]&K_<4/>J/W'?*S7'6Z%=-*F MLZ':=!ZD!N-7:KODP[MK3XCWY):9WJ,+OR^Y#%8U72T -Z_DU9+D+KYO4O5= M5>Y,]5T]%F^6"^H?TOS=RVV9;^&VS)?%;9GLU4AU2RSG/GHN5.G@F^;*]1^/ MZR_]H<-<7_UR?*G+BI.RU404/PX MK12+!/MC49Z:0Y1L64 =)BEPRZY6!6;/\5D2)>M*UC-K3U?O5NK-'72H*X.0 M%RI_R*.T%BG=EAT7*L1EJF=U 6-9M2R<>Q:%+4WZ8=)1C9..*MA.;VB[\K29 MSZDKJ(EE&:HM7<'670Y66EZ, ^KOFA6]V\U=)V EODI\U[HNMEW1.GI^[\#) MA1SG6&K5?H/*%U2^4.SMB7SH7$Z-W'&T[5%KK44.HCK:+B,H)>M*UO,CZWAI M4]O(W[Y"+J0\ISY4M5TK4-NU5JV+A$!K5HV(T]3^7IIV5UND!]O#^CLCE#.\ MG,@3N"SM$9,SR_:KG#ERH3KLE$9DMS)X[@G/$WI]U(7J"$3'XP"2R4AO3$QL MN,8X&5&.S;MQK*7]TVH).9K\!7 ,;=<> G3Q0#C.. *'<%O\B9-(B0XK=V!\ M:]JJ+;F@'O9R&](_/#X'@NT'X1/8E>V9$PRND,>\[)ANJ7MC !MX"S>]"4<\Q>U[9;U/YUS%UM,'HI*M;Z\F /J/K(+F(8#6[_)XUN3IR+,+IF M9^7<,X-\]UPK^HE9O$'173"BE61$ZX@8T0J= M;(9LN&=\^*,?4^$P5#_Y?%/_US*<9H&;0V&B\_C$$ DIH;T-#?R%)WQQ-P G M<$[! ]S0L;0>$_N0 M.3SVB>DJ8JT=#S2N2M*3+\.1XXT9(TDV;19 3(*G9F..3 _3#28@WF@9-HX"#:0(PI.:*<'@ =(8 M%K;%9;$8AR]/7@#D7?(.GXB8##;CXN.7NYN;Z>?+C^])(&137WCNW($4J7IG M#CP'2(Y A908>A9S:N1^ 5R(U7QNFPA/.#FZ"0A>!6'_#B"N@Y 1QP5A^9/Y MT]?P.PF_,\:I!5I#&?U9#*^D 6992-M9:A* 22PA&=@\$!S7PM_@)8 =!A8R MRI:AI@M!J"-#[0JQ A[C^H1<@+\AJ+8]:RFK%O%-1N K<'\>V.9 &G'L\4)C MW.$+"*N!F)4P_H]$P(JH3^7Y>5:]H-SQ(%(=!LX,Z7_'^:(V,?,TH&*YW$[Y M"H!2E)XJZ@$(O#_P+(*9:/@KXT\V(!120G9;CN0[#-/#- 7IM5;,/6*5ID:ZH'83%;9#>[M8YJ('F8MJE& M3>LHTN^8]$#7^0V#9JVANL(KD2\MZ97(Y[)-\'*-V'_P=/B*JR)5Q2T/D$I_ M:#\G?17KS64.HQ34+TU?164&C]8,EOXP84YZS.GMLIX^*7>/N4WX5L;2M,SY MEJ['7$H/E9=5SL.;O^)[J%*$BKMDT7,(6L]SK&4\NTMN-)UFS[7E*T)EZ,.2 MY>[4?LJKUUTW*D/3EL-3^\C4X? $/R;QSK_Q43'9T<9D6^:M1\:AWR6@6+8& M>D@?9^K6IA5!^XK,=LN[TB\Y[.*XYO[W]LJ_Q%!5^E0(/BE]*@:?TNF3B@US M$7FHV##O'%J(#?%L;;6/F[LRPV/")QP"1>7-2I0Y*R]6#"]VW'JD]$+IA8KN M[)PU9JCNV/"^*!\G;D3X5R>=2DXOBL(]YO[ZATB M>\G/M9S?6PN1$NS5E#HD*X'QRX-W.FX-R2F]E<2K>*Q\WE[%8\7BD&H<4J+5 M?]7HH!A\ I@[':53A>"5TJEB\$EOU Q#[7X6+P)1,6+>.:0:B*A5.^7)]J9N M6JWQ=Z5*:GE/J<82U=#3J8:*\7(10:@8+^\<4FU$5&"GO-=N=:Q%AAY>IJ?4 M205W2CVR40\5X.4B?% !7MXYI)J*J(A.N:R,E6;H9&_,$M?0DM=8GE?YF%#4AQ&@& M\9@BX30PU*<370Y$5E,\24&2_/#+AT!4'RD=G5[:PG0\$7#VHW_A#4?,%10W M^&X9! [,NO"$+^X&E+-S*IAU0\=#H*RX!P*>.Y[YY^>__H607^+!OE#N@JB* M&\;C=VR3F :/'_+^I].+@,NAW]H/^@/AJ8W'^Z]A^Y#79,?3DC@VN&#/^$/ MO7%"+&;:0^J(3R?&R6>MUNQ.05\ZV[8 M9( M=8 J+$50)>V$V"CSZ&YGC&V;QJ>-CS]5EJ8 M-$Q5^<:N#).VH66:X/S.>)_PMJG_BCE'@'5$\FX=^[8F?5_UU&4@?EJ_\!;= MDJAKF= QCU0+#3N+)6\$DB=0\H@MP%X,1]*>]<;$PET.>(3X T9Q/?PA:'GPO1@;0:> Q01^"Z^\CQ?ZNP&PQY,YO7#^03^E7R?>($O M?.KBI#7RU>/8RV#DB>A)ZI@!9N@ D159W44D*G)JX* WM%WJPQ@ M1-8, 9P M:K ]8 3^"2DR>4E"8S^QV7?8OP,;PFH, 8@(S &A(AY-E@4).1(6?'-;KC^$ M/Z)S$#6BS( R [NEVMV:LH@2OA VIYW,:#4JK?;BF:*TXT@XMQZEVZFTNNVM MAZF0/M@7M 7^ ]PA"47A('D6.2.C7PF+41=JQ",L"3L&)96D-*XZ @VPQE7 MP!Z!\74]/S95%A8+XK"A-99!V\3.++5Z:%OP!=;OP[#DV0L8RY, M[-O5V$K5E&E1IF4?$0:*^RLBNYGN$'PU#@70A0L8R'&\9T'>2:WQ @'/PD@O M)HR2F,^B/GU_NG/AWYMP=S;CTMM;4\NIDL@&HU5!3?O[26PZY4(4,9GC1$MP MGTZT$_E9C*@9?X[>C^AG M_H2+#3^(^/X< @@%H-!O\XGW7.HEN WI;W1JQM[[ ML)>_4.)>+A!\"Q<(OBQ9(-BFC$+9P>.Q@V4_Y+0G,VB\80;U!I[D*&-]WD'+ MQ32]M9&B[)1OJLQO#;XUE8-2#DHYJ)U??_$]&#*.-1^[N/-BZ7J0NF-ISZM M9;AC*:<$5Q*N)+RP!%=!DPJ:5-"T!H>^,Y]?<5(*O'?CF.[:)J_@QVV MW63ZZY&Y,\LB.>G'$P#YF=/1IY/P7TG,=JNB:^VI7U'2KJ2]O-+>,2I=_4UI M5[%3+CRSBIWRQZ$W%IPNI\>,U)+39@XFM%XJ0\^1TJ@U*"7R2N35HE1QW;8* MK(K%H?"\6'PLNQH?RXZ/4T=GLJ=GL NR=)4SOU/H]FS[KPG/1PJO-[1*N]/, M[XI5'H1<"6W^A+:N==7"4R&\KXJ/\LZA+V%;AV2K&<',@-N^S<3>5IY*X"A4 M-%1[9:D2Z$-.Z:WD6ZU!'9H=*L8Z+@ZMVPZM(-%6W@I)5+A5Q (2'=+X M'*\]Y4+(E=#F3FB[;5VM/17"ZZJX*.\J :,LB MD8(XEX91T;K:#F.B4@BZ$MP\"J[1>5-P55R4"Z^KXJ*\-\E@[F[5SP3NK>1GPW)W!LJ;X1__+ MBSF@[B.[I3[[X5Y0,3AS+?SG2^+^RLVO7#:2MQM7ZR>?JRV]T:J#W"4@3@'* MCI!X_8KF!23TMM[M9(7#<.1X8\;N&'^R33:]0#QYQ?AWSWUB @*ELV?*+7'O M^=1)_HYWCW_W_'\Q@-KT'EV0IMD[J<_$PX_^NA@V3SXW&PUI'1(8[@K./9$# M],'VK*\>C[["Y_14%V3?&/_2O[4N]T"2I;!N0*=[^G+.7-:W_:_<&R9_^?*" M?[(4FOT0S?QP9N%VI;S;'B $4WIFFN \\&+>&^ZY\*?)Y*]G+[9XX$/K8?K M'9[@1#+\'%F@(4A7K?M-MO)_4R2-YB82^28)]D[66;$Z#K)^I3;_)W4"=FW3 MGNW(@RO?&!4!9]8/]Q8/LW# Q?5Q4_7ZPF8&]W\E3L*I%ZX)KP5SGS8R^W5 M/8B[7F!5]R"N9EZK6=/4W5B'NA&NTU*D/\B-]PE97KWX/87>8S2D']/-^#F$J-E!D\6C-8^@J%PW:*2!TN%V/; M-:<$WT60G MZ%_*NR;VGD@5DU9$I2_GC,G7#YY''7LNK0X\S!K4L<0\E<]M]2C'<,QA'>Z5FDTM?=*RI64 MEUG**\U.8X60JS@J%T[Z$'%4Z=>PLF715X\#J"[!,BOFFF/B<^H*1U9,$3HM M/,M'TE^,!3&5]>?^A,&[59Y#B:X2W7R+;EMU:BF&:RWB*M*QA3]SRTC,M8JY M@%1 YW&<8 :5-^T1O@&/#CWA$VH]4=>GC\P+ M! &Z_&06PK2 M]QS'>YZ[D&]]*E3U6F-*C 4!V F>FW!PG1/0"[]_/'GK5/1D #[YRYH[5]"> MR%R2A(D?EZQ,3N%/1'YS 3-$PR"")+"7?A- 3B'8HPA\3 M46U%HEDC-+.5GZ-LT7N&K_#'Q M9TH6SW UR>^<<"ZE(0K3IBBA"H>Y9D_,(?KB-: ;#[L ^6M8)F.Z1 @]":D3 M:3=I=!+V;< M#S-;ZBZZD,C+5H@(().%8'_V"70H A)'A[Z=2$N/E'1'D%I'H\WZI=6O1^^% MR3)F'Z[GQV/"$"$B47(R>2:1Q,(S)F#9PX2>_()Q5"[Q1J84 MK?/&#BGA2USTC\%HY/'(S\RG9+55^U,[R;)2[4^4,QTK2Q:*J[+APJO<#0C] M:S $K. ML>;.!L1SH 8SW30(;A[*)_\1N&SR384$(MYV0-4(2ZAEJ#59'!Z3 M=Q"C^0,O$/"^>+_I@G 1MP3V$T#EOL&FZM&XBP:;:81K5K#>+IJ14>Y<;%7K MJ$:INVY]MTAW3:\UE?XB7U2NJ/C_1*ZI74 MEXGTB96Y(J7-)3KGEH?4N/S'$O=S%'K=E+@4QZP.3^X4?B*7QZ4*GB M5L8I18!5"GTI3.\&I4%[TR!#:9#2(*5!6VA076F0TB"E01MID+S1-I7^J.6" M,B\7+-7$W:P8'#7#HJY&*TJ7,E[QV8TWRT.OX&-R7;G0EX6F+7GE0&E%_KCC M-Z4$2@F4$B@E4$J@E$ I@'2(?W[*Y^5'S:^&.A0&S'O&HD.T*GP>R MUUJ%N,S?UU+S;IFY;_?TMFW<)7-WT)#U )5H.71HNV0:F7K JE*ZXO'OF)5N M/9JOWP.YI1MO72BAI%Y)O7(URM4HI3LNI3N JU$+#CE,8 NXX)"/4IR#%0!@ M*Q(F!*'FOP-;V+(5"=Z, , S&#?NKRY[E!3$*^6MODVYI2)6Q*E@4*F=4CNE M=DKMBL3 HU:[K+.P;"[W4R*O1+XD(J_6''*8PJI#!P5C6/+0P4QCU*VXMUS9 M2EMU=_@:N^4$5S5VA^: $GDE\DKDE<@KD5B7P!1%[EU3E,TPJXEW_4 M_%*'!]0B[Z$7>7.A@+EA6@%W$Y72*:7;R<9*HZ)WFNKX@)+[G,M]89FFG$VQ M^7?,2G<09Z,6'7*8Q!9PT2$?)93J (&J+SMJQY0/-P$G?=JEKVM0A5 CF"T)= MBS@V[=F.[=MX1$"0ON%9HG4S%)^UJ6_PE;\;?I72O[.L#3)[)RP;7O57:GU MC^1^P 1+6,?D@Y2ST(A:!-=>'\&TVMRJCBCWQ_('N=1*AI[%'$%Z5,"#^)GR M/YE/O)Y@_$FJO^V. BP)LUW3":P0'J =$S[AU&<([A.#WSVW&KTL1IX_Q6+$ M;1-_?_(VB5 9@ /4G512]3W3_[Z D,0\!(P@KT ,;'%O.>:(FL! MI%XOI,U8(BZ!P<<8#CJ9N$*>!S9\82,!F(O6P(0T'T?P/417X%1RGGUZG^-* M+\J2H]ZCYLD$4\8_H!R@2:##)HAAJ,*H!P,*RHWJNB2-7;77+141'_<'G('> MP&,#09AK@9PN7K4GXR;XHTG>R5E 8>$;\?[TB'BQ@P#HC6 G?C]:2P28'#H2 M[#3^XV,<>6A:#:.GD,#ADN6B#]FD>"AM-'R1;. MDA%]XT5N?<>%14M9V6K6M#W7@16%E1D>S%RU0=1I*=(?@O1ZO:8ITBNI/R[2 M*ZG?!>GG=D:+$E"5N[CW$$%3Z5NK[;:)!6 !"0Z0O''RNADSNLL\2"FHG^Y& MTETJT+W,_;^%N?^7Q=P_E5(I$ZE,Y'$<6#GL/_\ M>*&M>ZON+04M(...3'6.+8+#/1D5I:DH[34]/-)$=I<,BWJ$8XMPW$/M,0#( MQ2U:KR^_&#%N>]:^G%H9^FKFQZ3NX+S)LE,PKF2^2S%>: MG5W?T:+BKX+'7Z5?)=LEPQ:.+/B@>1G3;VKX:WJG(J."1T;:IW7&'1G-+4\RUBKDH54#'HC+THGBC M;*X.5E*OI+Y84E]IZFLN3(4?-SYM6-YS765!&]O?@$RZGD\&] GB!7=,! !M M]VV3NE+DJPO];SP^?GU>$0]W.G-3$CP'G8(?/J;#%=43&L1Q+ M'M.$^6Y9_]/)F7CXT7]H/=2U!]S>/R&!:X>__(0_=..$6,RTA]01GTZJ]9// M>K/3 +:^CMW6(!Z&"MT45-!+2X58%EIO4T%K-+6RDJ&;B@S[EP8;8&'7]A.S MKER?NH\VC'DF#>>9:0;#P,$^ F=#C_OV?^BD$_D*5C]$PSZ\,NSY^!O]P^,7 M#ICGLQ=;//"A]7#)GICCC9CU@U]XG-UPSPI,_YZ9 Q>\P./XF[3+;Y*P5>\8 MS5D2IL8OE_29/B3.7.N[YUYXPQ'SV=DC9U(LQ)H4TCO=;MD(%+]S <&*-V3\ MEH6;*F)@C]:EB]%J=^IE);.IE)<4]IQ;[3B%B79,:]4[=R!\Q MNGFQN&VCTJ=I=(J(]94+ M8FXR ?FG8)2; V!^I ?(]#7Q;^A:H01^,YO?;FCU1A'13&W/&^U.M[U?3',3 M'AM:76NLG4SE!?GLS+>^OBO/ _+9F.^NL7Y*E">LBVJ^#Q&RMSOUSIY]]('" M\4:G9>S(47UG_E8;!Y!"=K2UN0"S9079H=V*7N\8ZR]TYP'Q[!:P]>[:YN70 MB&?A3KIZNU$83A_.D^0%\W1>Q- :Z^\ZY 7%]!ZDH;7V*,+K[[@:G6ZKO4?Z MYR8MT>M:L[%'QYFCE$37C3T:E<.G(YUNBD U+P@7T7\<(@LQ]);1*AJ*Z?T' MV.FUUU!28/E3L'[@7-O]V;J=RR"\;>"A_:"'V-Y[2U"_Q0L,9A#[1E_L83", ML/I\HS?_M0[(4S .!CC,E 3)6&6!# M[\Q%%NDFWP[R%V&?NK;SZ<3G 3M9+^"*ASD?3_[\S68TL(EQR]2@/@9SSJE3SVE;B! M;?YFM.AS>$!SYECLJB-^5:U6CT_Y=6KU9GS0SP;KZOJGI!I_^U8#B3P>#PQ/ MA[;>+[LR\_6_)E9I@Y.3K;?)JDT)^FHSC^)1^V+VTD:3%8LN& MQYBTJ6YJK$RO:GQF$!A2$5T@*3*ZNC&M(BSGVX[XTMJ,+:V8*T=XQZ.Z+&HG M=SSNH7M.TZ@9ZE;'0]UOUS04Z0]ROUVWUE&D5U)_7*174I_C6QWW'4*5J('= M'BXI6QXFE?[ZBYSF]GJS$;WQRX4[ZI.^S6X-M!;JU3'BHG'BK%>F8I0L7]L>B -],M61M2MW1M MQ\U=]#]>NI)T#/=RZ16MV:T8C>9;-U$H@5<"7P:!-UJ-BM'2]W3QB@JNBA=< M;9F 'AF'9)%B\GJY"G&9OZ]8:K>\RJ%G.>0]7?O?;LN'RV@TVSN,CI0(*Q'. MD@.A(._/ 9 ICZIJ_:IX#KR (58^%HOWQZ*#WNR;OT M9BN_D9<28R7&:]XPUVC4U[MA3@5!QQ,$J2M]M]K%V\\EOCO8SBB@WSC._8QB MN!>]HK6,2KO9R?$.GA)Y)?*9[N$9E8[^IL#/Q5;AQXUO[TV>Z\WCX>E#7AW[ M2K>"Y6T-EC5/"=O-VW1H< 7%O6B.%M.'8"?\HV$G7(@S,%7V[: M7;DF9U2P2Q;^^UJ_I-0,^)!FXCUTW%@Z\1R,V%O^AGM]V\]2^(QZIZ7/7C*4 MF&DS$%(2Q6AU];GKD%>" #3RA@Q%YROWAMACRW8#<+,_(,@.F\.&;8W"Y^[I M"Q-?7GQ.P5/8+N7C*Y\-Q7?/1?"YYX"Y>KQ"D\A$IE3M=AN-68QV"'@^*)22 MZ5VC.]?[9\\4D@/<4-N:;_:Z)>OUCC[7BVIQOJW@2:M=G?E.7&O#\^5EQ%S! MSIG+,K8Z>JMIM)<#-3OI]I"E))?>FF\EMBYD,[;[RCTS36P+ R0>8U!WYEKP M#7@N*[Z/VF:91A&ZODC1#4#:.5HI^5'5.VUMGXC=,I/93V$?F QCO+K6Z"[( MU9L@9 QT6MK76\;:M%\?Z"OWZ?^W]Z;-C1O)G_#KG8CY#O5HQQ'=$1"-BP?: M[HY07]Z>[>MIR7;\7RD@H"AB# (TCE9K/OUF%0 2O$2"!(DJ("?&MD""0%6> MO\K*RH0%;AC5K0!#S5KSN=M?7="(,JL)7B>1C?Y*Q?7#AG3R:56U^I:FK:&1&N:U7)R]'=7RA TQ/!L>4 TO M2Q!=<(KDPK5/N&)#<;QY/&;0LPXAUJZMKC(QKR+/]@D(M!.ZE'RZ/I*:.UFT MH'1&-&]!-#LC&B]?!VAI%GDQG>]_9,7L>*6\F'VV7@&/%\#[=PH3G7]23^6[ MFMBQ>=-R;UZ<@!4[=P8WTPBKWYTZ1_6 HCH]M9^):2VU=; (GOP\Q*I@;>= M&XN#R<4!U(&F.8 Z@'7R&L@*VX]%@B;P 1.ZDKVW'Y^$+A;5*BXTF:"T'C(X M2(N0G6*PDX5Z%LIX$$O1O[72OW6JRE03G)JWT/[9"2-*9ED+;9+,>VC+DJ?> M^,ER,4RI+*F[4I12T%5#44XZ33U62]7UBHN2KS_\BR/\C2L_:P@TW!*1T'%)L"!B*9A@"HQZ4793= M)WH.CBR$/#(Y4MS+DH53N)?534:77PMH\4GE4 M&<%/-SGU)HV! #0B$3^RH"#+1.;)^('OE"Z47IQ=B7*.X5H5&W6+?, MJ:]V@A4=T7.T8=-D.!(\Z0F%%X5WJ_":BFKL;*[7#=@# U1E\)VXY2<+IW#+ M[RQ,$\YS"+6!D=.]]D-#_8$R'&QK]H1"BT(KI- :2K^OX4DW"9RGC,$<&?>Y MZHOFX%Y6%_Q$)W8#=$T9Z .!@SHHOBB^3XBOJIBCG>6W$.^(Y$01[TC#JILP ML7T2)A,:P5V)'=Q[=SYV9ZTC2](!($FC,_+R7_4SK,N.9V0I@Z'(A1]1[E'N M3R#WEJ6,U*HE([-+&WS'G >N][W\[9KP9)+#_]$'/:N_/,+_I''BC1^SC_*+ M%QZ3K$O/I>$]#'>R-/>KR -/]GO@.:%+R:?KLI -RD*VEX3M).A@)]B9DV6V M-QE&1]+@"3W3U*=HP-_@!;"J2;CF9X/+1)M=D]PLY-)JSB>_JGE'/I2LRNC% MI@=OMPG:W&Q]F(,98LAP-4IWU9+ M8SI.?>)[8\K&R+[,1JZ0>QK0R/;]1W)'DP=* _(DX?>A3_(0'OT,/K6CGS+V MQ@E,Z?C1/%([BGOD!K LD [^"4)"?\RHPZ@;T=AS4[ 08/=3&F<<@\^3D%$Z MIB7TFY.]1_9(>B=>/.>L6Y&K8>!P:=C^<#H>PZ-C/ADF?SX(H-LC5PGQJ[%0YBM.N[=>[/AAG$;T!NS% M:S]T_GKUSW\0\FOI!R $6B#G4.[U$W+.&)L7VT (C622M/-X<;AL!<=.(2*)!F8JK;W$+Z# M\(?1XP8QJS*D5TR8RX(-?R][_X4OS*\S3[B$O;> AGK\_CYV]9GQO!3.K/Q7 M04V/QD?"H[Y9P*,<5%SJPZ8 TSZ$JPD9#E8!<@E2"3OW$M?!(^7N*_)BYB0S M+S@.?3]\ /A'[(1OZU3UISFDY,L5XE#?SX'HRPOU@E_',]LIKO/?YZLU6(GY]BRF+XH_ M?LD>#"2#U;#ZTQK(72;C$S'IS8&#?D\=G3F%)7W%; M7Q0(=8:]XG;MYV^ 22W8SV\TGPAF :L8H+E^L4,_8-UR_KW)\Y"_R5W)]27M M0:J#?&R8CTLQB$HL1.^%WNM M>L8B[[9#X1ME[$M?*RD((EA/%':S?HJJ@NG MUP=]Q=1JR]+?$ 5 :4=I%T?:AXJF:S4G]2-^:@]^.O+D=, M5$*\(T:4]GPL>N\%7CRA+KD/0U<6N-/\<:VNNPHY#F!I(U;9I[:#A_5#'A1D M%.2]!+EO*(:U,ZB)L$<(GRKC-EG7<$]6K<';AP*/ URGPNJF8_:I0*KL\M"B#:17#RP^'3+,=,BFO$;"V9\ILF7\3<:T^@[C9=.FU[%MU_&MX.]3[P" M_ ;TK2Z?>=WYRCK&N/^I7%CKPE*WIC&N'J*N2C!0,M"QS8/9<%3ZR;?N3P+P M9>#*JK[UF_WPJ4B8JD]D!D--7STEO>N%-0RPPBGNOJEMX5#5 ;)-TP_!UZPT M0GTD-"S#VCS [2^L8X3[T] <]8\G:5EU8P M.7W3&JS8Q7U>>A6XUPD8\4GH T*(W_V=>LGC<:*B]P=#M;]M)!M?>/3P]B>4 M8>BZ/MC*G6K#>Y-&$:LT!S&#@U MD,'2C=%HZR 6+SEL'/L3P](MS=2JCR.@7\9O(NIZR7O;87<_O@FG4R]A%6?> M4_J51FRQ8M_3"K4V;O/'WVYZ_-4/+[Z-INXMS",,7MO!7Y]!>/]/?.>POW^/ M[4_\G,;\&=_LX)[R'Q6??+)_>--TFMVW2ABC3!CSXA6K Z#WRT39>\9M(!6@ MMDJDTDY%JG<_9EY&B+> "[1#2/0ZC>'!<7SE@'6+/?:+.85>\^5:1.E'WUFA MRA::WM!H^C&T@^SKJZ*.6$ZJ5_#FX:5J7JK&TP19F==9"+%A1G,1H-]#_[L7 MW"_?LT*2(X2-4V9TJ:F7AE8S97*]?AU&$2]%\L9FA3\V^DU-O34XA8Q]B/*1 M)@!%B]?52(LGC?* K2:R2,73A-HV[UHI9MX: @G1+L(-554@RIG-V:%=A#*Z M02A!)-."!8M:*\7#X)X)P%MZE]0$2$=# ]8*R^/;^)8#1[(_)(61]#7M@)'$ M\1MX+1"-!L[CE>-$J>U?)6_L*'J$#_]@)2.?(M%"#I:>!##X]>-G.TDCQJS2 M"\H"]EMJ1S8\&6[Y$+@P2NHR"?XR_L**LL?["$F_,%_E:>\QI7JHL %9-D6% M4>U4>)<7\OPR_@I?L J4[ :Q94'3K:?IL'E2]=!!(&G03/-X.GRF("WQY&L4 M?O=:S M'"@^;G!GFVC5ZJ7 -O/L$V51T#@Y*T: MWWY6'=7-P7XZNN?@SC;1BAP=#733..4\LT+%:T[F2/Z,=$L;K@Y[\:I#1U&1 M>,.!IE88Q0/@EC#E7@NH&\"?3E: _FOH>\YC]F_Q*A1O[NY0%*_EK4-V9EV* M4]_V(4OPN M]=V/!6_:>!9_(,J/(/@D)>U"0#>)_]5 EJ? MIH[R?J+8,MI]",@G^Y$7+S(57G?Y_=7U:^+%<4K=LL!>)W;@VI$;D]]G+NL= M\.SJ^O?G"H%_D\]ACS_@4K44DG,#KM_\\HU^IP$L"L=1."7,K$>V ]+^X"43 M\B;OC1$O?O#V%X4\3#QG0B+Z=^I%,&T[(, #%MU)0OC4">^#O$<&:ZL 8V/E MHJ/\-7!+]G,OR1L[Q.RS.YH]PX<9L08&[,TXC]? :CXY6G^6DA G>P M36V/]3N 7Q<]/++.$7R^#Y[OPTN!N XETS!F;_,X*ID/)1\JLZWD/O5LUX.E+E FKTG '['.[%C^[S_!>.3U2/O[,A_)/9L!JZ! M.P#VBB!,"#C 5'VO 6 M<"\NG[?"^DFD/O AA N4 8KW.T $B#LP 5<]F: MA ] WX@WL7!#/N",S_ SF$#*)=-=T W8-[&!9/:\>M#*L%G/%Y; QW^VF ,\ M(,DM,QMMT0O$G:=LQ;UN&9K^87:FCR:Z%A-]-8L\GQOI_@8CO;# _4O54,C% M-0BY#V,N5/4K:^P2)':A4RS623[ K[E5>@,&++[H%9K&GI%9N"GK?<0$GC+E M9Y3A3YNM/(W%7_A8^-,<]C0 N$#KLK%C%G_MQ]E=W(Y%O-8^[[D1\"]!"]_/ M]?$;G;$6.DMNZ-F']]^NGY.[Q]Q99).UDXWCN9N_F348R.:1-[4A\832)#-# M+O@6N5I7&?ZF]]2J'51]"0&M\CW24_1]W;',$X7HN]WJY%SMZUC#"XRFW-,62ZX31 ^)@\LU: MH;'^'A0P3\P4P..+686L'U"J^G:68G;T0_(L*0P.+M!*[^E> M-G6MXR3Q;8@*&D4%_T[!+^^!"31M>56V"@\^49MA6M[I#71VGNY;7I@]N2Z; M9@^8'SQ\Y/X^]VFQ ]A_;LG8P.R$?P'ZE#DYYIRX00W *$84J/U?C@9X)[X> M^;SA4[9<6>ZC!R#%9Q,"I,06;OG+@;L (B*6&Y!&,1_&79X"H! _ZWEGQX V M[H"4,[9=[N1=?PJ'F;?5XYZ!\26,;3_KV M J>FR]1?T! >L(R=GKJ3@:&-QFGW6K(B$!EM?,V?N""3S("@\3W*^+ZG=U'* M+ N#;4\:X,&EJB\;X(^@R'0I[M4CO_.U4))K:V$T,B-%:=;B,[>^[G(LC+7Z MG#>QY;BT=!)BXUJ':3W_54Q**P8&1XO-F.+K?(66I]XP<\3L7&[']XQ*<3>E M*7GD:2VJE#1Z AIS^=IF(>JO]B/W_XO(_)/A\TP; MO2R2O3 9[)QX'F1)[!^@JP$=>PD/?=.L]>MJ V22;[MGT?$D\>%?B[-V9_8"QS-((,!;-+!F/U"\& M""2%8?,^U_.Y9"']A26(YJ&BXDG/F67+%IQ+#UM,EJ&>Q4H5+."$FV+ N/!% MB58SVW/!)L!Z<.8E# ;F:*GT3L THK7'#*Z^I4[66(6MC#)3P#$TS38]BN#*\E8'];,^ MX$"%TGV+18N;1@51Q^"(X'';-UBRYJ3,S;%9TW&XYKO9%$KNCN^"L-:E]QG2 M9R^&3Y=]$'(JPR-=<")8$^7B+4DL(4^_UZPMAPFR/?ABUP5;4,35N,"<19:O- M()DO\E^@HF,K\H';D $,."+/$5X+(I=:N<.-N=.V4NGS2H.)1*\^#IX5_&5WSI MQ3^/V&Q^Q-Z+P/-?7B112B^.2T_[N8X!U4A>;61I5>B[>41KDYK[BRS+[5WN M6>K,O#0U:W7@F]]:Q^ JY[_J^AI9]QG=/'OR78'F:B69VK>6S_>OO>^8X505 MO6%?-48'#>S+5FSZH@JDL@R-7-0<40,HF;J6=-Q+V.D#9:% M>>,[#AM&A3(FFMX?'32,-^6MR@7=W@.,]^Z#K(H#N#X6_K&NM$,7>HOXJ'IV@8=VJ-^ M1J7Q5+ L*V5X*@WG+ [^$G#?!O;OZT@/'V=5-Z8/]8.'F8?_F/3R,DS4C=]' MX?0MK-*^VPD7\!A0)[MGPTF9.LEM6,9*<9?CQG:V>5:%9M904\\QSV]TED;. MQ([YN<=8?COK#;7/9\O[-X_TR?NNQ8SR!6ZM0P=IM:&T<8.F% MQXVH(OO-@3$<'3:BFS!?[Q1%!VC\6U0SX#-4:[-P;GOYWD/EWNY-L9AC@F MND-2MX[C)..O"I*R0JMUC#^B8PK -"M&^-6.OD37+%G Y9&IKS3BNZN;RQ.I MMYIE#>=5!ZZ+)(,W;)?NRY@_<:DNP35E1?>OEM^YN1J!69[RA\_O>;&S4OVJ M_<9=TURWKDN$&N56\3G]*/D-\56:3,*([XJ=75[6IJBOUOQY>L1'SFZKA#0\ MKJTR;ZQCB%7*'NNZ=>P0%V&EXICFR8)"IM%?67[M>GN=@ZVX+A@8QJH3KV&P MY1J M88+U@LS[AY K0.NNLY=JPY[P'A9LMB?=L0*M!45]9[0^7VV65>#+AO? M<> X*M0&&HU..(XJ71'4-1MX H+LM2&_&AL]>"#%\KY>]3-6#?%3KZYMF%65 M;K32,N#X8>:7WD8 >VQH:;@:N]UK"+4/NR*5^ZOUR&H8]H863@)6UQK-5MMT MZ<,3MNDZ^AC(L]'SHU,GGSZFO>.O8U^>2PE9R-*19Y+ZY@H+3\K!P6$,')SB M8.&H*4%=K9RVJH\D[[68:Z0YG_Q3PG/ 0TEI]OS3BT.E\LV$]>*8GXR>%ROA M9RL>#ZK#& M+#^MR>_R=)_HT9V=^-W0HWN]!?1)>W17Z[(*[Y"+S@ .K[_I?*U#C-!VYD?1G(#WK.(RD1ZGO%NE1ZD]!^NPZ MD@U"'=;_O$[>E&!2#7WIFX!).UK4;_Y:)A;-%8:I"K(N,89MUZL WT4^J@N0O5Z6?0ZWP/*2_XN*G7E M]>NS\D+U,V]S=.C$S*L6I#C>4/(WGY&9_ZJ?3YM#23OXU(@9W(_,HTT$H^HI^4E#4 I&MA(E0AAM ]LK04A'L M2.%*$>R(SJ$_ES*363XR.S'IKD">)XH=HP-!S".TOWBF*Z-^_SF**F(=&657 M-:PMLHL81P@/*B'&$6-/^GPLRHL1YUW1G,>LMV16@)C8\PK$ZVTXQ$0YN]B' M,*=>@W8:=:E]76P.Q8WL""&R788[=]>T6JN!M;GNNA35L$RK$(AY-:S%1T)6PS*?-UW,BK-;(9SAO"[/ MG.7[B&V;F%%K::N>T5^;OE;Z4$0"+*1A-I<&.F\ \4!YW?[I+/)8-:@5 MFWA[;MZ_>4NQIW^GX-7FG^PJ\[1SX ^9][H+?7<[*]=5I"Y&+GTJ!"?W(D@[ MRTUMQLC]GJYB%0M)RTT9/1/+3356> ?+M#55>$?#PCLH]=TB/4J] .6F1(%0 M;=L*:0(FM7^[2NA"*^T@?Y,%.]8C" >I#O*Q83XNA7PJL1"]%WJO ]6N8RSZ M9#L3^"IZ7([5GB;%8GV%U+(J%&!LF"*66.?0FG,Y2L(?G1U'M.LJYAU=I]G##N+2:1C$2927G0M< M$H$!M'W<[T(W(H"1J]N-C Q%Z^L(AE"*99;BH:4,3 W1D!2^%M&0Z!SZ2.V8 M3D+?)=YT%H%!.V'=7?08Z#$:\!B&J6CZSGT"E&*48J&EV%"&%F;YR.%5$?>( MSJ&/=G"BLKOH'] _--%)LJ]HEHDH!Z58:BDV%AUZOEL:+)$=$0KN=X]-R%',74=EL-JC?V54)!1D)L19-U2^NK.75E$/$*X M4ZS_(UWQ.BQJ(J/I[T*YDI$V4G1]9RH#"C(*LMB"/+1&RA Q#&(8C-K4PZ(K MQTFGJ6\GU"4NG474\18YRO8TC!+OO_P#C.ITQI%T83'\S-2'BJF;6SH.HP"C M (LNP)H) CRHIV4V(J#V(*!V%$\_'X^>;+RGD(!*4]%90M]1+RMEJ7$KAXLQ M+%496J?<^4*!1X$72>!'IJ)7KO.375;LG$TNU9XQ:[+-:6M:;._=,GO/9MN_ M16$<+[77OHIOOXQO!_-^VB0-O.R;W^$/3;\@+G6\J>W'+R\NC8M70VLT5'60 MY#W&R=]6U\AN\T?<;GW$Z\>;QQF]^N'%M]'4O2U.J+\MGT^'^[_QT^GS7WWB M+8'VF/? U$2?=G%OD:^TY]QTW>J+S]/BWJ*>=E4.:GU@8%^66<[K9\)][_/J MF7M.U%2'PX$L\V0G"/:<5]\TC)$T\RI.A'XH'0C=99Q8/W-'!3T\\(P8Z;Z)$> M7!V>T8,?-].*'GQH#D]@;3[3Y*@5N#$R]7WQ/;SKJ%'MCRH,2QU:>U)K_U'- MXQM+8WN;9E#@=GBK9<)P$Y:&^HJ%4\JA%?A[.4J5!?=8@#._SJ)U2U'1E1_F M 415_>FBB.7PN!AQJ._G8=67%^H%OXYGME-R)-CFK!:7SEK5U[F!MOSD^?[]VO;] M,QGM2'I)TUZ0]"CU8I,>I?X4I,=,,2&RD#!33+X#?S +6,4 S6&E][1^P+JE M"[W7@6K7,1;- M(]C+"4APCUJRAH@YWEKA%<4=Q;XNXFR.LZ"R'HQ9OPP2A MU$I?KSPW![MWX=EB 4Q9[>YB8"C#D< 5#U&,48SW$..^J6@JHAXY?"JB'M$Y M-,_5Y0&D<9ZMB\@'749K7(9I*L; 0."#4BRU%*O*L/(I=L0]B'L0]VSB4'$@ M I$.^HC6^(BA8@XQPH-"++406XHZ4!'G2.%%$>>(SJ&BDH!"W'(M 1[MB7@U M =SO0C<^ 4HQ2K'04FPH0PNS?.3PJHA[1.<0JU2'* ?] M0VO\0[^O:):)* >E6&HI-A7#&"'*D<*'2HARQ*A!<3X6%;6C98GH2-CIJ&5N M0HX61CHLAU53X,P>%&04Y+T$6;>4/G9ZE\2=8OT?Z8K785$3&4U_%\J5C+21 MHNL[4QE0D%&0Q1;DH352AHAA$,-@U*8>%ETY3CI-?3NA+G'I+**.M\A1MJ=A ME'C_Y1]@5*D: M!"K:P"EDQAK!+1=S5DA I:GH+*'OJ)>5LM2XE1ISS <[6QI<,>KLP?#6EQ<: M?Q#9+ESE69+RQ1Y]6.?=59>[L7ZC,_N1'PGZ,OX8!O MK/W=S=C5TO'GN,=US]9 MUP:J;EDKH]OURAJ&6$$*-1B>OJHCU89X;?LT_@:D#E+Z6QBZ\6J'YR,%T=2T M@;G<\'G3*X\<5$6Y,P=]LZ]6'90SH6[JTR_C-V&F^(?6$;:\F+>M-42]X^MN1%J>\6Z9G4 MGWFKH0.DK[@)) J$:ML&0VTP:2.#-L,D3.4]REC-^Q>;C?0O%H+Z3<:U;R81 MI>03?#&)R;O I2Y9ZDQ=28W0#';6#+8^&_!,9O"P-N[=2X6J5V,J]VX_"]^: MV>N3C&]]]% =]E 5XIFM@(IGK#)@^W;@4&(G))E0K6XA-I3^J MN^8!0IWV0!T\\7=4$(D&KISAH\YOD,@2/Y+D^-- Z0\-@0-(*.^21) DD7=5 MT2KCJNP23_NMG/:K=)IEVT$8=L -S[W4<^Y%Q:,3\IY[T3$-O;$3 'CXHJD3 M ",D/4I]MTB/4B_PN9=S0ZBVA=EJ@TE _;TP4OOCH$*G>[>#_$W&=Y;.N)"F MTK^1C\?R\=]I0!?J=Q OT8>URX=56.IC2G@UHSD)H^02%'Q*7%:7ZS2[=V<_ MY(F;&74MI[J0#FNHJJ+NSH=%<4=Q[Y"X(X@2PD.+MU^"&&J90V_IF$81=0G, M- H?V($Z)XR3^&Q@JGM'Q9M-I*T]ZBQ'RL;'%H)%O'V+M)$C-!1-+XZEL-3Z):E#/3Z:@&@**,H-RC*IK'S""<" M("'<*P(@V7(^<">@@Z8?91YE'F6^$S*/P B!44N!4;T<8EWV%H$A2?:]T*V( M?=A"C#7T:-@_<7(0BC&*L2ABC(A'"'^*B$=T#FU+^I$$^^ 60M->0XX=A&>: M8HXLS/I!\955? >#$>;]B.Q)$>N(SJ'EZ Y/^\&LG^XXBDZD2HR&AM+7-,SZ M05%N@R@;QKEJ7B/\Z1S\$:-&Q?E8=!,FMG_6G:T.^HIN'AB6PZ-HB@8^13,& M"(]0Y+LC\KHR'%;=,TCKSO=N)]IQ^".(E27@S[-]L+ M/H9Q_"&X3NR$LL^^C-][@1TXGNU_A?5&&$U9@PHL@[TL*1*TLY&ENJ;X9; - MK6=A#?/&"@*CWC15$-A$TJ/4=XOT*/4H]=TC/9-Z+/XN:/%W[(,I\I[ YL5! M.PI7-[<;.:\;;F+=\$;BGRPR1'Y^QH)#S\DWZH3W 7SO'E:@!JO -\S-#X$3 M3BF9!_G(&WO& G>5N(GN#-W9@1HH/(M:[$0V7=4Q?$:4*! /EQ6BN"!.=CT?LP@J$&Q$FC MB ;.(YE0]Y[5G? 6V9$8%CC(^F5YP+*G:F_( A$Q=E!WIO:@UO)<*.LHZ^+* M^C/#4HR^<6P]EG8*N53K!Q&E5:;E]I=D0J/JI2APN2$$EL6PL/ LX@I&QMFB MX[)8=%R"[0RG7F GU"5)9 >Q[;"TC+.M/##T)7EJN1S'/Y_U%*.JJOF%$[Y5A@J<7]!EPOX'I![NT),71.4"-WFBB4$&X%8ZTM 5$C M]90("F4=95T<67^F*_I0%V]?00@I%]2'GF1C00S4(D*(807Z9Y=8V.N)PEZU ME.O:5@WLG1T%($(Q_.9Z8D?TM1U[SE7@OO7\-*'N4W5@+"1],W5@#BAPC:1'J9>;]"CU(E<_.K-2-!](EBG8OQDFM?XL M@B#E(O113Q^UD_HBEXNH5@0)[6!G[>"1>1W";N/SA_" MMS9&W&OG6[6C\^B@T$&UU$$=RZ&';&AWH>]N8MGG=$HC.X&IU,^PS?$@/%EV MYBA0&TZ6"4IPE'"4<&D)CJ )01."ICTX])DF)"L_?2Z,A O_XSAVBES0$^RP MR9$*.APHFCJL*_,9I1VE761I'^F*I>V4=L1.0GAFQ$[B<6A'P.EM42\"0TZG M.UF#*_16K-!1Y%'D.R;R"*P06"&PVH-#_+@3R< 6=2]MT$;[GA(GG$[#@,3L M1%1,PC2)$SM@4Y D="68W_E/&B?>^#'[*+]XX;'U_:7GTO >5HT3N=R2@&:P M[B6\9JK*<-07-V(E@I"CT(HGM(9J8>!)"N^+^$AT#KT;CZF3D'!,7'8@W/M. M24R=-/(2C\9GBSRUP%$@&I+7Z D7EFJ!/@A*;Y1OC$$US0[$6-WBT'7"2NN$ M,U[PG=B!2R(:)Y'GL&+P,?\R#;P3=:%J?R()PBT9$T@T6,8+''L20LA1:(43 M6FNXL[@IXB(AO"[B(M$YE)<@G._.D6)W+M^6DR7O20A?T6I )&1QUOJW-G1% MM6IKR=E604?!%5%P]=%.P45<)(3715PD.H>RG"6:%VXF,QIEB$@6/"3"]D,G M#AJ)F#M;MW-1>WU38$B$LHZR7J>L8V:3'#Y:0A0E1L&T\X>7F@-2;=B#Z(1S MZ<+>Q8F!%,HZRKI(LCZJ"*2R2^Q3M;5/5:5&4MNZ4;VWO>@/VT_I51S3)(:? M?_3L.\_GZ<:?J!VG$76_!-]8"G($;V,OB;%'U8H%.Q3S8^L+\7M4 6=6.-?7 M>R/L%W/J?C'K=-_\>Z5'J M4>K;1/JZ-L7 *G=%19U!G4&V[X=./ ".UGI;7]PV^=S1PM$.&/1)8BFZF4367BR M2U0L&3C69<6J^\3K0-/K.MR-W\G7JQQTI4\+H5,%Q8_;,_8P](P&M72.)K1,L40VI>(SW35,7LF\]1R%'(.RKD& ,08H&)B??"LZB< M>/_O%*9>2\[]9H5J;>99\WEFFPF.>69-11Y%'D4>11Y%'D5> I'' MM;,0"S,)]\\[QB%,H,?P;$O2M"1BDX2[>ZA8G56LNK<]3$4;]3&%'B5=.$F7 MB$WH0F3C6)<5JQ$7@D$ (9:8$@8!Q$@_Q"1ZS-1JO;L10]40R*%JH6JUC4^H M6M*QK-.J=9K\8A63Z%'(NRKD*S& [)*UD)]3/N]97WQ[Q$),T\NBL4LNGEX; MSP<[6QI<,>KLP?#6EQ=:[NJVBE1YEJ1\\>O/:7QY;]NS%]?.A+JI3[^,W]M> M](?MI_0JCFD27P7N1\^^\WQ8$M+X$[7C-*+NE^ ;91O&H&ZO[=B+;QA!;X!; MK_W0^>O5/_]!R*]///K_9%O,'Q8[S->)G5#^%]SF!7;@>+;_E4;C,)JRS&X8 MQN+C,%N??@P=OAQ=?CE?M<+%-SI^>?$VS5:LM\-;[9;E@]_>A+?6K:'RBXM7 MC!AEPL#?R]S/=(6)0'Z="?^2B5GY8::.FJK^=%%P@LL;<:COYS;JY85ZP:_C MF>T4U_GOX+'@2A+FJ&?GF>F02[6"# MKYTG!&9H/6N S,.VOITBO6;U3"0]2GVW2(]2CU+?/=(SJ=>1]-C"O8V;KR=L MX;YY97#J1I;-,^BTQWI@%K!P!X+K%SL\!BS5U\U6.\C?9!/+FIKK(1\;YN/Q MM1J0A0VS,"^]0:XGE";DC3VKG"&$**1=**1"B!++W-1^5N]<:0YM.!C>KAW@ MS9$A$<^3U[T#; S,$YXF0DE'21=%TG7%, OD,L<*U6K7H K$B'@KGA)$[@@.?."9#VBW86#J>*[+2DL6_W@JZ^> MP10L%K'\AK,^JV[J)H3M8&0F5!I4&E:9#2M.]Y9%P6M/0CHH? M!O>7\.(I\1<%A7"I)!\.E_&@B!A***C5.TTJL&B>!_/>92[R-]!.F;2"LHZR M+HZLG[H]4MND7<8UA9""+",/5A8%V276=]U=W_6415BW5H#U B^A'[WOU/T0 M)'9P[\&OLD*S6,6UGBJN:ML*@?94,$VDKFI9XA=S[>L]O6U5YNKEX3G6PVTK M-B<7!P SC9 #J -=Y@#J@/B5+\\-MLZPK-N/18+N**RG^F]&4RW83MB/3U@' M\UQDN_4S^<4?=G)XPHF46A MFSH)2:@S"6!>]X^G2?NJWY@V?BI&#%-ZFHW)#>LR$:MVU;TOJ:N&HII:;3N3 M*/4H]3)(O:ZH?767U"/B$LF/B[=%(]?RYZR')]-IZML)=8D]#:/$^Z]=N83\ MR4+:$N3"B! (.GL@6XY$KF=#73&MHX_,H]"BT)Y1: >&,M+[^[731IC3.9C3 MJC"O0)$EA02T6HFY!A?:Z$&:63'+X4(T0U7ZYDC@0!'*+\KO4_([4G1]YQ$, MQ$(B.5@9L5 W.743V2XE@3VM>/X;-Q:ZYBZDV" P1\I KZ\O HO"N\9A7>H MC*PA(AV9_"=N;LG"*=S 6EE2.5$;,TTU.?0X# MF,!T1A-*[/N(TA-VG\ -@98X#BDV! Q%,PR!40_*+LKN=ME51Q9"'ID<*>YE MR<(IW,OJIN/HQ+Z KJ@:[F6AS,HDLYHRLBSLAZI ?WN;K@1CJQ4: IFKZSN@E*+TJOJ-)K86T>J3RJC."GFYQZD\9 !J1 MB/H\UA-/O!GN#%8T5>1\'Y1=E-VC9!?Q3]?Q M3P>WO6K /[CMU4W'(>(.PO%--S,ON0+I1>E%V-?HKA7A$;=8MTRI[[:"59T1,_1ADV3 MX4CPI"<47A3>K<)K*JJQL[E>-V /#%"5P7?BEI\LG,(MO[,P33C/(=0&1D[W MV@\-]0?*<+"MV1,*+0JMD$)K*/V^AB?=)'">,@9S9-SGJB^:@WM97? 3G=@- MT#5EH \$#NJ@^*+X/B&^JF*.=I;?0KPCDA-%O",-JV["Q/9)F$QH!'Y/X'<6Y8R4JN6C,PN M;? =Q5'-,DOF%DNP'F MO/9#YZ]7__P'(;^N/^"W,'0?/-^?WT@<&!1#7\3.#)/7CX+ZL#7!8%"6!^ M-4-\0)Q^ARHM/WF^CEU;QA+M8&.LB;NEVQ'FG3H&<<@6%Y)>V%TN)#U*O=BD M1ZD_!>DQ4GH@;P0-D6YD4%OS^QO=H8%9P"(&2&Y>[/ 9L&PY>^[S>:C?9)CG M9A)12C[!%Y.8O M&:H[?XGC9/IV4_&G)97 GH6XC*L"]R65X4>13Y6O?P=&6DX0GDFD\@KQT@WG;2 M^$/P'10HC![?\(!$LGP^&8\=[T+QFRTOH/@1GF:2]MBQAF?&\0!FMTC/((B* MI&](Z@=8YP"EOC6DKQ@(%05"M2W(U@1,:G\@5.@#=^T@?Y/1G:53QJ2I WC( MQV/Y^.\4;/U!+$3OA=[K0+7K&(N^V0]D:H->>[://3$E,8PGVKY87T5UX032 MH*^86FUY31NB "CM*.WB2/M0T?2ZC]LA?FH/?L+C=E4X]&<8_05?DUD4WD$2-* M>\:S;U[@Q1/JDOLP=&6!.Q+FN[;,5H-'ME$KJ,;FX?R.%9=/ L([VVPVTG MV"Y#@4>!KU/@=5,Q=]>]6(%2V24>;MMZN.WI,VO;3KI]C4(W=9(_[2BR@^3Q MHV??>;Z7/.*)MVHGWD2I6R%+(KT4)]ZPT2:>>.L8Z;'E($I]]TB/4B_ B3=1 M(%3; FTREOX2GD78:+/-YZ2PT:8(.B:_&6Q]*HS0YWY;07WLM(F,PU:;Z*,0 MJHO!(FRUV:+6+K)4+97B7(#65U2SME1/%'84=H&%W5)&^DY91U0EA,N6<.7? M,0X5Z2?$=IPHM?V8C,.H 3C5@O.3 I\R(X3(=AGN MR"'#SP:6AFA'9% (6\KCW'Z\XKI KY\W95]]D+/.G_L&*'L7>64'WJ@'%RQ > +.G6FE1B)J*$+J&&C>IX&-%0)W,I\?N(3^G7HSEB9=?U3GD,T!*3R_5 $& 2U;[0YZ;W3?4KOOF\@&5;2G1[8Q1%^-OKHY7ZT-%5/=6>@#G75CH:7A MFG&I^ #R2.VHFHE"8(# H'5*?#Z5_1P&,/+IC";5]LX0&2 R$ @9(# 0&ABL M5_M'8""#@T%@("??:E#9M_0[]<,9=4E"G4D <[A_1(2 "$%2A*"K2E_K(T1 MB( 0 2$"0H1Z\O]BF#F-2$2SRFGQQ)OA!@."!%E!@C%4#+6>:O@($L0$"4FX M7OFAXC-&B%3$DDA$*I(>)#J?X?@M#-T'S_E*X:. M00S,5D1W+9F[;L?!W_/YZZP(&K'S*FCULZG%-0SP<&%;'#XX>\6T*EA. MVNOPT;U+PXZVNO>VJU'=^P99W0!_4=A4DG4Y;AK@IL%Z1RY-TC M;Q:3'>B;Y52CNM/^[GA!'U9F')VRP'8.G?(NIZRKVSI'H5-&IRP'.] IRZE& M=3OE,>4]V"/ZG08IGM03V=:A8W[2,9N*/C+0+XLAJ^B7T2]C6ED-CCFQ?T@8 MSA9BN[I#'EJ.7>=GF@5K9PQH"R*MZ*/11V,NV1%.^B9,;+_LG6N);V-6&6:5 M2>K?!WUE9(S0OZ-_1_^._EUZ__Z9%BUH,%\MY3!H'(AO/.Y>/%- MTUE\?';)6MO/I=[UOI>_/<87ZF6UW*633WNY^6!G2X,K1IT]&-[Z\D++3K9O M5^?R+$GYXM>?T_CRWK9G+ZZ="753GWX9?Z-.>!_ @]T/P(/$&WO4S8X$7>46 M_BIP/RY6=%?9@NZ&D?0&5.6U'SI_O?KG/PCY]40/)PY,$BZ^T?'+B[=IQ.N? MW YOM5M=U0:W-^&M=6NHV44^A-O7:0PDC[/7Q![[Q=4/+[Z-IN[M:ZX$$:4? M?><3G=[1Z.(5HU*98O#WLEADFL=D([_.-&E)4%=^F-M(4.V+@D5<$(E#?3]7 MI)<7Z@6_CF>V4USGO\]5%M31MVIOK MFDT.@KX9S*T=Y5;HT(S,:ZQ3,Y)>TOTC)/U>I#\$NB+I,4Z%<:I*'KS]<:KS MI!]4\-RMB#M2\0G8?@B1 2*#X$%+K*R] M#E &JJF8QBF/,G0/H6 JI*A6OU7NNAVGBL_GKZ^P(*>42S193B[*X?!'VE 9 M]35Q"W(*[T_0O0O%CK:Z][:K4=T[!UE1 ODZ7N&V 6X;K/7#L!3#LK =AABR MBJX977.GU*CN[$-L%2V-K4._O*-5='^HH5\60U;1+Z-?Q@WL&APSMHJ6R.JU M;$/[B)V(S%&?3U_(@DF7]>L((@-$!HVSHZW( /?*JYDZ;%"-N^:X:UY:^&N& M8@U57/FC?T?_COY=>O^.#:K1LZ-GY_EPJJ&,1@+GPXEOFK!!=5DAYX-M4X/J MZXD=T==V3-TWX71&@YB?SOY&XR3RG(2ZUPG\^/? @Y<]V)%[Y23>=R]Y/+A! M-7::7@:JV+95_$[3&SVKH?4L;'?<2,]=5>OU46^:Z31M]2PD/4I]MTB/4H^D M;Q7IZPJS"ITKJ.N]OMC!NMH0*E!_+W@J5C3U% PZ;6H.S )6CT!P_6*'LX;U MHMY2\HM0,P$9(DC,^D\^=.J2*^"S?4_);Y$--[VU$TK>VUY$_K#](T\&5, % MR,_:^?F-3FTO@.&3-W!W9#M):OODAD93> KYG\:*DPD-/32MI_>[ 3TJ!,>. MUA+FL2)';#1$3LA=Q2&P!4Q'),9C;SP%#N[&X,,)V9, N60N=OG#X54#[5;VG0^@GAX\408019@H!8A!FBLZA/VB,*%,VZX8.^ND#JZJB M#_1H*RBC$B#.%0#$2 MXDPQ=*BQ5% :N/(E@:+O;CPI3@[GK2DC4U.& Y'30"44YF[F@@S6MY&4DUK1JY2ZYC+"C8RS"FE:8S="I M$C^:8NFFHNNG+ S0/5'N9BZ#% )OC'K#>C)WL*;52:3=Z.D(;N5#3N+M^LJA M:N?C$-:TZAA^;8']6O/IYU,7LN#1)>H,Z@SJ3-,Z@U45\+1;ZU$:XFC1.51L MLR&2ELO M0L5U!T7>Z;KFC+0L7 7BJ^,XJN/>J9YPK!N&URD"%*,*%,(#(,H M4W0.S6MW28(R)3QQWC(_+=PAZ'9%GU!K4&M0:X1 T\+Q3!8XO5Y"#K$T8NG6 MQ+6(:SO(H?F!WQD[\,LP[7V6XTO"K&R<+.!6OCW>;L(!(?2KM;$RU*UV MKAOETYKS<&#?AA8=/%*'T>*V8C8)4;48R].FPL:XO]RX M]Q=Q?[G^H+%F]175&)XP:-P]499TD=@%@3>,WDC##FR"6^T5P)I=8I>*BETJ M=C>2V-V8XJO]. 4IX,TMRL_[P_93_I*K.$ZGV6?8I&)%YG>LL[8FN:M8@%G. M)A5]JS=:+WF*S#M'N7Z]IXZ0]"1EZM'PIG!4]N" MH$T I%9L]#07VYQ7Y#=W5.0W^IL<1BNHWV2 [F8244H^P1>3F+P+7.J2:SI+ MZ/2.1L10E4IJA&:PLV:P%>%# K7&!;(.TA33LHWZ8Z!-L&W M_BD]E"A1SN;-G_P>JA50\90L>LB&=A?Z[B:>\1V4(DG[Q0ER239&A%J62?J? M-$Z\\6/V47[QPF-6\])S:7@?V;.) )DF^\:-VI!DVCRU.Z8.S1.\2^(MOO%! M3-993(9'YZIP:-YST)PWR0&PH.H?6L&'DQ7]=CMGF+E_AT3@A$0!%]&8M M6CFC%Y/#BW5;CU O4"\0W0F,'1#=B.KNJU'J!>H%XCA!$8($F(X,4XD-1"7^Q[Z=N+Y7O(HB0<2[<@?0CD1 M-4D>G]5Q34+-0,U -"/O.+Y/$1EU7Q/RX[TB5V;OKTZ(BC! M4>;QH*J ;EI0)(5[F^>J'?+N^NM7,DLC9V+'[&@"W'N^$B(MV*MI-21K@?$3 MP3MU6T,$I3=*/.*Q]GE[Q&-R<0@+A[0H^H^%#N3@$XQY-$*=DH)7J%-R\$DS M>[J.NY_R(1#$B*)S" N(8-0./=G9U$WMF3^A*F%X#U5C@VIHU50#,9X0" (Q MGN@YU6QP9D&K)F>JA.".Y0/>I1#P1X0L '!'BB]_.T1;E73R_/;-;FGDU4*<^2E"]^_3F-+^]M>_;BVIE0-_7IE_'UQ([H:SNF[E?[ M<0KW5_^2=5?_P_93F_UU%&#@_X1L%/;CU]>7!H7KS1-4ZT^:$!I M@GL-HO:!#\H#'^P>N#X:];7C!S[GX9MPRK[G8ZJ5PKHQ,I;'N?&=1X^K,@%5 MTZII7%=19 ?WE.G Z\?-:L'_]0<%R!;K;P6=[2J]^ M>/%M-'5OO]%X2MT/@:.KJ@7_@?5^'T9CZB6,)-F;#Z$R?]7-XVR95$#J)/+8@I"["J:=\;?KWW/2K:AM66L_ M?'X/:CM4M9TZ>Q(*G)GT:43C(I?Y*DME_HV==GMK)_2][47,MU;Q*'5RQ2RS M1;]XU5=[ ^N,3-F+-N?B%W]S+)J>#/O&63BR//MF:"Z+F@R,WF!T?J8(HRF? MP^ [T(^ZGU-&KB6N7,6W7\:W@_/XD-% ZY_'BZQ,61Q*G\E;CTQM..@$I:L9 MH1.*^P;GW-?/R@'Q#,XAS#D;UMW:L'[,O(RTA^O"86%!L$7# MU7!?'3.H29SGA"YMPA0I&46>[3=606G_H/\6,644>S>=^>$CI5Q O^:5,AFM MBK^_\:*9FT76*(NL>?%*[:G:T*A!9O>EP;E)_B/V7@2>__("=(E>',^!XM,E M+F1JN97B/XLD9WN9PU/(F:Z9*&>5'=*QJXF[JJ3QM\S2T6YVJ YD56W$)R$3G2=&W82)[2]SIK;,=Q"HD567 M>E68@& DJY*4ST@VDIYDI135^;;LP8!JW8;7A8LV)Z_*,M#C]ES/LSA=-:&\ MYGM]DMU,CN>!W&A\X6H*+9#G6<:N"21K[($"V&@JZ)B;:#U M:_;)6P=Z,GKLSC??O5BR=%/7ZTAJVC:\\\_^">^]?NI*'YQ(!DX\^XHKHJT2 ML;8B&O6&IR'(^59$AY-I[X6CJ?9JB94>3:8CUO'5\S_U"IG*%Z^^&O^C?]+T MU5S6\XY8;)*MK#:$)=E3HAU77:ONK9/5UF:K*JJ/>F85%:UU'C73<,/J^TDJ MUK;@/0#/[9K+DYCVO--8TZO5#8?? Y=&)=#+UB3QTACYF?E2W"^?Y%/3TIZ: MUVX_M!<_#IQ($?!>G]!Q.$NS^JHQW*6,M0]ZE5)AE# +]SJ,HO !+-^F66U% M2FNE-G3+,HW1RAIB[16'C&'_KS@&[S[PQIX#:GCE.&$:\$(,H>\Y M'HWG)6PJ^2U64Z=<7P?^7BXBE!5X8I6$\NNL8M-2O:4MM8=(\8\^A+MW58;D ME9D\$)P@>7')?U%GH;ERJ2.U2JFCQ0^U^9R?:<]+!;KC]$IY!S^H7TI#+!V#X_D*D MGJQ/]K2\B2A=5>MJ=9IV#UDYN+O0=S<2\TMT;P?>?[D-)("F"?@N+V:J]Q4\ M%M"#?U,3F=FP+O,"=7WUIV6RMX?F**^UT>X;C3]1EWP(G!YY%M$QC2*X3$(R MH1'U0&)CDI,7W/6;7Q[HXNKM+\K2=VF\_;LPCQ9[KV1'X#X4\4 !/,7!/(<"!=,R6 MO# >ILX@1'_1A-"_4V_&UBOSU\&/[X.0Z3J[+8FHG?#O0?-CG]+9);"'2PV, MZ8Y].V O>&[/@@ >O 3[^%X*B+6V$H7N#X*9]?>,<.'#HLT25[(K%G ;4W M3NT+3&DQ.#J0!NLY.,GE[8"Z""XMX'D5"'O8>WEP'\_ MV2!2L6=GLX)Y,G0)/[P&0T;CC2__9/\':.*RNGO>73HWA+'M@US'\.NU(:P] M5R&_ 2P%;BX&4KKG_\(PW7 *XWWPDO_2","^JY3G\6\;)$$AG\/HP7[D+[]^ MH*#N>^0^JX+I/[*OZ8PW MA%Z [1D8!<>;,8U\5K;*_*>_75U]7;;+S,AQVGG3TL"\@%GE!=3A+V=ZZ@6Y MJ6+F!IS+>[@-B'CY__/;C@;Z[!51ZM/UWE-5G\2L,S0@2FN16'$3 ]XM7 MKA)O'(8)W HOCYASX6[BDG"=TH'!MM\8?,N(8S+V O@G>#:-M9 M^$WAPPFH0^.8+0]MEZD)?Q:XP(D'7I9)I!?S1I.!SQ>0 1NT#V,$6G'' C(\ MA?L7DIG/=6[8E\1^HU2#A,PR<$S&MA?!BSB':9SZ2;R@5R9^,QX,W#S;F^6? ME7Q>X:57GE*\ERD'N"3&JH(>8!+@;A>6RMSCYJ,HGIY,[ 1(^0A3)K0H[U^\ MA'7A))1'TLF_4[!/AJH0D)%A7?Y'!G_3/\QD]@7R-D)[DRINHQ#,9!)1FO?M M8P+*\!9S#7Q[/!?2 ;=&;)..J\3"3W$,-PE3WV5"#PB6:SB\_#]IP$W]PO[O M'A%[6&;M&/BE8 '*9H,A\L)G_-\UM8)[REHU.#.JDP]\"*!*\M!N5X"'O:<4 MM?P:A0'\[>1RC0L,E--&:/>!!48>N4$TL\7R^ZOKUP1P:PKVLB2PUVR/WXX M^_P^8P::/+NZ_OTY+)^O?X<%\3YDV [NB>W7,H_[53C+-'F/]D M\WWP? 9E@;@.YO'JXW/AY(/E?NW^]3+5EG@HA; _&'"0&\"HP.<"Z^B MXS'E49KL/0'P.\YISN);\Z_G4R@"5W<4I#C@F#I#SF,O@B']G=I1DDUP[,4. M^%'N"(',5H^\LQE3B&IH6H'*93?35#-:5W$CW-QCIA07N7ZJ&0BZN0@,&++[H%9K&GI%9N&G(U!\$GC+E9Y3A3YNM M/,UE3_.*ISGL:0#_@=9E8U= _*4?9W=Q.Q:QI K"3U,'_$O0PO=S??Q&9V&T MXH:>?7C_[?HY"W9DSB*;+"RO-XWGCI:6[&$VCSO;YW?$$TJ3S RYX',<]@0W MBT)ECHL;6SN*.#T77B=;U^>6@;W3]^P[7MIB@P5_L%=->!KO;[EY$(!<;;>4 MW"+"V'VPT=[8*T:T0@7XT=&AKW^IO<'Q\3/0&K^(8!T_)*TWK&U(2L;S;'.% M>;P,0\0LY^42N#+-*,L&[H?!_>(C[NYF&8-9',_;X&'61 XXLKPFY9)3]G_< ML:_Y/X^]VFQ M ]A_;LG8P.R$?P'ZE#DYYIRRR!X8Q8@"M?_+T*+=SRE_-M%;9) >O8*.;#N$MA"0/K&(7X\&_VY!C0QAV0$NR3 MZSF\<^'"8>9[)]PS,+Z$L0U(+-NKAR4DPR4DR M]1G[F1@:.O>QM-KR8I 9+3Q-7_B@DPR X+&]RCC^Y[>12FS+ RV M/6F !Y>JOFR /X(BTZ6X5X_P5'3^&*:MA='(C!3-4U_F.[Q+L3"?/:V JAR7 MYNL0MB.]<:W#M)[_*B:E%0.#HUF4!NQ _G6^0LM"0-P<,3N7V_$]HU+<36E* M'GE:BRK1[UFSTY6P4NXOYI9C7_O0E!WH-,026%&/7]YDB8/;U?SH-S [H2L'^)R/RF8)[67!\8858?^L\ M;I/8/T#] SKV$AY-IUD#W7CNMN&'C)#?LPZ=6< ]2?PYLJ'%,&,^3'Z(BK#< M3A;VR9(FP>Z _7!8[DCRP-)'LI01=L2P>'=FDF LLS0"V):GY_#@_V* 0%(8 M-L]WFL\EVR58&)=H'GTJGO2<&F568@<\S1O#\H- ! UHRQ;8?AUM8E%OXQW+,/0LB M\<0:%NS82.]9)A9+N:19R*D^1J_S5V&4+8TT"\;,W9+-G$WFVQ;>RQXS!/R6.EFV UML9:: PW*:[:,4\9KEW1/J9_D]0(72 M?8MUD)M&!5''X-O@<=OW;++T"N8Y>>+#.%R# VP*)0_*-U:2"<]43O)]JXGM M9KE6?"!9)+3DG?N];9&,0X_HS)/:'FA9O5@4LXBP>D%9D0KMX9/EWT0(M22U14[_7KBXK";(]^&+7!5M0QM94$H.-GF>O8\0_:DHET](-K MB&_SW/':!W:\B.V%CI:%ETUI[__R7_*)\0+.X*!T;W>M4Z,I)TMQT M7P7NNQ\)9_C7*&2VXT^;'0A/'N%1L [SWX-!A.>_XO!I:V?"*VOF$V,_\JY09A_I>:.3P7 4 F\O!\UD#KJ!/5 MVL R1\8J\U9?<< 0]J>=-ASJ_<'HR"%\#A/Z=A[]$OE,]6AER4B$/S2M/3_: MSNY]V/K8%Y4E8VG[*A.38Y?\(Z$XM2O'LLY@AUPS9V=- #AR:>B=37JO/;8" MS\Y'L+-"^98U/Q@YR0*6L[R^(DNR R)-BT5X=H1R/8N<+Q7X%L'BMVS!D+#R ML[7@65/K'8_$"JA>)ZF/?10G>GX37,W9E)9I 5\2N"#;#<6]2K M8O=GIQ%LWTG];'591&W8.B7[30W1N3]SH09I9T>3^2FA.(UGV1+F*84A;I;8 M"LMGMI:U';#K,0_ ;$Y&6%UVLXR1HX#V3#GXHF@$[+V Q9Z8G0+\$'$RQETA='QZ^T>J9%R M5\E&XW_T4F,'(&=%O0OG=/EN<&LKL4PVYY:U_R\* 4/E!Z_SZ3 RI7] *H]A M.Z$%%RO(L\N"A4_G-B@LC3!: MC##[DD4>L[((-(K#(*!^>?/V>(T?CST'GLQ?/O8- MMPBOUDI8M
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
ZP

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company